An Open-Label, Extension Study of the Effects of LMTM in Subjects With Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia (bvFTD)
Phase: PHASE3
Conditions: Alzheimer's Disease, Behavioral Variant Frontotemporal Dementia
Sponsor: TauRx Therapeutics Ltd

Protocol: TRx-237-020 
TauRx Therapeutics Ltd 
24 March 2016 
EUDRACT # 2014-002013-37 
Protocol Version 3.0 / 24 March 2016 
CONFIDENTIAL  
 
 
Page 1 of 80 
 
 
CLINICAL STUDY PROTOCOL 
 
An Open-Label, Extension Study of the Effects of 
Leuco-methylthioninium bis(hydromethanesulfonate) in Subjects with Alzheimer’s Disease 
or Behavioral Variant Frontotemporal Dementia 
 
STUDY CODE:  TRx-237-020 
 
STUDY PHASE:  3 
 
VERSION 3.0 DATED 24 MARCH 2016  
 
Previous Versions:  
VERSION 2.1 DATED 22 JUNE 2015 
VERSION 2.0 DATED 2 JUNE 2015 
VERSION 1.1 DATED 11 JUNE 2014 
VERSION 1.0 DATED 25 APRIL 2014 
 
 
 
TauRx Therapeutics Ltd. 
Liberty Building 
Foresterhill Road 
Aberdeen AB25 2ZP 
Scotland, UK 
Tel: +44 1224 438550 
Fax: +44 1224 555173 
TauRx Therapeutics Ltd. 
3 Shenton Way, #21-04 
Shenton House 
Singapore 068805 
Republic of Singapore 
 
THIS PROTOCOL IS A CONFIDENTIAL DOCUMENT 
This Protocol is the property of TauRx Therapeutics Limited.  The information within it is confidential and is 
provided to you, for review by you, your staff, and applicable Ethics Committees.  The Protocol must be kept in a 
confidential manner and must be returned to TauRx upon request.  No part of this document may be reproduced in 
any form without permission from TauRx.  By accepting this document, you agree that the information contained 
therein will not be disclosed to a third party without written authorization from TauRx. 
 

Protocol: TRx-237-020 
TauRx Therapeutics Ltd 
24 March 2016 
EUDRACT # 2014-002013-37 
Protocol Version 3.0 / 24 March 2016 
CONFIDENTIAL  
 
 
Page 3 of 80 
1.2 
Responsible Personnel 
TauRx Global Project Lead for TRx-237-020 
Sean Neville 
Liberty Building 
Foresterhill Road 
Aberdeen AB25 2ZP 
Scotland, UK 
Tel: +44 1224 438578 
Fax: +44 1224 555173 
Mobile: +44 7867 743 890 
E-mail: s.neville@taurx.com 
Global Lead Medical Monitor 
Meera Jessani, MD 
Worldwide Clinical Trials 
1000 Continental Drive 
King of Prussia, PA 19406 
United States 
Tel: +1 610 964 2012 
Fax: +1 610 225 0050 
Mobile: +1 310 728 5684 
E-mail: meera.jessani@wwctrials.com 
TauRx Head of Safety and Medical Monitoring 
Jiri Hardlund, MD 
Liberty Building 
Foresterhill Road 
Aberdeen AB25 2ZP 
Scotland, UK 
Tel: +44 1224 438543 
Fax: +44 1224 555173 
Mobile: +44 7825 280632 
E-mail:  JHH@taurx.com 
Pharmacovigilance 
Andrew Monaghan, BSc PhD 
Director, Global Pharmacovigilance 
Isaac Newton Centre, Nottingham  
Science Park, Nottingham, NG7 2RH, UK 
Tel: +44 (0)115 956 7711 
Fax: +44 (0)115 922 0960 
Mobile: +44 (0)7771 858142 
Email: Andrew.monaghan@wwctrials.com  
Drug Safety e-mail: drugsafety@wwctrials.com 
Central Laboratory 
Covance, Inc. 
United States and Canada 
8211 SciCor Drive 
Indianapolis, IN 46214-2985  
United States 
Tel: +1 317 271 1200 
Fax: +1 317 273 4030 
 
Europe 
7 rue Marcinhes 
1217 Geneva 
Meyrin Switzerland 
Tel: +41 58 822 7000       
Fax: +41 58 822 6999 
 
Asia and Australia 
1 International Business Park 
#05-12A/B The Synergy 
Singapore 609917 
Tel: 65 6560 8793 
Fax: 65 6565 5901 
Study Monitor and Project Management 
Worldwide Clinical Trials Limited 
2nd Floor, 172 Tottenham Court Rd 
London Q1T 7NS, UK 
Tel: +44 20 7121 6160 
IWRS 
BioClinica, Inc. 
800 Adams Ave 
Audubon, PA 19403  
United States 
Tel:  +1 484 928 6736 
Data Management and Statistics 
SynteractHCR, Inc. 
5759 Fleet Street, Suite 100 
Carlsbad, CA 92008  
United States 
Tel: + 1 760 268 8200       
ECG 
BioClinica, Inc. 
100 Overlook Center 
Princeton, NJ 08540 
United States 
Tel: +1 301 795 2500 

Protocol: TRx-237-020 
TauRx Therapeutics Ltd 
24 March 2016 
EUDRACT # 2014-002013-37 
Protocol Version 3.0 / 24 March 2016 
CONFIDENTIAL  
 
 
Page 4 of 80 
1.3 
Investigator Signature Sheet 
 
 
By signing below, I agree to the conditions relating to this study as set out in this protocol (TRx-237-020 
dated 24 March 2016). 
 
I agree to conduct this study according to Good Clinical Practice (ICH GCP) and applicable regulatory 
requirements.  
 
I fully understand that any changes instituted by me without previous discussion with TauRx or their 
designated representative constitute a violation of the protocol.   
 
I agree to adhere to the protocol in all circumstances other than where necessary to protect the well-being of 
the subject. 
 
I will ensure that the drugs supplied by TauRx will be used only for administration to subjects enrolled in 
this study and for no other purpose. 
 
 
Study Site Principal Investigator’s Name, Title, Address and Contact Information:  
 
                _______________________________________ 
                _______________________________________ 
                _______________________________________ 
                _______________________________________ 
                _______________________________________ 
                _______________________________________ 
 
 
Signature: ______________________________________     Date: ________________ 
 
 
 
 
 

Protocol: TRx-237-020 
TauRx Therapeutics Ltd 
24 March 2016 
EUDRACT # 2014-002013-37 
Protocol Version 3.0 / 24 March 2016 
CONFIDENTIAL  
 
 
Page 5 of 80 
SYNOPSIS 
Name of Sponsor / Company: 
TauRx Therapeutics Ltd (TauRx) 
Name of Finished Product: 
Leuco-methylthioninium bis(hydromethanesulfonate) (LMTM, TRx0237) Tablets, 100 mg 
Name of Active Ingredient: 
Methylthioninium (MT) 
Number and Title of Study: TRx-237-020: An Open-Label, Extension Study of the Effects of  
Leuco-methylthioninium bis(hydromethanesulfonate) in Subjects with Alzheimer’s Disease or Behavioral Variant 
Frontotemporal Dementia 
Study Site(s):  Approximately 170 sites in North America, Europe, Asia, and Australia 
Study Duration: 
The study will continue until alternate options for access to treatment are available, 
i.e., commercialization or, depending on country, on a Named Patient or 
compassionate basis or via a Managed Access Program.  
Phase of Development: 
Phase 3 
 
Objectives: 
The primary objectives of this open-label extension study are to provide subjects who have completed participation 
in a Phase 2 or Phase 3 trial continued access to therapy and to evaluate the long-term safety and tolerability of 
leuco-methylthioninium bis(hydromethanesulfonate) given in flexible doses of up to 300 mg/day, or in those 
countries where limited by a Competent Authority (CA) or Ethics Committee (EC), 200 mg/day. 
Study Design:  
This is a multicenter, flexible dose, open-label extension study.  Appropriateness of continued treatment will be re-
evaluated every 12 months on the basis of benefit and safety/tolerability; informed consent must be obtained for 
each subsequent extension.  For subjects who do not re-enroll for a subsequent extension of treatment, identified end 
of treatment evaluations will be performed at the final on-treatment visit (e.g., Visit 6).  If a subject discontinues 
prematurely, an early termination visit should be conducted at which time all assessments identified for Visit 6 
should be performed.  For subjects who cease to take LMTM, a post-treatment follow-up visit 4 weeks after the last 
dose of study drug is to be scheduled, regardless of the reason for discontinuation. 
 
The trial will be monitored for safety by a Data Safety Monitoring Board (DSMB) throughout its duration. 
Number of Subjects:  
It is anticipated that approximately 1050 to 1400 subjects may enroll if all eligible subjects elect to continue 
treatment beyond the double-blind study in which they participated (assuming 60 to 80% of subjects in each double-
blind study complete). 
Subject Population:  
Inclusion Criteria 
1. 
Subjects with a diagnosis according to NIA/AA criteria of all cause dementia and probable Alzheimer’s 
disease (AD) at enrollment and who completed participation in one of the following three TauRx studies 
(inclusive of the 4-week post-treatment follow-up visit):  TRx-237-005, TRx-237-008, or TRx-237-0151.   
 
OR 
 
Subjects with a diagnosis of probable bvFTD according to the International Consensus Criteria for behavioral 
variant frontotemporal dementia (bvFTD) at enrollment and who completed participation in TauRx study 
TRx-237-007 through Visit 9 (Week 52). 
 
Treatment will not be made available to subjects who have withdrawn from the double-blind study of prior 
participation prior to completion. 
                                                 
1 Subjects who participated in Study TRx-237-015 and did not consent to extended treatment for up to 
15 months as per Protocol Version 3.0 (extended from 12 months as per the original study protocol) may 
be enrolled into this open-label extension study following completion of the 12-month double-blind 
treatment period and 4-week post-treatment follow-up visit for Study TRx-237-015. 

Protocol: TRx-237-020 
TauRx Therapeutics Ltd 
24 March 2016 
EUDRACT # 2014-002013-37 
Protocol Version 3.0 / 24 March 2016 
CONFIDENTIAL  
 
 
Page 6 of 80 
Name of Sponsor / Company: 
TauRx Therapeutics Ltd (TauRx) 
Name of Finished Product: 
Leuco-methylthioninium bis(hydromethanesulfonate) (LMTM, TRx0237) Tablets, 100 mg 
Name of Active Ingredient: 
Methylthioninium (MT) 
2. 
Females of child-bearing potential must continue to use adequate contraception (or, if in Italy, agree to avoid 
pregnancy) defined as follows:  
• 
barrier method (such as condom, diaphragm or cervical/vault cap) with spermicidal foam, gel, film, cream, 
or suppository; intrauterine device (IUD) or system; oral or long-acting injected or implanted hormonal 
contraceptives for at least 3 months prior to Baseline; or vasectomized partner (with the appropriate post-
vasectomy documentation of the absence of spermatozoa in the ejaculate); or true abstinence (when this is 
in line with the preferred and usual lifestyle of the subject) 
• 
subjects must agree to continue to maintain adequate contraception throughout participation in the study  
3. 
Subject and/or, in the case of reduced decision-making capacity, legally acceptable representative(s) consistent 
with national law and IRB/EC approval, is/are able to read, understand, and provide written informed consent 
in the designated language of the study site 
• 
In Germany and the Netherlands, subjects must be able to provide their own written informed consent (see 
Section 13) 
4. 
Has an identified adult caregiver who meets the following criteria: 
• 
Either lives with the subject or sees the subject on average for ≥ 1 hour/day ≥ 3 days/week, and in the 
investigator’s opinion, the extent of contact is sufficient to provide meaningful assessment of changes in 
subject behavior and function over time and provide information on safety and tolerability 
• 
Is willing to provide written informed consent for his/her own participation 
• 
Is able to read, understand, and speak the designated language at the study site 
• 
Agrees to accompany the subject to each study visit  
• 
Is able to verify daily compliance with study drug 
5. Able to comply with the study procedures in the view of the investigator 
 
Exclusion Criteria 
1. History of swallowing difficulties (note: study drug should be swallowed whole and MUST NOT be broken 
crushed, chewed or dissolved in fluids prior to ingestion)  
2. Pregnant or breastfeeding 
3. Clinically significant laboratory, pulse co-oximetry, electrocardiogram, or imaging abnormality (in original 
study) or emergent intercurrent illness that, in the judgment of the principal investigator, could result in the risk 
of participation outweighing the potential benefit  
4. Current participation in, or intent to enroll in, a clinical trial of a drug, biologic, device, or medical food 
5. In Germany, subjects who meet the following criteria are to be excluded: 
• 
Subjects who reside in a continuous care or assisted living facility if mandated by an order issued by either 
the judicial or the administrative authorities 
• 
Subjects whose willingness to participate in the clinical trial may be unduly influenced by the expectation 
(regardless of whether justified) of benefits associated with participation, or of a retaliatory response from 
family, caregivers, or treating personnel in case of refusal to participate 
Dose/Route/ Regimen: 
The initial dose in this study is LMTM 200 mg/day (one 100-mg tablet given twice daily [b.i.d.]).  Thereafter, 
dosing is flexible up to a maximum of 300 mg/day (or in those countries where limited by a CA or EC, 200 mg/day).  
The dose may be increased (at Visit 3 or at any subsequent dispensing visit as determined by the investigator during 
the treatment period) or decreased (at any time at or after Visit 2) in one step of 100 mg higher or lower as needed in 
response to safety assessments and benefit as judged by the investigator.  Interruption(s) of dosing (for up to 30 days 

Protocol: TRx-237-020 
TauRx Therapeutics Ltd 
24 March 2016 
EUDRACT # 2014-002013-37 
Protocol Version 3.0 / 24 March 2016 
CONFIDENTIAL  
 
 
Page 7 of 80 
Name of Sponsor / Company: 
TauRx Therapeutics Ltd (TauRx) 
Name of Finished Product: 
Leuco-methylthioninium bis(hydromethanesulfonate) (LMTM, TRx0237) Tablets, 100 mg 
Name of Active Ingredient: 
Methylthioninium (MT) 
on a given occasion) may also be allowed at any time if the investigator determines this is indicated, e.g., tolerability 
concerns or laboratory abnormalities.  In the event of continued poor tolerance or the need for a dose interruption 
(for safety reasons) of more than 30 days on a given occasion, subjects should be withdrawn from treatment.  
 
LMTM tablets are available in the 100-mg strength only (expressed as MT base equivalents).  Study drug shall be 
dispensed at 3 monthly intervals.  Study drug preferably should be taken twice daily, in the morning and evening.  
Once daily dosing or three times per day dosing are also acceptable; no more than 200 mg is to be administered at 
one time and the dose shall not exceed a maximum of 300 mg/day (or 200 mg/day in countries limited by a CA or 
EC).  Tablets may be taken with or without meals.  Subjects will be instructed to take each dose of study medication 
with water.  Tablets are not to be broken, crushed or chewed or dissolved in fluids prior to ingestion. 
Methodology: 
The final designated visit in the double-blind study in which the subject previously participated will serve as 
Baseline (designated Visit 1) for this open-label extension study.  If the Baseline visit does not coincide with the 
final double-blind visit, selected assessments will be repeated (see Assessments). 
 
Subjects may continue participation at the same site at which they participated in the originating double-blind study 
or transfer to a geographically close investigational site (that also participated in the same study).  Eligibility for 
continued open-label treatment is to be determined by the original investigator and, if applicable, a referral to a new 
site made.  The new investigator will have access to the subject’s prior study eCRFs and is to confirm eligibility; 
Baseline testing can be repeated as necessary in the judgment of the new investigator.    
 
The first on-treatment visit will occur approximately 2 weeks (± 3 days) after Visit 1 (designated Visit 2).  
Thereafter, on-treatment visits are to occur approximately every 13 weeks (± 14 days) relative to Baseline (e.g., after 
approximately 13, 26, 39, 52 weeks, etc.) or upon early termination.  Safety assessments will be performed at each 
visit.  In the intervening time, caregivers will be contacted by telephone at approximately 6 weeks after Baseline.  In 
the event of tolerability problems, subjects and/or caregivers will be asked to contact the investigator and an 
unscheduled visit will be arranged to assess the subject.  Safety assessments will be performed at the final off-
treatment follow-up visit (approximately 4 weeks after the last dose of study drug) for subjects who discontinue 
prematurely or who do not wish to proceed to an additional extension phase.  Resource utilization and quality of life 
will be evaluated at Baseline (if not available from the prior study of participation or within the required time frame 
as detailed below) and approximately every 6 months thereafter (or upon early termination). 
 
The Mini-Mental State Examination (MMSE) will be performed at Baseline (if not available from within the prior 
42 days in the previous study of participation) and approximately every 6 months thereafter (or upon early 
termination).  The MMSE scores will be used to inform the evaluation for possible serotonin toxicity (to be included 
in the targeted physical and neurological examinations). 

Protocol: TRx-237-020 
TauRx Therapeutics Ltd 
24 March 2016 
EUDRACT # 2014-002013-37 
Protocol Version 3.0 / 24 March 2016 
CONFIDENTIAL  
 
 
Page 8 of 80 
Name of Sponsor / Company: 
TauRx Therapeutics Ltd (TauRx) 
Name of Finished Product: 
Leuco-methylthioninium bis(hydromethanesulfonate) (LMTM, TRx0237) Tablets, 100 mg 
Name of Active Ingredient: 
Methylthioninium (MT) 
Assessments: 
Baseline: 
Following the signing of informed consent and review of inclusion and exclusion criteria, the following Baseline 
assessments are to be performed in order to confirm continued eligibility for the study:   
• 
If the Baseline visit does not coincide with the final double-blind study visit, intervening medical history, 
adverse events (AEs), and concomitant medication use are to be recorded; serum pregnancy testing in women 
of childbearing potential is to be performed.  
• 
If the final double-blind study visit occurred more than 42 days prior, additional safety assessments are to be 
repeated, including seated blood pressure and pulse, body weight, clinical laboratory tests, 12-lead ECG 
testing, and targeted physical and neurological examinations (including an assessment for signs and symptoms 
of serotonin toxicity). 
 
Baseline assessments may be repeated (also within 42 days) as determined by the new investigator for subjects 
transferring to a new site. 
Safety and Tolerability: 
At each post-Baseline visit (unless otherwise noted), whether or not subjects are on study medication, all AEs, 
concomitant medications, vital signs, clinical laboratory findings, ECGs, and targeted physical and neurological 
examinations will be assessed (unless otherwise noted) according to the following: 
• 
AE recording. 
• 
Concomitant medication use.  
• 
Seated blood pressure and pulse (after the subject has been at rest in a seated position for approximately 
5 minutes, with pulse recorded over 60 seconds). 
• 
Body weight. 
• 
Standard clinical laboratory testing, including hematology and serum chemistry.   
• 
A serum pregnancy test (women of childbearing potential). 
• 
A 12-lead ECG obtained in triplicate (approximately every 6 months). 
• 
Targeted physical and neurological assessments (including an assessment for signs and symptoms of serotonin 
toxicity).  
Post-treatment safety assessments will be conducted at a follow-up visit, to be scheduled to occur approximately 
4 weeks after the last dose of study drug for all subjects who cease to take LMTM (regardless of the reason for 
discontinuation). 
Resource Utilization and Quality of Life: 
The following scales will be evaluated at Baseline and approximately every 6 months thereafter (or upon early 
termination): 
• 
The Resource Utilization in Dementia – short version (RUD-Lite) (to be performed at Baseline if not available 
from within the prior 42 days in the previous study of participation). 
• 
The EuroQol – 5 Dimension – 5 Level version (EQ-5D-5L) (applied to the subject and to the caregiver on 
behalf of the subject). 
 

Protocol: TRx-237-020 
TauRx Therapeutics Ltd 
24 March 2016 
EUDRACT # 2014-002013-37 
Protocol Version 3.0 / 24 March 2016 
CONFIDENTIAL  
 
 
Page 9 of 80 
Name of Sponsor / Company: 
TauRx Therapeutics Ltd (TauRx) 
Name of Finished Product: 
Leuco-methylthioninium bis(hydromethanesulfonate) (LMTM, TRx0237) Tablets, 100 mg 
Name of Active Ingredient: 
Methylthioninium (MT) 
Statistical Analysis: 
The Safety Population will include all subjects who are documented to have taken at least one dose of study drug.  
Subjects dispensed study medication who subsequently are lost to follow up without any contact are not included in 
the Safety Population but will be included in the study disposition tabulation and listings.  With the exception of 
study disposition, all tables and listings will be generated on the basis of the Safety Population. 
 
Baseline Characteristics, Dosing, and Study Disposition:  Tabular summaries of demographics and baseline 
characteristics will be prepared based on data collected at the Baseline visit for the original study of participation 
and at baseline for the open-label extension study.  Tabular summaries of concomitant medication use (ongoing at 
start of study and newly initiated) will be restricted to the open-label extension study. 
 
Tabular summaries will be prepared of study disposition and drug exposure during the open-label extension study 
(dose and duration as well as the proportions of subjects with dose interruptions and/or dose reductions). 
 
Safety and Tolerability:  Tabular summaries and listings will include: AEs coded using the MedDRA version 
adopted at the start of the double-blind study in which the subject previously participated (Version 15.0 or later); 
vital signs (blood pressure, pulse, and body weight); laboratory tests; ECGs; targeted physical and neurological 
examinations; and signs and symptoms of possible serotonin toxicity).  Additional safety evaluations, if any, 
performed to evaluate changes in medical history will be listed (e.g., pulse co-oximetry).   
 
In addition to by-subject listings of all safety data, individuals with laboratory abnormalities, ECG abnormalities, or 
vital sign measurements that meet pre-specified criteria for possible clinical significance will be listed separately, 
taking into consideration their results from the original double-blind study of participation.  The numbers of subjects 
for each parameter will be tabulated (by visit and overall).   
 
For health economics and quality of life measures, the individual items and overall scores for the RUD-Lite and the 
EQ-5D-5L will be summarized descriptively by visit.  Results will be listed by subject.  A summary of the planned 
analyses is provided in the statistical analysis section of this protocol; a detailed description of the planned analyses, 
as well as intended sensitivity analyses, will be provided in the Statistical Analysis Plan. 

Protocol: TRx-237-020 
TauRx Therapeutics Ltd 
24 March 2016 
EUDRACT # 2014-002013-37 
Protocol Version 3.0 / 24 March 2016 
CONFIDENTIAL  
 
 
Page 10 of 80 
TABLE OF CONTENTS 
PAGE 
1 
PROTOCOL APPROVAL, RESPONSIBLE PERSONNEL, AND INVESTIGATOR 
SIGNATURES ............................................................................................................................................................. 2 
1.1 
PROTOCOL APPROVAL ................................................................................................................................ 2 
1.2 
RESPONSIBLE PERSONNEL ........................................................................................................................... 3 
1.3 
INVESTIGATOR SIGNATURE SHEET .............................................................................................................. 4 
SYNOPSIS ................................................................................................................................................................... 5 
2 
BACKGROUND ................................................................................................................................................. 16 
3 
OBJECTIVES..................................................................................................................................................... 19 
4 
STUDY DESIGN ................................................................................................................................................ 19 
4.1 
GENERAL DESCRIPTION ............................................................................................................................ 19 
4.2 
POPULATION ............................................................................................................................................. 21 
4.3 
DURATION ................................................................................................................................................. 21 
4.4 
SCHEDULE OF ASSESSMENTS .................................................................................................................... 21 
4.5 
ASSIGNMENT OF TREATMENT ................................................................................................................... 24 
4.6 
STUDY TREATMENT .................................................................................................................................. 24 
4.7 
CONCOMITANT MEDICATION .................................................................................................................... 24 
4.7.1 
Dementia Medication ............................................................................................................... 24 
4.7.2 
Drugs with Serotonergic Potential ........................................................................................... 25 
4.7.3 
CYP and P-gp Substrates ......................................................................................................... 25 
4.7.4 
Drugs Used to Manage Behavioral Disturbance ...................................................................... 26 
4.7.5 
Other Medications ................................................................................................................... 26 
4.7.6 
Dietary Tyramine ..................................................................................................................... 26 
4.7.7 
Contraceptive Measures ........................................................................................................... 27 
4.7.8 
Folate and Vitamin B12 ............................................................................................................ 27 
4.8 
DATA AND SAFETY MONITORING BOARD / INDEPENDENT DATA MONITORING COMMITTEE .................... 28 
5 
SELECTION OF SUBJECTS AND CRITERIA FOR WITHDRAWAL ..................................................... 28 
5.1 
INCLUSION CRITERIA ................................................................................................................................ 28 
5.2 
EXCLUSION CRITERIA ............................................................................................................................... 29 
5.3 
DISCONTINUATION/WITHDRAWAL ............................................................................................................ 30 
5.4 
TERMINATION OF THE STUDY .................................................................................................................... 31 
6 
TREATMENTS ADMINISTERED .................................................................................................................. 31 
6.1 
TREATMENT .............................................................................................................................................. 31 
6.1.1 
Active Ingredient ..................................................................................................................... 31 
6.1.2 
Inactive Ingredients ................................................................................................................. 32 
6.2 
STUDY REGIMENS ..................................................................................................................................... 32 

Protocol: TRx-237-020 
TauRx Therapeutics Ltd 
24 March 2016 
EUDRACT # 2014-002013-37 
Protocol Version 3.0 / 24 March 2016 
CONFIDENTIAL  
 
 
Page 11 of 80 
6.2.1 
Initial Dose .............................................................................................................................. 32 
6.2.2 
Flexible Dosing ........................................................................................................................ 33 
6.2.3 
Dose Adjustment for Selected Adverse Events / Test Abnormalities ...................................... 33 
6.3 
PACKAGING, LABELING, AND STORAGE .................................................................................................... 34 
6.4 
DISPENSING ............................................................................................................................................... 35 
6.5 
COMPLIANCE ............................................................................................................................................. 35 
6.6 
ACCOUNTABILITY ..................................................................................................................................... 36 
7 
ASSESSMENT OF SAFETY ............................................................................................................................ 36 
7.1 
ADVERSE EVENTS ..................................................................................................................................... 36 
7.1.1 
Intensity ................................................................................................................................... 37 
7.1.2 
Relationship to Study Drug ...................................................................................................... 37 
7.1.3 
Adverse Events of Special Interest .......................................................................................... 38 
7.1.4 
Serious Adverse Events ........................................................................................................... 39 
7.1.5 
Pregnancy ................................................................................................................................ 40 
7.1.6 
Reporting Requirements and Timeframes ............................................................................... 41 
7.2 
URGENT SAFETY MEASURES ..................................................................................................................... 43 
7.3 
CLINICAL LABORATORY TESTS ................................................................................................................. 44 
7.3.1 
Serum Chemistry ..................................................................................................................... 44 
7.3.2 
Hematology ............................................................................................................................. 45 
7.3.3 
Other Laboratory Tests ............................................................................................................ 45 
7.3.4 
Review of Laboratory Results ................................................................................................. 45 
7.4 
VITAL SIGN MEASUREMENTS .................................................................................................................... 46 
7.4.1 
Blood Pressure and Pulse ......................................................................................................... 46 
7.4.2 
Temperature and Respiratory Rate .......................................................................................... 46 
7.4.3 
Weight ..................................................................................................................................... 46 
7.5 
ELECTROCARDIOGRAPHY .......................................................................................................................... 47 
7.6 
PHYSICAL AND NEUROLOGICAL EXAMINATIONS ...................................................................................... 47 
8 
OTHER ASSESSMENTS .................................................................................................................................. 47 
8.1 
MINI-MENTAL STATE EXAMINATION (MMSE) ........................................................................................ 47 
8.2 
RESOURCE UTILIZATION IN DEMENTIA QUESTIONNAIRE (RUD LITE) ...................................................... 48 
8.3 
EUROQOL – 5 DIMENSION – 5 LEVEL INSTRUMENT (EQ-5D-5L) .............................................................. 48 
9 
STATISTICAL PLAN ....................................................................................................................................... 49 
9.1 
EFFICACY ENDPOINTS ............................................................................................................................... 50 
9.2 
SAMPLE SIZE CALCULATIONS ................................................................................................................... 50 
9.3 
STATISTICAL ANALYSIS ............................................................................................................................ 50 
9.3.1 
Analysis Populations ............................................................................................................... 50 
9.3.2 
General Considerations ............................................................................................................ 50 

Protocol: TRx-237-020 
TauRx Therapeutics Ltd 
24 March 2016 
EUDRACT # 2014-002013-37 
Protocol Version 3.0 / 24 March 2016 
CONFIDENTIAL  
 
 
Page 12 of 80 
9.3.3 
Health Economic Analysis ....................................................................................................... 50 
9.4 
BASELINE CHARACTERISTICS AND CONCOMITANT MEDICATIONS ............................................................ 52 
9.5 
STUDY DRUG EXPOSURE ........................................................................................................................... 52 
9.6 
SAFETY ANALYSIS .................................................................................................................................... 52 
9.6.1 
Adverse Events ........................................................................................................................ 53 
9.6.2 
Laboratory Tests ...................................................................................................................... 53 
9.6.3 
Vital Signs and Weight ............................................................................................................ 54 
9.6.4 
Electrocardiogram .................................................................................................................... 54 
9.6.5 
Physical and Neurological Examinations and Serotonin Syndrome (Toxicity) ....................... 55 
9.6.6 
Health Economics and Quality of Life Measure ...................................................................... 55 
10 REGULATORY ................................................................................................................................................. 55 
11 APPROVAL OF THE PROTOCOL AND AMENDMENTS ........................................................................ 56 
12 SERIOUS BREACHES ..................................................................................................................................... 56 
13 INFORMED CONSENT ................................................................................................................................... 56 
14 INVESTIGATOR RESPONSIBILITIES......................................................................................................... 58 
15 CONFIDENTIALITY AND DATA PROTECTION ...................................................................................... 59 
16 QUALITY ASSURANCE AND CLINICAL MONITORING ....................................................................... 59 
17 DOCUMENTATION ......................................................................................................................................... 60 
18 PUBLICATION .................................................................................................................................................. 61 
19 INDEMNITY, INSURANCE AND COMPENSATION ................................................................................. 61 
20 ADMINISTRATIVE AND FINANCIAL AGREEMENT .............................................................................. 62 
21 STUDY ADMINISTRATION ........................................................................................................................... 62 
22 REFERENCES ................................................................................................................................................... 63 
23 APPENDICES .................................................................................................................................................... 65 
23.1 
APPENDIX A: ASSESSMENTS BY VISIT ....................................................................................................... 66 
23.2 
APPENDIX B: SUMMARY OF CHANGES TO THE PROTOCOL ........................................................................ 73 
23.2.1 
Protocol Version 1.1 ................................................................................................................ 73 
23.2.2 
Protocol Version 2.0 ................................................................................................................ 74 
23.2.3 
Protocol Version 2.1 ................................................................................................................ 77 
23.2.4 
Protocol Version 3.0 ................................................................................................................ 78 

Protocol: TRx-237-020 
TauRx Therapeutics Ltd 
24 March 2016 
EUDRACT # 2014-002013-37 
Protocol Version 3.0 / 24 March 2016 
CONFIDENTIAL  
 
 
Page 13 of 80 
ABBREVIATIONS 
 Abbreviation 
Definition 
 β-hCG 
beta subunit of human chorionic gonadotropin 
 5-HTP 
5-hydroxytryptophan 
 AA 
Alzheimer’s Association 
 AChEI 
acetylcholinesterase inhibitor 
 AD 
Alzheimer’s Disease 
 AE 
adverse event 
 AESI 
adverse event of special interest 
 ALT 
alanine transaminase 
 AMG 
Arzneimittelgesetz (German Drug Law) 
 ARIA 
amyloid related imaging abnormalities 
 AST 
aspartate transaminase 
 ATC 
Anatomical Therapeutic Classification 
 b.i.d. 
twice daily 
 bpm 
beats per minute 
 bvFTD 
behavioral variant Frontotemporal Dementia 
 °C 
Degrees Celsius 
 CA 
Competent Authority 
 CCA 
cost consequence analysis 
 CFR 
Code of Federal Regulations (United States) 
 CK 
creatine kinase 
 CNS 
Central Nervous System 
 CPMP 
Committee for Proprietary Medicinal Products 
 CRF 
case report form 
 C-SSRS 
Columbia-Suicide Severity Rating Scale 
 CUA 
cost utility analysis 
 CV 
curriculum vitae 
 CYP 
Cytochrome P450  
 DES 
Discrete Event Simulations 
 DSMB 
Data and Safety Monitoring Board  
 EC 
Ethics Committee 
 ECG 
Electrocardiogram 
 eCRF 
electronic case report form  
 EDC 
Electronic Data Capture 
 EQ-5D-5L 
EuroQol – 5 Dimension – 5 Level 
 EU 
European Union 

Protocol: TRx-237-020 
TauRx Therapeutics Ltd 
24 March 2016 
EUDRACT # 2014-002013-37 
Protocol Version 3.0 / 24 March 2016 
CONFIDENTIAL  
 
 
Page 14 of 80 
 Abbreviation 
Definition 
 FDA 
Food and Drug Administration (United States) 
 g, kg, mg 
gram, kilogram, milligram 
 GCP 
Guidelines for Good Clinical Practice 
 GGT 
gamma-glutamyl transpeptidase 
 HDPE 
high-density polyethylene 
 HIPAA 
Health Insurance Portability Accountabilty Act 
 ICER 
incremental cost effectiveness ratio 
 ICF 
informed consent form 
 ICH 
International Conference on Harmonisation 
 IEC 
Independent Ethics Committee 
 IRB 
Institutional Review Board 
 IUD 
intrauterine device 
 IWRS 
interactive web response system 
 L, dL, mL 
liter, deciliter, milliliter 
 LDH 
lactate dehydrogenase 
 LMT 
leuco-methylthioninium 
 LMTB 
leuco-methylthioninium-dihydrobromide 
 LMTM 
leuco-methylthioninium bis(hydromethanesulfonate) 
 MAO A 
monoamine oxidase A 
 MAO B 
monoamine oxidase B 
 MAPT 
microtubule-associated protein tau 
 MCH 
mean corpuscular hemoglobin 
 MCHC 
mean corpuscular hemoglobin concentration 
 MCV 
mean cell volume 
 MedDRA 
Medical Dictionary for Regulatory Activities 
 mg 
milligram 
 mmHg 
millimeters of mercury 
 mmol 
millimole 
 MRI 
magnetic resonance imaging 
 MMSE 
Mini-Mental State Examination 
 msec 
millisecond(s) 
 MT 
Methylthioninium 
 MTC 
methylthioninium chloride 
 NDA 
New Drug Application 
 NIA 
National Institute on Aging 
 P-gp 
P-glycoprotein 
 PE 
physical examination 

Protocol: TRx-237-020 
TauRx Therapeutics Ltd 
24 March 2016 
EUDRACT # 2014-002013-37 
Protocol Version 3.0 / 24 March 2016 
CONFIDENTIAL  
 
 
Page 15 of 80 
 Abbreviation 
Definition 
 QA 
quality assurance 
 QALY 
quality adjusted life years 
 QTcB 
QT interval corrected using Bazett’s formula 
 QTcF 
QT interval corrected using Fridericia’s formula 
 RBC 
red blood cell 
 RUD-Lite 
Resource Utilization in Dementia – short version 
 SAE 
serious adverse event 
 SAP 
statistical analysis plan 
 SOP 
standard operating procedure 
 SSRI 
selective serotonin reuptake inhibitor 
 SUSAR 
suspected, unexpected serious adverse reaction 
 TEAE 
treatment-emergent adverse event 
 UK 
United Kingdom 
 US 
United States of America 
 WBC 
white blood cell 
 WCT 
Worldwide Clinical Trials 
 WHO 
World Health Organization 

Protocol: TRx-237-020 
TauRx Therapeutics Ltd 
24 March 2016 
EUDRACT # 2014-002013-37 
Protocol Version 3.0 / 24 March 2016 
CONFIDENTIAL  
 
 
Page 16 of 80 
2 
BACKGROUND 
Methylthioninium (MT) is proposed for treatment of Alzheimer’s disease (AD) and other 
dementias that involve pathology of the microtubule associated protein tau, and with 
potential for benefit in other progressive neurodegenerative diseases characterized by 
pathological protein aggregation.  The investigational product LMTM (also referred to as 
leuco-methylthioninium dihydromesylate and LMT.2MSOH, as well as by its code name, 
TRx0237) is a crystalline form of the reduced form of the active MT moiety.  
Chemically, the drug is named N,N,N’,N’-tetramethyl-10H-phenothiazine-3,7-diaminium 
bis(methanesulfonate).  It is provided as a solid oral immediate-release dosage form.  As 
a dihydromethanesulfonate salt (also known as dimesylate), LMTM stabilizes the 
reduced form of the MT moiety in the solid state. 
AD is a severe irreversible neurodegenerative disease resulting in complete loss of mental 
faculties.  In AD, the microtubule associated protein tau is redistributed exponentially 
into paired helical filaments forming neurofibrillary tangles which correlate with 
pyramidal cell destruction (Wischik et al., 1997).  There is a robust clinico-pathological 
correlation between tau pathology, tau aggregation, and clinical measures of dementia 
(Bierer et al., 1995; Mukaetova-Ladinska et al., 2000).  These relationships are 
maintained from the earliest detectable stages of dementia and progress in parallel with 
clinical deterioration.  
Behavioral variant frontotemporal dementia (bvFTD) is one of the other dementias under 
investigation.  It is a rare, progressive neurodegenerative disease characterized by 
progressive deterioration of behavior and language, associated with atrophy of the frontal 
and temporal lobes.  Recent developments in molecular genetics and molecular 
neuropathology have confirmed that the diverse histopathological appearances can 
actually be understood at the molecular level to be based on deposition within various 
types of brain cells of aggregated forms of either Tau protein or TDP-43 protein.  It is 
estimated that about half of bvFTD subjects have underlying pathology related to the 
protein Tau (Hodges et al., 2004; Shi et al.; 2005), with approximately 10% having tau 
gene (MAPT) mutations (Rademakers et al., 2004).  MT has the potential to provide 
therapeutic benefit as it is postulated to dissolve neurotoxic aggregates composed of 
microtubule associated protein Tau and TDP-43 in the brain as well as to prevent further 
formation.  
Details regarding nonclinical and clinical findings from completed studies with LMTM, 
LMTB, and MTC are described in the Investigator’s Brochure. 
Double-blind, placebo-controlled trials of LMTM are ongoing in subjects with AD 
(TRx-237-005 and TRx-237-015) and bvFTD (TRx-237-007).  These allow for 12 to 
18 months of double-blind treatment at doses of 150 to 250 mg/day (or placebo), 
depending on the study.  At completion of the study in Studies TRx-237-005 and 
TRx-237-015, subjects are to return for a 4-week post-treatment visit before entering this 
open-label extension study.  Given the nature of the patient population in Study 
TRx-237-007, subjects are not required to return for a 4-week post-treatment visit prior to 
entering this open-label extension study (subjects are only required to return for the post-
treatment visit if they discontinue participation early or complete treatment but do not 
enter this extension study).  As of 30 September 2015 (data available at the time of the 

Protocol: TRx-237-020 
TauRx Therapeutics Ltd 
24 March 2016 
EUDRACT # 2014-002013-37 
Protocol Version 3.0 / 24 March 2016 
CONFIDENTIAL  
 
 
Page 17 of 80 
Development Safety Update Report #4 cut-off date of 14 October 2015), 1902 subjects 
with AD or bvFTD have been randomized to receive study drug (LMTM or matching 
placebo) in the ongoing double-blind Phase 3 studies. 
A double-blind, placebo-controlled, Phase 2 study was also conducted (TRx-237-008), 
however, this study was terminated early for administrative reasons; 9 subjects were 
randomized.  These subjects are also eligible for the open-label extension study. 
The intent of this extension study is to provide LMTM treatment to those subjects in 
whom the benefit is judged to outweigh the risk, and to assess the longer-term safety and 
tolerability of LMTM given in doses of up to 300 mg/day, or in those countries where 
limited by a Competent Authority (CA) or Ethics Committee (EC), 200 mg/day.  
Treatment with LMTM in this study will either be de novo in subjects having been 
randomized to placebo or will be a continuation of treatment, albeit not necessarily at the 
same dose, to those subjects having been previously randomized to LMTM.   
LMTM 150 mg/day is the lowest dose to which a subject participating in the Phase 2 or 
Phase 3 studies may be randomized.  However, 200 mg/day has been chosen as the initial 
dose for continuation of treatment in this open-label extension study as it is intermediate 
to the doses previously used.  This dose has been chosen because 250 mg/day was the 
active treatment in Study TRx-237-008 and is the active treatment for half of the subjects 
receiving LMTM in Study TRx-237-015, and 200 mg/day is the active treatment in 
Studies TRx-237-005 and TRx-237-007.  Subjects previously randomized to placebo will 
receive LMTM for the first time at this dose.  All subjects with AD will have undergone 
at least a 3-week period off-treatment prior to entry into this study; as prior treatment 
assignment will be blinded, this provides a standardized approach for treating all subjects.  
Dose interruptions are allowed at any time (to a maximum of 30 days on a given 
occasion) and dose adjustments are flexible to a minimum of 100 mg/day and a 
maximum of 300 mg/day (or 200 mg/day in those countries where limited by a CA or 
EC), to be based on safety and tolerability and benefit as judged by the investigator.  As 
the acceptable risk/benefit balance will vary from subject to subject, the selection of dose 
is left to the discretion of the investigator, together with the subject and caregiver(s), 
based on judgment of the risk/benefit balance in any given subject.  
Because some subjects will receive LMTM for the first time in this study, the initial 
safety assessments will be made after 2 weeks.  Thereafter, safety assessments will be 
made approximately every 3 months.  Investigators are encouraged to continue with their 
routine clinical assessment of subjects consistent with good clinical practice to evaluate 
continued benefit from study participation. 
Safety assessments are guided by the accruing safety information in the ongoing double-
blind studies.  The majority of the safety evaluations made in the double-blind studies 
will continue; specifically, intervening medical history, adverse events, and concomitant 
medication use will be assessed and recorded; seated blood pressure and pulse as well as 
body weight will be measured; clinical laboratory testing will be performed, including 
serum pregnancy testing in women of childbearing potential; 12-lead electrocardiograms 
(ECGs) will be monitored; and targeted physical and neurological examinations will be 
performed.  The rationale for not mandating routine pulse co-oximetry measurement, 

Protocol: TRx-237-020 
TauRx Therapeutics Ltd 
24 March 2016 
EUDRACT # 2014-002013-37 
Protocol Version 3.0 / 24 March 2016 
CONFIDENTIAL  
 
 
Page 18 of 80 
assessment of the potential for suicide or self-harm, and magnetic resonance imaging 
(MRI) for amyloid related imaging abnormalities (ARIA) is given below: 
• Routine pulse co-oximetry has been included in all studies performed to date.  As 
of 17 August 2015, 6 subjects (< 1%) in the ongoing Phase 3 trials have had a 
methemoglobin value >3.5% (the pre-specified threshold for possible clinical 
significance); all were isolated values, the highest of which was 8%.  Relevant 
laboratory-related adverse events of special interest (AESIs) have been reported in 
only 5 subjects (< 1%):  positive Heinz bodies (without other evidence of 
hemolytic anemia, considered a false positive due to a prolonged delay in 
preparing the slides for testing); hemolytic anemia (Heinz body negative, 
recovered with treatment interruption); and 3 reports of isolated increased 
methemoglobin.  Pulse co-oximeters will not be routinely provided to sites and no 
specific monitoring is mandated in this open-label extension study protocol.   
• The Columbia-Suicide Severity Rating Scale (C-SSRS), which queries five 
aspects of suicidal ideation, is evaluated at each visit in the primary double-blind 
study of participation.  While not validated for use in patients with dementia, the 
scale has been used in other studies of CNS-active medications and provides a 
systematic means of collecting data in dementing syndromes for future potential 
regulatory use.  As of 17 August 2015, 69 unique subjects across the ongoing 
double-blind Phase 3 studies have reported experiencing suicidal thoughts.  There 
were 64 subjects with an on-treatment affirmative C-SSRS score (regardless of 
pre-treatment score) and 5 subjects with suicidal ideation recorded as an adverse 
event that was not identified via the C-SSRS.  The majority of cases represented a 
general “wish to be dead”.  Such feelings are not uncommon in these patient 
populations.  This scale will continue to be used in the double-blind Phase 3 
studies but not in the open-label extension study as any emergent change is likely 
to be attributable to the evolution of the underlying disease.  At entry into the 
extension study, subjects receiving active medication will already have been 
followed for approximately 12 to 19 months for drug-induced change. 
• As of 30 September 2015, ARIA has been reported for 12 of 1902 subjects, 
representing 0.6% of subjects, comparable to or lower than the incidence reported 
for subjects randomized to placebo in four recently published large Phase 3 
studies (two studies per publication) of humanized anti-amyloid-beta monoclonal 
antibodies, solanezumab and bapineuzumab (Doody et al., 2014; Salloway et al., 
2014).  Thus, the frequency of ARIA is not considered to represent a safety signal 
and MRI monitoring for ARIA will not be undertaken in this open-label extension 
study.   
Electronic Case Report Forms (eCRFs) will be available for recording results of 
additional safety evaluations should these be warranted in the opinion of the investigator 
to further evaluate a change in a subject’s status (e.g., pulse co-oximetry).   
The need for additional safety monitoring for any given subject is to be judged by the 
investigator based on historical information for the subject from the respective 
originating double-blind study and/or repeat of selected baseline testing as well as 
ongoing review of safety measurements made during this open-label extension study.   

Protocol: TRx-237-020 
TauRx Therapeutics Ltd 
24 March 2016 
EUDRACT # 2014-002013-37 
Protocol Version 3.0 / 24 March 2016 
CONFIDENTIAL  
 
 
Page 19 of 80 
The formal efficacy rating scales used in the double-blind studies will not be continued 
given the open-label design of this extension study; however, resource utilization and 
quality of life will be evaluated approximately every 6 months.   
 
3 
OBJECTIVES 
The primary objectives of this open-label extension study are to provide subjects who 
have completed participation in a Phase 2 or Phase 3 trial continued access to therapy and 
to evaluate the long-term safety and tolerability of LMTM given in flexible doses of up to 
300 mg/day (or in those countries where limited by a CA or EC, 200 mg/day). 
 
4 
STUDY DESIGN  
4.1 
General Description 
This study is a multicenter, open-label extension study of LMTM in subjects with mild to 
moderate AD or bvFTD at the time they first enrolled in a double-blind trial.   
Participation in this study will be offered to any subject who completed participation in a 
TauRx-sponsored Phase 2 or Phase 3 double-blind study, i.e., Studies TRx-237-005, 
TRx-237-007, TRx-237-008, or TRx-237-015.  Only AD subjects who have completed 
the full double-blind period of the originating studies (including the 1-month post-
treatment follow-up), or bvFTD subjects who completed the full double-blind treatment 
period through Visit 9 in TRx-237-007, will be eligible for inclusion in this open-label 
extension study (see Section 6.2.1 for guidance regarding study drug dosing for bvFTD 
subjects entering this extension study).  
Subjects may enter this study at the final designated visit in the double-blind study, 
provided subjects and caregivers have had sufficient time to consider the study prior to 
giving consent, or at any subsequent time.  Subjects may continue participation at the 
same site at which they participated in the originating double-blind study or transfer to a 
geographically close investigational site (that also participated in the same study). 
Eligibility for continued open-label treatment is to be determined by the original 
investigator and, if applicable, a referral to a new site made.  The new investigator will 
have access to the subject’s prior study eCRFs and is to confirm eligibility (see 
Section 5); Baseline testing can be repeated as necessary in the judgment of the new 
investigator.  The initial visit will be designated Visit 1. 
The initial LMTM dose is 200 mg/day (one 100-mg tablet twice daily [b.i.d.]).  The dose 
may be increased (at Visit 3 or at any subsequent dispensing visit as determined by the 
investigator during the treatment period) to a maximum of 300 mg/day (or in those 
countries where limited by a CA or EC, 200 mg/day) in response to benefit as judged by 
the investigator.  Alternatively, the dose may be interrupted at any time (for up to 30 days 
on a given occasion) or decreased to a minimum of 100 mg/day (at any time at or after 
Visit 2) as needed in response to safety assessments (see Section 6.2.2).  The 
recommended decrement or increment of dose adjustment is 100 mg/day.  The study drug 
will be dispensed in 13-week (± 2-week) supplies. 

Protocol: TRx-237-020 
TauRx Therapeutics Ltd 
24 March 2016 
EUDRACT # 2014-002013-37 
Protocol Version 3.0 / 24 March 2016 
CONFIDENTIAL  
 
 
Page 20 of 80 
The first on-treatment visit will occur approximately 2 weeks after Visit 1 (designated 
Visit 2) for the initial post-treatment safety assessment.  Thereafter, subjects will be seen 
in the clinic at approximately every 13 weeks (relative to Baseline).  Required 
assessments will be performed at all visits as described in the Schedule of Assessments in 
Section 4.4 and, for further detail, in Section 7; additional optional safety assessments are 
also described.  Caregivers will be contacted by telephone at the mid-point between 
Visits 2 and 3; they will also be asked to contact the investigator in response to any safety 
concern.  An unscheduled visit will be arranged to assess the subject as needed.    
Resource utilization and quality of life will be evaluated as described in Section 8. 
Continued participation will be re-evaluated approximately every 12 months on the basis 
of safety, tolerability, and continued benefit as judged by the investigator.  Subjects 
deemed eligible for continued treatment (and/or their caregivers) must provide informed 
consent for re-enrollment.  Subjects for whom consent is not provided consistent with 
national requirements and IRB/EC approval will be discontinued. 
For subjects who cease to take LMTM, a post-treatment follow-up visit 4 weeks after the 
last dose of study drug is to be scheduled, regardless of the reason for discontinuation.  
Subjects who fail to complete the initial 12-month extension period will not be eligible to 
continue to receive treatment during any subsequent extension period. 
A schematic representation of the first 12 months of the study is provided in Figure 4-1. 
Figure 4-1 
Schematic Representation of Study (First 12 Months) 
 
← Open-Label Treatment → 
LMTM 200 mg/day initial dose and flexible dosing thereafter (to max. 300 mg/day and min. 100 mg/day a) 
 (52 weeks) 
← Follow up → 
(4 weeks after last 
dose) 
 
 
First dose of open-label treatment                                                                            Last dose b      
↓                                                                                                                                                 ↓  
 
Follow up Visit c 
↓ 
 
Visit  
↑ 
1 
↑ 
2 a 
(T) d 
↑ 
3 a  
 
↑ 
4 
 
↑ 
5 
 
↑ 
6 
↑ 
-- 
 
 
 
 
 
 
 
 
 
 
 
 
Week 
0 
2 
6 
13 
 
26 
 
39 
 
52 
56 
 
 
 
 
 
 
 
 
 
 
 
 
Day 
(± days) 
1 
15 
(3) 
43 
(14) 
92 
(14) 
  
183 
(14) 
  
274 
(14) 
  
365 
(14) 
393 
(14) 
a In those countries where limited by a CA or EC, the maximum allowable dose is 200 mg/day. The dose may be 
increased (at Visit 3 or at any subsequent dispensing visit as determined by the investigator during the treatment period) 
or decreased (at any time at or after Visit 2) on the basis of safety; the dose may be interrupted at any time (for up to 
30 days on a given occasion).  See Section 6.2.2 for more details regarding dose reduction or interruption due to safety 
and tolerability. 
b For subjects who do not re-enroll for a subsequent extension of treatment, identified end of treatment evaluations will 
be performed at the final on-treatment visit (Visit 6).  If a subject discontinues prematurely, an early termination visit 
should be conducted at which time all assessments identified for Visit 6 should be performed.  Continued participation 
will be re-evaluated approximately every 12 months on the basis of safety and continued benefit; informed consent for 
continued treatment must be provided.  The same visit schedule (with the exception of the initial 2-week visit) will be 
followed for each 12-month treatment period; scheduled visits will be numbered in an ascending fashion. 
c All subjects who discontinue treatment or who do not wish to proceed to the subsequent extension phase will be seen 
for a post-treatment follow-up visit 4 weeks after the last dose of study drug. 
d A telephone contact (T) will occur between the scheduled Weeks 2 and 13 study visits (at approximately Week 6). 

Protocol: TRx-237-020 
TauRx Therapeutics Ltd 
24 March 2016 
EUDRACT # 2014-002013-37 
Protocol Version 3.0 / 24 March 2016 
CONFIDENTIAL  
 
 
Page 21 of 80 
4.2 
Population 
Subjects enrolled into this study will either have a diagnosis according to the National 
Institute on Aging / Alzheimer’s Association (NIA/AA) criteria of all cause dementia and 
probable Alzheimer’s disease or a diagnosis of probable bvFTD according to the 
International Consensus Criteria for bvFTD (Rascovsky et al., 2007).   
Subjects must have completed participation for the full double-blind period in a TauRx-
sponsored Phase 2 or 3 double-blind clinical trial in AD (TRx-237-005 [19 months], 
TRx-237-008 [2 months], or TRx-237-015 [16 months2], including the 4-week off-
treatment follow-up visit) or for the full double-blind period of 12 months (through 
Visit 9) in TRx-237-007.  Subjects who have withdrawn from the original study, or who 
have had any treatment interruption longer than 30 days making them ineligible to 
continue in the original study, will not be eligible to participate in the extension study.  In 
the opinion of the principal investigator, there should be a reasonable expectation of 
continued benefit and that safety and tolerability findings would not pose an unacceptable 
risk; see Section 2 for a discussion regarding judgment of the risk/benefit balance in any 
given subject as well as appropriate safety monitoring in this open-label extension study.  
The study will be open only to approximately 170 participating sites in North America, 
Asia, Australia, and Europe.  If all eligible subjects elect to continue treatment (assuming 
60 to 80% completion), it is anticipated that as many as approximately 1050 to 
1400 subjects may enroll. 
4.3 
Duration 
The study will continue until alternate options for access to treatment are available, i.e., 
commercialization or, depending on country, on a Named Patient or compassionate basis, 
or availability via a Managed Access Program.  (See Section 5.4 for a discussion of other 
reasons for study termination.) 
4.4 
Schedule of Assessments 
Baseline safety assessments may be made at the final designated visit of the prior TauRx 
study in which the subject was enrolled.  For purposes of the open-label extension, these 
will be designated as Baseline (Visit 1, Day 1).  If Visit 1 does not coincide with the final 
designated visit of the previous double-blind study of participation, medical history, 
concomitant medication use, and adverse events should be updated; serum pregnancy 
testing should be performed in women of childbearing potential.  If more than 42 days 
have elapsed since that final visit, additional baseline safety assessments must be 
repeated.  The additional safety assessments include clinical laboratory testing (e.g., 
hematology and serum chemistry panels), seated blood pressure and pulse, body weight, 
12-lead ECG testing, and targeted physical and neurological examinations (including 
serotonin toxicity assessments).  Baseline assessments may be repeated (also within 
42 days) as determined by the new investigator for subjects transferring to a different site. 
                                                 
2 Subjects who participated in Study TRx-237-015 and did not consent to extended treatment for up to 
15 months as per Protocol Version 3.0 (extended from 12 months as per the original study protocol) may 
be enrolled into this open-label extension study following completion of the 12-month double-blind 
treatment period and 4-week post-treatment follow-up visit for Study TRx-237-015. 

Protocol: TRx-237-020 
TauRx Therapeutics Ltd 
24 March 2016 
EUDRACT # 2014-002013-37 
Protocol Version 3.0 / 24 March 2016 
CONFIDENTIAL  
 
 
Page 22 of 80 
During the first year, post-Baseline study visits will occur at approximately 2 weeks 
(Visit 2), 13 weeks (Visit 3), 26 weeks (Visit 4), 39 weeks (Visit 5), and 52 weeks 
(Visit 6) after Baseline.  Caregivers will be contacted by telephone at approximately 
6 weeks after Baseline (the intervening time between Visits 2 and 3).   
The majority of the safety assessments (described further in Section 7) will be repeated at 
each visit, i.e., approximately 2 weeks post-Baseline and at visits occurring 
approximately every 3 months (13 weeks) relative to Baseline.  These assessments 
include adverse event and concomitant medication recording, seated blood pressure and 
pulse, body weight, clinical laboratory testing (e.g., hematology and serum chemistry 
panels), serum pregnancy testing in women of childbearing potential, and targeted 
physical and neurological examinations.  The 12-lead ECGs will be obtained 
approximately every 6 months (26 weeks) relative to Baseline.  Throughout the 
assessments for safety, the investigator is to be cognizant of the potential for serotonin 
toxicity, taking the MMSE into consideration as well.   
The EQ-5D-5L, applied to the subject and to the caregiver on behalf of the subject, will 
be evaluated at Baseline (as it is not used in the Phase 3 studies of prior participation).  
The RUD-Lite will be also be evaluated at Baseline if not available from within the prior 
42 days.  These evaluations will be repeated approximately every 6 months (26 weeks) 
relative to Baseline. 
The same aforementioned 13-week and 26-week schedules of in-clinic assessments will 
be maintained for continued treatment beyond the first 12 months (if there is re-consent at 
Visit 6), with no requirement for the Week 2 visit or Week 6 telephone contact in the 
second or any subsequent year of participation.  Continued treatment will be restricted to 
those subjects for whom continued benefit is expected by the investigator to outweigh 
risk and informed consent is provided.  
For subjects who do not re-enroll for a subsequent extension of treatment, identified end 
of treatment evaluations will be performed at the final on-treatment visit (e.g., Visit 6).  If 
a subject discontinues prematurely, an early termination visit should be conducted at 
which time all assessments identified for Visit 6 should be performed.   
Post-treatment safety assessments will be conducted at a follow-up visit, to be scheduled 
to occur approximately 4 weeks after the last dose of study drug for all subjects who 
cease to take LMTM (regardless of the reason for discontinuation). 
A schedule of assessments is shown in Table 4-1.  Assessments are listed by visit in 
Appendix A: Assessments by Visit. 

Protocol: TRx-237-020 
TauRx Therapeutics Ltd 
24 March 2016 
EUDRACT # 2014-002013-37 
Protocol Version 3.0 / 24 March 2016 
CONFIDENTIAL  
 
 
Page 23 of 80 
Table 4-1 
Schedule of Assessments 
Visit Name 
Baseline a 
First 12 Month Open-Label Extension b 
Follow-up c 
Overall Visit Number: 
1 
2 
3 
4 
5 
6 
Months Relative to Baseline Day: 
-- 
-- 
-- 
-- 
3 
6 
9 
12 
13 
Weeks Relative to Baseline Day: 
2 
13 
26 
39 
52 
56 
(Allowable Time Window in days): 
(± 3) 
(± 14) 
(± 14) 
(± 14) 
(± 14) 
(± 14) 
Informed Consent (Subject and Caregiver) (M) 
X 
 
 
 
 
X d 
 
Inclusion/Exclusion Criteria Review (M) 
X 
 
 
 
 
 
 
Concomitant Medication Recording/Review (M)  
X* 
X 
X 
X 
X 
X 
X 
Adverse Events / Medical History Review (M) 
X* 
X 
X 
X 
X 
X 
X 
Study Drug Dispensing 
X 
 
X 
X 
X 
X d 
 
Study Drug Compliance Assessment e 
 
X 
X 
X 
X 
X 
 
Blood Samples for Laboratory Tests  
X* 
X 
X 
X 
X  
X 
X 
Serum Pregnancy Test (women of childbearing potential) 
X* 
X 
X 
X 
X 
X 
X 
Seated Blood Pressure and Pulse  
X* 
X 
X 
X 
X 
X 
X 
Temperature and Respiratory Rate 
X* 
X 
X 
X 
X 
X 
X 
Body Weight 
X* 
X 
X 
X 
X 
X 
X 
12-Lead Electrocardiogram f 
X* 
 
 
X 
 
X 
X 
Physical and Neurological Examination (M) g 
X* 
X 
X 
X 
X 
X 
X 
MMSE h 
X* 
 
 
X 
 
X 
X 
RUD-Lite 
X* 
 
 
X 
 
X 
 
EQ-5D-5L i 
X 
 
 
X 
 
X 
 
Notes:  (M) = requires medical assessor   
a 
Unless otherwise indicated, the safety assessments completed at the final designated visit of the prior TauRx double-blind study 
in which the subject was enrolled will serve as Baseline (Day 1) for this extension study and are not required to be repeated.  If 
the final visit does not coincide with the open-label Baseline visit, changes in medical history, adverse events, and concomitant 
medication use are to be recorded, and serum pregnancy testing in women of childbearing potential performed.  If it occurred 
more than 42 days prior, the assessments indicated by an asterisk (*) are to be repeated.  Baseline assessments may be repeated 
(also within 42 days) as determined by the new investigator for subjects transferring to a different site. 
b Study visits during the treatment period are to occur within stipulated time windows.  If a visit is delayed, the next visit should 
occur earlier to return to the schedule.  After the Day 1 visit (Visit 1), a documented telephone contact will occur between the 
scheduled Visit 2 and 3 study visits, scheduled to occur at approximately Week 6 (± 14 days) and will include AE and 
concomitant medication review.  Subjects who complete 52 weeks of treatment (Visit 6, 10, etc.) will be offered an opportunity 
to continue with open-label treatment if, in the opinion of the principal investigator, the potential benefit continues to outweigh 
the risk; informed consent must be obtained at each re-enrollment for any subsequent 12-month treatment extension.  The same 
schedule will be followed in subjects who enter subsequent 12-month extension phases, i.e., safety visits approximately every 
13 weeks (with no requirement for the Week 2 visit or Week 6 telephone contact in any subsequent year of participation), as 
well as resource utilization and quality of life assessments approximately every 6 months; visits will be numbered in an 
ascending fashion.  For subjects who do not re-enroll for a subsequent extension of treatment, identified end of treatment 
evaluations will be performed at the final on-treatment visit (Visit 6); if a subject discontinues prematurely, an early termination 
visit should be conducted at which time all assessments identified for Visit 6 should be performed.   
c 
An off-treatment follow-up visit is to be scheduled (approximately 4 weeks after the last dose of study drug) for all subjects 
who cease to take LMTM (regardless of the reason for discontinuation). 
d For subjects who wish to proceed to an additional extension phase, informed consent will be obtained at Visit 6 for continued 
participation.  If informed consent is obtained, study drug dispensing will also occur at Visit 6. 
e 
Compliance with study drug will be assessed by questioning the subject and caregiver at Visit 2; thereafter, compliance will 
also be assessed by counting returned tablets (in addition to questioning the subject and caregiver).  
f 
A 12-lead ECG of at least 10 seconds in duration will be obtained in triplicate (taken within a period of 5 minutes) and 
evaluated by a centralized ECG reading facility approximately every 6 months and at the 4-week follow-up visit (if applicable).  
g Targeted physical and neurological examinations are to be performed at each visit (or upon early termination), including the 
4-week follow-up visit if applicable; these targeted examinations will include assessments for signs and symptoms indicative of 
potential serotonin toxicity (see Section 7.1.3.2 for guidance on assessment). 
h  The MMSE will be performed approximately every 6 months and at the 4-week follow-up visit (if applicable) to inform the 
evaluation for possible serotonin toxicity (to be included in the targeted physical and neurological examinations). 
i 
There will be two applications of the EQ-5D-5L at each visit:  one version will be completed by the subject and a second copy 
of this version will be completed by the caregiver (see Section 8.3 for further detail). 

Protocol: TRx-237-020 
TauRx Therapeutics Ltd 
24 March 2016 
EUDRACT # 2014-002013-37 
Protocol Version 3.0 / 24 March 2016 
CONFIDENTIAL  
 
 
Page 24 of 80 
 
4.5 
Assignment of Treatment  
This is not applicable to this open-label study as all subjects will receive LMTM.  
Treatment assignment from the prior double-blind clinical study will be recorded in 
listings; however, this information will remain unknown to the subject and caregiver as 
well as to the investigator and study site personnel until the blind for the respective 
double-blind trial has been broken.    
Subjects will be assigned a study identification number with the first three digits for the 
study (020), the next two letters for the country, the next three digits for the site, and the 
last two digits for the sequential order of enrollment at a given site. 
4.6 
Study Treatment  
The initial LMTM dose for all subjects will be 200 mg/day.  Thereafter, dosing will be 
flexible (in 100-mg decrements or increments).  The dose may be increased (at Visit 3 or 
at any subsequent dispensing visit as determined by the investigator during the treatment 
period) or decreased (at any time at or after Visit 2) in response to benefit as judged by 
the investigator and safety and tolerability.  The maximum allowable dose is 300 mg/day 
(or in those countries where limited by a Competent Authority or Ethics Committee, 
200 mg/day).  The dose may also be interrupted at any time as needed (for up to 30 days 
at any one time). 
Study drug and regimens, including dose interruptions and modifications in response to 
adverse events, are further described in Section 6. 
4.7 
Concomitant Medication 
Current medications (and medications used since the last double-blind visit in the prior 
study of participation) will be recorded using the eCRF mapped from the originating 
double-blind study of prior participation.  “Medication” is used to encompass prescription 
and over-the-counter drugs or biologics, vitamins used in supra-pharmacologic doses, 
alternative pharmacotherapies for dementia, medical foods, and for women, forms of 
contraception.  At each scheduled or unscheduled visit, and at each telephone contact, 
any changes to existing concomitant medications and any new concomitant medications 
will be reviewed and recorded. 
It is desirable, but not mandatory, that concomitant medications identified at Baseline be 
maintained at a constant dose for the duration of the study if clinically indicated.  The 
investigator should evaluate any changes in the dose of existing concomitant medications 
and/or initiation of new concomitant medications, and the medical monitor should be 
contacted to discuss any concerns as needed.  The date of commencement, dose, and date 
of any change of dose of concomitant medications are to be recorded in the eCRF. 
4.7.1 
Dementia Medication 
Subjects are allowed to take an AChEI and/or memantine, a medical food (e.g., Axona, 
Souvenaid) or a stable dose of alternative pharmacotherapy for dementia (e.g., Vitamin E, 
folate [in doses up to 5 mg/day; doses of approximately 1 mg/day in the management of 

Protocol: TRx-237-020 
TauRx Therapeutics Ltd 
24 March 2016 
EUDRACT # 2014-002013-37 
Protocol Version 3.0 / 24 March 2016 
CONFIDENTIAL  
 
 
Page 25 of 80 
folate deficiency are acceptable], a specific neurocognitive vitamin formulation [such as 
NeuroVits comprising 20 mg Vitamin B6, 1 mg Vitamin B12, 0.8 mg folate], ginkgo 
biloba, hormone replacement therapy, treatments related to coconut oil, or circumin).  
Ideally, the dosage and time of dosing should remain unchanged during participation in 
the study.  There are no restrictions for other non-pharmacological treatments during the 
treatment period. 
Results suggest that MT may inhibit cytochrome P450 3A4 (CYP3A4), an enzyme 
system that is involved in the metabolism of two of the AChEIs allowed in the study, 
donepezil and galantamine.  Because drug-drug interaction studies have not been 
performed with these drugs, it is not known whether systemic exposure to either of these 
drugs will increase or by how much.  Therefore, subjects receiving these drugs should be 
monitored and if adverse events suggest an increase in systemic exposure, dose 
adjustment of donepezil or galantamine may be considered.  If any change in dose occurs 
for whatever reason, the subject may continue on study drug unless it is judged to pose a 
risk to the subject.   
4.7.2 
Drugs with Serotonergic Potential 
The oxidized form of MT (MT+) is an inhibitor of MAO A and B in vitro, and the 
investigator should be aware of the potential for drug interaction resulting in serotonin 
syndrome (toxicity).  Recent (within five to seven plasma half-lives) or current treatment 
with medications identified by FDA in an October 2011 Safety Alert (augmented to 
include drugs not approved in the United States) should be undertaken only if the 
potential benefit is judged to outweigh the risk.  Refer to the Investigator’s Brochure for a 
list (not exhaustive) of such medications and their plasma half-lives (majority taken from 
U.S. approved product labeling).  It should be noted that some of these are available 
without prescription and their use should also be recorded in the eCRF.  
Drugs with serotonergic potential may be initiated after Visit 3 (Week 13) provided 
potential benefit is judged by the investigator to outweigh risk.  The subject's general 
practitioner will be informed of the potential risk.   
Guidance for monitoring subjects for potential serotonin toxicity, to be undertaken 
whether or not a subject is on serotonergic drugs, is described in Section 7.1.3.2. 
Note, dietary supplements containing tryptophan or its metabolite 5-hydroxytryptophan 
(5-HTP) are considered serotonergic concomitant medications as 5-HTP is a precursor in 
the biosynthesis of serotonin.  Tryptophan is a naturally-occurring protein, however, 
eating foods containing tryptophan does not significantly increase 5-HTP levels; thus, 
avoiding dietary sources of tryptophan is not necessary.  
In the event of any question, the medical monitor should be consulted. 
4.7.3 
CYP and P-gp Substrates 
Results of a recently completed drug-drug interaction study indicate that MT is a weak 
inhibitor of CYP3A4, CYP2C8, and CYP2C19 enzymes (see the Investigator’s Brochure 
for examples of drugs metabolized by these enzymes).  The extent to which this occurs 
within a given individual or with a given drug is not known, especially for those drugs 
with multiple metabolic pathways.  Therefore, subjects on drugs known to be 

Pr ot oc ol: T R x -2 3 7 -0 2 0  
T a u R x T hera pe utics Lt d  
2 4 Marc h 2 0 1 6  
E U D R A C T #  2 0 1 4 -0 0 2 0 1 3 -3 7  
Pr ot oc ol V ersi o n 3. 0 / 2 4 Marc h 2 0 1 6  
C O N FI D E N TI A L    
  
 
P a ge 2 6  of 8 0 
meta b olize d b y o ne or m ore of t hese e nz y mes (es peciall y t h ose t hat ha ve a narr o w 
t hera pe utic i n de x) s h o ul d be cl osel y m o nit ore d f or a d verse e ve nts t hat c o ul d s u g gest a n 
i ncreas e i n s yste mic e x p os ure.  Dose a dj ust me nt of t he c o nc o mita nt me dicati o n ma y b e 
warr a nte d.   
L M T M is als o a w ea k i n d ucer of C Y P 2 B 6 a n d t h e P - gl yc o pr otei n ( P-g p) tra ns p orter (see 
t he I n v esti gat or’s Br oc h ure f or e x a m ples of s u bstrates).  C oa d mi nistrati o n of L M T M 
wit h di g o xi n, a P- g p s u bstrate, was s h o w n t o res ult i n decrease d c o n ce ntrati o ns of 
di g o xi n.  T heref or e, it is a d visa ble t o o btai n a bas eli ne di g o xi n le vel i n s u bjects o n t his 
dr u g a n d t o m o nit or di g o xi n le vels peri o dicall y w hile o n st u d y.  A n y s uc h res ults 
o btai ne d fr o m t he l ocal la b orat or y s h o ul d be e ntere d i nt o t he e C R F (t o get h er wit h t he 
ti me of t he pri or d ose of di g o xi n a n d t he ti me of t he sa m ple). 
4. 7. 4  
Dr u gs Use d t o M a n a ge Be h avi or al Dist ur b a nce 
S u bjects ma y be treat e d wit h a nti ps yc h otics ( ot her t ha n cl oza pi ne or ola nz a pi ne).  S h o ul d 
treat me nt be i nitiate d d uri n g t his o pe n-la b el e xte nsi o n, t he reas o n(s) s h o ul d be clearl y 
d oc u me nte d b y i n dicati n g o ne or m ore of t he f oll o wi n g reas o ns:  del usi o ns, 
hall uci nati o ns, a gitati o n/ a g gressi o n, de pressi o n, a n xiet y, el ati o n/e u p h oria, 
a pat h y/i n differ e nce, disi n hi biti o n, irrita bilit y/la bilit y, a b erra nt m ot or be ha vi or, ni g htti me 
be ha vi or, or a p petite/eati n g c h a n ge.  
“ As- nee de d” us e of a nti ps yc h otics is t o be a v oi d e d if p ossi ble, b ut s uc h use d oes n ot 
precl u de f urt her p artici pati o n.  Si milarl y, re g ul ar or occasi o n al use of be nz o diaze pi nes t o 
ma na ge distress, a gitati o n, etc. d oes n ot precl u de f urt her partici pati o n.     
4. 7. 5  
Ot her Me dic ati o ns  
A n xi ol ytics a n d/ or se d ati ves/ h y p n otics ma y b e use d as se dati o n f or cla ustr o p h o bia or 
a gitati o n.  Re g ular or occasi o na l be nz o diaze pi nes, c hl oral h y drat e, l o w d ose traz o d o ne 3 
( 5 0 m g) or z ol pi de m ma y be use d as nee de d at be dti me  f or slee p. 
U nless ot her wise pr o hi bite d, c o nc o mita nt me dicati o ns ( prefera bl y at sta ble d oses) 
c o nsi dere d a p pr o priat e b y t he s u bject’s p h ysicia n are all o w a ble b ut s h o ul d be ke pt t o t he 
mi ni m u m p ossi ble as cli nicall y i n dicat e d.  If t here are q u esti o ns a b o ut w h et her or n ot a 
me dicati o n is per mitte d i n t he st u d y, t he me dical m o nit or s h o ul d be c o ns ulte d.  
4. 7. 6  
Diet ary Tyr a mi ne  
Hist oricall y, M A O i n hi bit ors as a class h a ve bee n re p orte d t o be ass ociate d wit h 
h y perte nsi ve crises ca us e d b y i n gesti o n of f o o ds c o ntai ni n g hi g h a m o u nts of t yra mi ne 
( k n o w n as a t yr a mi ne or "c h eese" reacti o n). W hile t here is a t he oretical p ot e ntial f or a 
t yra mi ne reacti o n wit h M T, t here ha v e bee n n o re p orts t o date i n s u bjects ta ki n g part i n 
Ta u R x -s p o ns ore d st u dies, e ve n t h o u g h t here h a ve bee n n o dietar y restricti o ns i n t hese 
st u dies. N o net heless, as a preca uti o n, s u bjects a n d t heir care gi vers s h o ul d b e a d vise d 
a b o ut t his p ote ntial w hile ta ki n g L M T M (s ee t he I n vesti gat or’s Br oc h ure f or e x a m ples of 
t yra mi ne-ric h f o o ds a n d be vera ges, s uc h as air- drie d, a ge d or fer m e nte d meats a n d 
                                                 
3  If traz o d o ne is use d i n t his wa y, ste ps m ust be i m ple me nte d f or m o nit ori n g si g ns a n d s y m pt o ms 
i n dicati ve of p ote ntial ser ot o ni n t o xicit y. 

Protocol: TRx-237-020 
TauRx Therapeutics Ltd 
24 March 2016 
EUDRACT # 2014-002013-37 
Protocol Version 3.0 / 24 March 2016 
CONFIDENTIAL  
 
 
Page 27 of 80 
cheeses, fava bean pods, non-pasteurized beers, sauerkraut, and most soybean products). 
They should also be advised to seek medical care immediately in the event of signs or 
symptoms of hypertensive crisis (sudden onset of severe headache, nausea, stiff neck, 
tachycardia or palpitations, profuse sweating, and/or confusion) or other sudden or 
unusual symptoms following ingestion of tyramine-rich foods or beverages. 
4.7.7 
Contraceptive Measures 
As a precautionary measure, women of childbearing potential (i.e., not documented to be 
post-menopausal for at least 1 year or not having undergone hysterectomy or bilateral 
salpingectomy or oophorectomy for at least 6 months minimum) must use adequate 
contraception with the exception of female subjects in Italy.  Examples of adequate 
contraception include bilateral tubal ligation or occlusion at least 6 months prior to 
Baseline; use of a barrier method (condom, diaphragm or cervical/vault cap) with 
spermicidal foam, gel, film, cream, or suppository; intrauterine device (IUD) or system; 
oral or long acting injected or implanted hormonal contraceptives for at least 3 months 
prior to Baseline; or sexual activity restricted to a vasectomized partner (with the 
appropriate post-vasectomy documentation of the absence of spermatozoa in the 
ejaculate).  Abstinence is only acceptable as true abstinence when this is in line with the 
subject’s preferred and usual lifestyle; periodic abstinence (e.g., calendar, ovulation, 
symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of 
birth control.  Subjects must be competent to use adequate contraception and must agree 
to continue to maintain adequate contraceptive measures throughout study participation 
and until the final off-treatment visit.  In Italy, subjects must accept to avoid a pregnancy 
throughout participation in the study.  Women of childbearing potential should be 
encouraged to return to the clinic in the event of a delayed menstrual period to rule out 
possible pregnancy.  
Males should practice abstinence or use acceptable birth control with any female sexual 
partner of childbearing potential.  The risk of drug secretion through the ejaculate is not 
fully studied.  To ensure that the fetus is not exposed to MT through vaginal absorption, 
male subjects (including men who have had vasectomies) whose partners are pregnant 
should use condoms for the duration of the study and for an additional 4 days after 
cessation of study treatment.  The investigator must provide appropriate counsel to male 
subjects regarding this issue. 
4.7.8 
Folate and Vitamin B12 
Folate and Vitamin B12 are necessary for the production and function of red blood cells.  
Given the risk of anemia with the use of MT, it is important that subjects not become 
deficient in folate and/or Vitamin B12 while on study.  Chronic hemolytic anemia depletes 
folate stores, and it is general medical practice to place all hematology patients with risk 
of chronic hemolytic anemia on prophylactic folate replacement, with a recommended 
dose of 1 mg by mouth, per day.  

Protocol: TRx-237-020 
TauRx Therapeutics Ltd 
24 March 2016 
EUDRACT # 2014-002013-37 
Protocol Version 3.0 / 24 March 2016 
CONFIDENTIAL  
 
 
Page 28 of 80 
4.8 
Data and Safety Monitoring Board / Independent Data Monitoring 
Committee 
Safety will be overseen by a DSMB throughout the duration of study conduct.  At any 
time, the DSMB may recommend that dosing be modified or enrollment stopped due to 
safety concerns; the DSMB may also request to receive additional data for individual 
subjects in response to identified safety concerns. 
Routine meetings are to be scheduled as determined by the DSMB.  Ad hoc meetings will 
be convened if needed in response to safety concerns.  This DSMB will also be assessing 
data from other clinical studies sponsored by TauRx with the same active moiety.  The 
DSMB Charter will describe the composition of the DSMB and safety monitoring details, 
as well as the frequency of meetings needed as the study progresses.  
 
5 
SELECTION OF SUBJECTS AND CRITERIA FOR WITHDRAWAL 
To be eligible for enrollment in this extension study, a subject must meet all of the 
inclusion and exclusion criteria listed below. 
5.1 
Inclusion Criteria  
1. Subjects with a diagnosis according to NIA/AA criteria of all cause dementia and 
probable Alzheimer’s disease at enrollment and who completed participation in 
one of the following three TauRx studies (inclusive of the 4-week post-treatment 
follow-up visit):  TRx-237-005, TRx-237-008, or TRx-237-0154.   
 
OR 
 
Subjects with a diagnosis of probable bvFTD according to the International 
Consensus Criteria for bvFTD at enrollment and who completed participation in 
TauRx study TRx-237-007 through Visit 9 (Week 52). 
 
Treatment will not be made available to subjects who have withdrawn from the 
double-blind study of prior participation prior to completion.  
2. Females of childbearing potential must continue to use adequate contraception 
defined as follows (or, if in Italy, agree to avoid pregnancy):  
• Barrier method (such as condom, diaphragm or cervical/vault cap) with 
spermicidal foam, gel, film, cream, or suppository 
• Intrauterine device [IUD] or system 
• Oral or long-acting injected or implanted hormonal contraceptives for at least 3 
months prior to Baseline 
                                                 
4 Subjects who participated in Study TRx-237-015 and did not consent to extended treatment for up to 
15 months as per Protocol Version 3.0 (extended from 12 months as per the original study protocol) may 
be enrolled into this open-label extension study following completion of the 12-month double-blind 
treatment period and 4-week post-treatment follow-up visit for Study TRx-237-015. 

Protocol: TRx-237-020 
TauRx Therapeutics Ltd 
24 March 2016 
EUDRACT # 2014-002013-37 
Protocol Version 3.0 / 24 March 2016 
CONFIDENTIAL  
 
 
Page 29 of 80 
• Vasectomized partner (with the appropriate post-vasectomy documentation of 
the absence of spermatozoa in the ejaculate) 
• True abstinence (when this is in line with the preferred and usual lifestyle of 
the subject) 
Subjects must agree to continue to maintain adequate contraception throughout 
participation in the study. 
3. Subject and/or, in the case of reduced decision-making capacity, legally 
acceptable representative(s) consistent with national law and IRB/EC approval, 
is/are able to read, understand, and provide written informed consent in the 
designated language of the study site 
• In Germany and the Netherlands, subjects must be able to provide their own 
written informed consent (see Section 13) 
4. Has an identified adult caregiver who meets the following criteria: 
• Either lives with the subject or sees the subject on average for ≥ 1 hour/day 
≥ 3 days/week, and in the investigator’s opinion, the extent of contact is 
sufficient to provide meaningful assessment of changes in subject behavior and 
function over time and provide information on safety and tolerability 
• Is willing to provide written informed consent for his/her own participation 
• Is able to read, understand, and speak the designated language at the study site 
• Agrees to accompany the subject to each study visit  
• Is able to verify daily compliance with study drug 
5. Able to comply with the study procedures in the view of the investigator 
5.2 
Exclusion Criteria  
1. History of swallowing difficulties (note: study drug should be swallowed whole 
and MUST NOT be broken, crushed or chewed or dissolved in fluids prior to 
ingestion)  
2. Pregnant or breastfeeding 
3. Clinically significant laboratory, pulse co-oximetry, electrocardiogram, or 
imaging abnormality (in originating study) or emergent intercurrent illness that, in 
the judgment of the principal investigator, could result in the risk of participation 
outweighing the potential benefit  
4. Current participation in, or intent to enroll in, a clinical trial of a drug, biologic, 
device, or medical food 
5. In Germany, subjects who meet the following criteria are to be excluded: 
• Subjects who reside in a continuous care or assisted living facility if mandated 
by an order issued by either the judicial or the administrative authorities 

Protocol: TRx-237-020 
TauRx Therapeutics Ltd 
24 March 2016 
EUDRACT # 2014-002013-37 
Protocol Version 3.0 / 24 March 2016 
CONFIDENTIAL  
 
 
Page 30 of 80 
• Subjects whose willingness to participate in the clinical trial may be unduly 
influenced by the expectation (regardless of whether justified) of benefits 
associated with participation, or of a retaliatory response from family, 
caregivers, or treating personnel in case of refusal to participate 
5.3 
Discontinuation/Withdrawal 
For a discussion of reasons for dose adjustment or permanent discontinuation of study 
medication on the basis of safety, see Section 6.2.3.  These include clinically evident 
hemolytic anemia (Section 6.2.3.1), serotonin syndrome (Section 6.2.3.2), prolongation 
of the QT interval on ECG and decrease in renal function (Section 6.2.3.3). 
Subjects may discontinue study drug and withdraw (drop out) from the study at any time 
for any reason.  The caregiver may also withdraw his or her consent at any time for any 
reason.  If a caregiver withdraws his or her consent, the subject must then also be 
withdrawn if alternative arrangements are not available (e.g., an alternate caregiver).  
Furthermore, the investigator also has the right to discontinue trial medication if he or she 
judges that treatment is no longer appropriate, the subject's clinical condition is 
worsening, or for an adverse event. 
At the completion of each 12-month period of open-label treatment, the principal 
investigator must determine whether or not continued treatment is warranted on the basis 
of continued benefit and safety and tolerability profile.  If eligible, the subject and/or 
caregiver must give informed consent for continued participation.  In Germany and the 
Netherlands, continuation of treatment is not permitted if the subject is unable to give 
consent. 
If study drug is discontinued or the subject/caregiver elect(s) not to re-enroll in a 
subsequent open-label treatment phase, the reason should be recorded as one of the 
following: 
• AE  
• Death 
• Lack of efficacy (including progressive disease or worsening of cognitive 
capacity; in Germany, this includes loss of the ability to give consent if the legal 
representative or caregiver is not available or does not agree to continued 
participation) 
• Lost to follow up 
• Withdrawal by subject or legal representative (or caregiver), including specific 
reasons wherever possible 
• Protocol deviation 
• Non-compliance with study drug 
• Pregnancy 
• Study terminated by Sponsor 
• Physician decision, including specific reason(s) wherever possible 

Protocol: TRx-237-020 
TauRx Therapeutics Ltd 
24 March 2016 
EUDRACT # 2014-002013-37 
Protocol Version 3.0 / 24 March 2016 
CONFIDENTIAL  
 
 
Page 31 of 80 
• Other (specify) 
If the reason for discontinuation of study drug is an AE, the principal event(s) associated 
with discontinuation must be specified and recorded.  In this case, reasonable effort must 
be made to clearly document the outcome.  If the reason for premature discontinuation is 
an SAE, this must be documented and an SAE form must be completed (also see Sections 
7.1.4 and 7.1.5). 
For subjects who withdraw from the study for reasons other than death, or subject or 
caregiver consent withdrawn (or refusal to continue participation), an early termination 
visit should be scheduled as soon as possible after the last dose of study drug and 
identified end of treatment evaluations performed.  For subjects who withdraw consent or 
when a caregiver withdraws consent without available alternate caregiver, the 
investigator should request that the subject have any clinically indicated safety 
assessments performed and the reason for withdrawal of consent given.  
5.4 
Termination of the Study 
The Sponsor reserves the right to terminate the study for duly justified reasons in 
accordance with national laws (e.g., in Germany: §40, section 1 of the Arzneimittelgesetz 
[AMG]).  These reasons include in particular: 
• Administrative reasons:  e.g., financial reasons 
• Interest of subject welfare:  e.g., new information or events that result in an 
unfavorable risk-benefit profile. 
 
6 
TREATMENTS ADMINISTERED 
Study drug tablets are formulated as blue film-coated oval tablets.  Only one strength of 
LMTM will be provided as follows: 
• LMTM tablet containing 100 mg (expressed as MT base equivalent) 
The active and inactive ingredients are described below. 
6.1 
Treatment  
6.1.1 
Active Ingredient  
The active ingredient is methylthioninium (MT), provided as leuco-methylthioninium 
bis(hydromethanesulfonate) (LMTM, TRx0237).  The chemical name is N,N,N’,N’-
tetramethyl-10H-phenothiazine-3,7-diaminium bis(methanesulfonate).  
The potential for LMTM to cause urinary and/or fecal coloration should be explained to 
the subject and caregiver and will be described in the informed consent form (ICF).  If a 
subject is known to have incontinence, such coloration could adversely affect compliance 
with study drug unless adequate precautions are taken (e.g., use of incontinence pads).  
Even with the latter, discoloration in the context of incontinence may prove unacceptable 
to the subject/caregiver, and subjects should be entered into the study only after careful 
discussion of this possibility with them.  Staining of underclothes and other fabrics is 

Protocol: TRx-237-020 
TauRx Therapeutics Ltd 
24 March 2016 
EUDRACT # 2014-002013-37 
Protocol Version 3.0 / 24 March 2016 
CONFIDENTIAL  
 
 
Page 32 of 80 
difficult to remove using standard washing products; therefore, subjects and caregivers 
should be informed about available techniques for washing stained clothing (see the 
Investigator's Brochure).  The possibility of such staining should be clearly discussed 
with subjects and their caregivers. 
6.1.2 
Inactive Ingredients  
Tablets also contain the following inactive compendial excipients:  mannitol, 
crospovidone, microcrystalline cellulose, and magnesium stearate.  
The film coat of study drug tablets contains polyvinyl alcohol-part hydrolyzed, talc, 
titanium dioxide, Macrogol PEG 3350, lecithin (soya), as well as non-compendial FD&C 
blue #2 (indigo carmine aluminum lake).  
6.2 
Study Regimens 
All LMTM doses cited represent doses expressed as MT base equivalents.   
Subjects will be instructed to take each dose of study medication with water (see Section 
6.4 for discussion of study drug dispensing).  Tablets may be taken with or without 
meals.   
Subjects and caregivers will be instructed that study drug should be swallowed whole and 
MUST NOT be broken, crushed, or chewed or dissolved in fluids prior to ingestion.  
Subjects and caregivers should be warned that if the product is not swallowed 
immediately and is allowed to dissolve in the mouth, it will cause discoloration of teeth 
and oral mucosa. 
The study supplies are further described in Section 6.3. 
6.2.1 
Initial Dose  
The initial daily study drug regimen to which all subjects will be assigned is summarized 
in Table 6-2, including the number of tablets and LMTM doses.   
Table 6-2 
Initial Daily Study Drug Regimen: Tablets and LMTM Dose 
 
Tablet Contents 
(amount of MT) 
Number of Tablets 
Dose of MT  
Treatment 
AM 
PM 
Daily 
Total 
   AM 
   PM 
Daily 
Total 
LMTM  
200 mg/day 
100 mg 
1 
1 
2 
100 mg 
100 mg 
200 mg 
AM = morning; PM = evening 
 
As the bvFTD subjects from Study TRx-237-007 are not required to return for a 4-week 
post-treatment visit prior to entering this open-label extension study, these subjects may 
choose to enroll in this extension study at Visit 9 of Study TRx-237-007 (i.e., on the same 
day that they receive the last dose of study drug in the prior study).  These subjects are to 
continue taking study drug (under the Study TRx-237-007 protocol) at the usual 

Protocol: TRx-237-020 
TauRx Therapeutics Ltd 
24 March 2016 
EUDRACT # 2014-002013-37 
Protocol Version 3.0 / 24 March 2016 
CONFIDENTIAL  
 
 
Page 33 of 80 
designated time, and the first dose of study drug under this open-label extension study 
protocol will be instructed based on the last dose received under the prior study.  Subjects 
from Study TRx-237-007 who are taking a reduced dose (i.e., 100 mg/day) should 
continue taking this reduced regimen upon entering this extension study. 
6.2.2 
Flexible Dosing  
After Week 2 (Visit 2), dosing is flexible.  The dose may be increased (at Visit 3 or at 
any subsequent dispensing visit as determined by the investigator during the treatment 
period) or decreased (at any time at or after Visit 2) on the basis of benefit in the 
judgment of the investigator and safety and tolerability.  Dose increments/decrements of 
100 mg/day are recommended, with once daily dosing also allowed.  The maximum 
allowable dose is 300 mg/day (or in those countries where limited by a CA or EC, 
200 mg/day); no more than 200 mg is to be administered at a single time.  The maximum 
dose (if 300 mg/day) may also be given as 100 mg three times daily.   
Interruption(s) of study drug administration and resumption of dosing at the same or at a 
reduced dose is allowed at any time if the investigator determines this is indicated, 
provided the duration of any single interruption is ≤ 30 days.  If there is an interruption 
for safety reasons5 longer than 30 days on a given occasion, treatment should be 
discontinued.  The investigator should contact the medical monitor to discuss any 
interruptions and dose reductions.  If after allowable interruptions, the subject does not 
tolerate re-introduction of the study drug or a clinically significant laboratory abnormality 
recurs, then study drug should be discontinued.  
Guidance with respect to dose modifications in response to selected adverse events or 
clinical laboratory abnormalities are described further below. 
All dose changes, including escalations, interruptions, decreases (and subsequent 
increases), should be recorded in the eCRF together with the corresponding date.  The 
reason for each dose interruption and each dose reduction also should be recorded in the 
eCRF.  The medical monitor should be informed of any dose decreases or interruptions.  
6.2.3 
Dose Adjustment for Selected Adverse Events / Test 
Abnormalities 
In this open-label extension study, the adverse events of special interest (AESIs) are signs 
and symptoms consistent with hemolytic anemia and serotonin syndrome (toxicity).  
Potential interruption or discontinuation of study drug in response to these events is 
discussed below.  Further guidance on monitoring subjects is given in Section 7.1.3. 
6.2.3.1 
Hemolytic Anemia 
When there are clinical symptoms and/or laboratory signs of hemolytic anemia, dosing 
should be discontinued.  Clinical symptoms are described in Section 7.1.3.1 and 
laboratory signs are described in Section 7.3.2.  Follow-up laboratory monitoring is also 
                                                 
5 Administrative reasons (or other reasons not related to safety) are not to be considered safety reasons 
warranting treatment discontinuation. 

Protocol: TRx-237-020 
TauRx Therapeutics Ltd 
24 March 2016 
EUDRACT # 2014-002013-37 
Protocol Version 3.0 / 24 March 2016 
CONFIDENTIAL  
 
 
Page 34 of 80 
described in Section 7.3.2.  The medical monitor should be contacted to discuss whether 
or not resumption of dosing is indicated or for any other questions.  
6.2.3.2 
Serotonin Syndrome 
Subjects are to be monitored at each visit by a medically qualified person for signs and 
symptoms indicative of potential serotonin toxicity, especially when initiating LMTM in 
this study or any medication with serotonergic potential.  At each post-Baseline visit, 
subjects are to be evaluated by targeted physical and neurological examination and 
measurement of temperature, respiratory rate, blood pressure, and pulse (see Section 
7.1.3.2 for guidance on assessment).  Should serotonin syndrome (toxicity) be suspected 
clinically, treatment should be immediately discontinued.  The event should be reported 
as an AESI and the medical monitor should be contacted for further guidance on subject 
management.   
6.2.3.3 
Other Safety Reasons Requiring Dose Adjustment 
Treatment should be discontinued if the following treatment-emergent change occurs on 
ECG (based on the means of the three recordings) without other explanatory cause: 
• QTcF interval > 500 msec:  repeat ECGs should be obtained, in triplicate, 
within 2 weeks; if confirmed by the mean of the repeat ECGs, study drug 
should be discontinued pending further evaluation. 
Other clinically significant changes in the ECG should be discussed with the medical 
monitor. 
If renal concerns arise and the calculated creatinine clearance is < 30 mL/min, study drug 
should be discontinued. 
6.3 
Packaging, Labeling, and Storage 
The open-label study drug will be packaged, labeled, and distributed to study sites by a 
designated vendor.  
Study drug supplied to subjects will be packaged in 35-count 60-mL white HDPE bottles 
containing a 2-g desiccant bag and induction-sealed.  The number of bottles dispensed is 
to be adequate to ensure sufficient supplies until the next scheduled study visit (with 
2-week overage). 
Study drug package labels will be in compliance with applicable regulatory requirements 
and will include the statement “Keep out of reach of children”, the cautionary statement 
“Caution: New Drug – Limited by Federal (United States) law to investigational use” 
and/or “For clinical trial use only” as appropriate, as well as any other locally mandated 
statements.  Labels will also be translated into the local language. 
At a minimum, labels will also include the following information:  the name and address 
of the sponsor, the study code, a unique identifier, and appropriate contact information.  
In those jurisdictions where required, a re-test or expiry date will be included.  
At the study site, study drug must be stored securely (e.g., locked area, pharmacy) and at 
a temperature not more than 30°C.  The temperature at which study drug is stored at the 
study site will be recorded daily using a centralized temperature monitoring system if this 

Protocol: TRx-237-020 
TauRx Therapeutics Ltd 
24 March 2016 
EUDRACT # 2014-002013-37 
Protocol Version 3.0 / 24 March 2016 
CONFIDENTIAL  
 
 
Page 35 of 80 
is available.  If not, study drug storage temperature will be recorded each working day 
using a maximum-minimum thermometer.  While closed, the packaging protects the 
study drug from light and moisture; study drug should be ingested immediately after 
removal from the package. 
Subjects and caregivers should also be provided with information about required storage 
conditions.  Study drug should remain in the package as dispensed until it is ingested by 
the subject, and should not be placed in an alternate pill box including commonly-used 
weekly pill organizers.  
6.4 
Dispensing 
All dosing will be on an outpatient basis.  Study drug will be first dispensed to 
subjects/caregivers on Day 1 (Baseline, Visit 1); enough study drug will be dispensed to 
last the subject until Visit 3.   
Thereafter, study drug will be dispensed at Week 13 (Visit 3) and at each subsequent 
study visit so long as the subject will continue on study drug.  The supplies dispensed to a 
subject at each of these times will be sufficient to allow for intake of the necessary 
number of tablets for the scheduled number of days, with additional supplies as overage 
in the event of a delay in the visit.  Subjects should bring all study medication, including 
the overage supply, with them to the Week 13 visit (Visit 3) and to each study visit 
thereafter during the treatment period for compliance assessment. 
Subjects and caregivers will be provided with information about storage conditions and 
taking study drug, including instructions indicating that study drug must be used only as 
described in this protocol.  They will be informed that subjects are to take each dose of 
study medication with water and that the tablets may be taken with or without meals.  
They will also be informed that tablets should be swallowed whole and not broken, 
crushed, or chewed or dissolved in fluids prior to ingestion (see Section 6.2).  In the event 
of interruption or dose reduction or increase, the subjects and caregivers will be provided 
with updated dosing instructions. 
6.5 
Compliance 
Subject compliance with prescribed dose of study drug will be assessed by questioning 
the subject and caregiver at the Week 2 visit (Visit 2) and at each study visit thereafter 
during the treatment period.   
At the Week 13 visit (Visit 3) and at each study visit thereafter during the treatment 
period, the subject/caregiver will bring all unused study drug to the study site.  The 
number of tablets (all tablets remaining in the bottle plus any tablets that have been 
removed from the bottle) will be counted and recorded by study site staff.  Empty bottles 
and packaging should also be returned by the subject/caregiver to the study site.  At each 
post-Baseline visit beginning with the Week 13 visit (Visit 3), the number of tablets 
dispensed to the subject/caregiver will also be recorded. 
Any apparent discrepancies between the number of tablets taken and the number of 
tablets which should have been taken since the last visit will be discussed with the subject 
and caregiver.  Compliance data obtained at Visit 2 and each study visit thereafter, 
including dates of any dose deviations and/or interruptions, and any other pertinent 

Protocol: TRx-237-020 
TauRx Therapeutics Ltd 
24 March 2016 
EUDRACT # 2014-002013-37 
Protocol Version 3.0 / 24 March 2016 
CONFIDENTIAL  
 
 
Page 36 of 80 
information, will be recorded in the source documentation and on the appropriate field of 
the eCRF based on the investigator determination.  
If during participation in the study a subject’s compliance is determined to be < 80% or 
> 120% (taking into consideration allowable reductions/increases determined and 
recorded by the investigator in the number of tablets taken, or dose interruptions), the 
subject and caregiver should be reeducated about taking study drug properly and the 
clinical research associate should be informed promptly.  If compliance problems are 
recurrent, the investigator should inform the clinical research associate and contact the 
medical monitor to determine the course of action.  
6.6 
Accountability 
The investigator or designee will keep a record of all study drug received, and of all study 
drug dispensed to and returned by subjects. 
The investigator will ensure that the supplied study drug will be used only for 
administration to subjects enrolled in this study and for no other purpose.  
The study drug accountability record will be checked by a study monitor at monitoring 
visits. 
All unused and returned study drug will be either returned to the Sponsor or designee or 
disposed of after study completion according to provided instructions. 
 
7 
ASSESSMENT OF SAFETY  
Safety will be assessed over time by means of adverse events (AEs) and concomitant 
medication recording; clinical laboratory tests of blood (e.g., hematology and chemistry 
panels); vital sign measurements; 12-lead ECGs; and targeted physical and neurological 
examinations.     
Assessments to be performed in the clinic are described in the subsections that follow.  At 
an intervening time between Visit 2 and Visit 3 (approximately 6 weeks after Baseline), 
caregivers of subjects are to be contacted by telephone.  An unscheduled visit is to take 
place if needed in response to a safety concern.   
7.1 
Adverse Events 
An AE is any unfavorable or unintended sign, symptom, or disease, whether or not 
considered related to the study treatment.  This also includes events resulting from 
medication error or inappropriate use.  Recording of new AEs and changes to ongoing 
AEs will begin at the time the ICF is signed using the eCRF mapped from the double-
blind study of original participation.  AEs will be ascertained by asking the subject (and 
caregiver) how the subject has been since the last visit.  A clinical abnormality or 
laboratory test value abnormality that the investigator deems to be clinically significant 
should be recorded as an AE.  
Every attempt should be made to describe the AE in terms of a diagnosis.  Once a clear 
diagnosis has been made, individual signs and symptoms shall not be recorded unless 
they represent atypical or extreme manifestations of the diagnosis, in which case they 

Protocol: TRx-237-020 
TauRx Therapeutics Ltd 
24 March 2016 
EUDRACT # 2014-002013-37 
Protocol Version 3.0 / 24 March 2016 
CONFIDENTIAL  
 
 
Page 37 of 80 
should be reported as separate events.  Events and signs/symptoms leading up to a 
diagnosis should be retained.  If a clear diagnosis cannot be established, each sign and 
symptom must be recorded individually.   
All AEs must be fully recorded in the source documents and in the eCRF, regardless of 
whether or not the event is considered related to study drug.   
For all AEs, the investigator must pursue and obtain information adequate both to 
determine the outcome of the AE and to assess whether it meets the criteria for 
classification as a Serious Adverse Event (SAE) or pregnancy requiring immediate 
notification (see Sections 7.1.4 and 7.1.5).   
Follow-up of an AE, even after the final dose of study drug, is required if the AE or its 
sequelae persist.  Follow-up is required, including beyond the scheduled final off-
treatment visit if needed, until the AE or its sequelae resolve or stabilize at a level 
acceptable to the investigator. 
For each AE, information recorded will include the following:  the date when the AE 
started, the date when the AE stopped (or whether it remained ongoing), the intensity of 
the AE (see Section 7.1.1), the relationship of the AE to study drug (see Section 7.1.2), 
action taken with regard to study drug (none, dose reduction, interrupted, or 
discontinued), other drug therapy (no change, new medication, altered medication, or 
both of the latter), outcome, and whether or not the AE was considered an SAE (see 
Section 7.1.4).   
7.1.1 
Intensity 
The intensity (severity) of each AE will be assessed by the investigator and graded as 
mild, moderate, or severe, as follows: 
• Mild: An AE that is easily tolerated by the subject, causes minimal discomfort and 
does not interfere with everyday activities 
• Moderate: An AE that is sufficiently discomforting to interfere with normal everyday 
activities 
• Severe: An AE that prevents normal everyday activities 
7.1.2 
Relationship to Study Drug  
The investigator will make a judgment considering whether or not, in his or her opinion, 
each AE is related to the study drug according to classifications described here.  
However, even if the investigator feels that there is no relationship to the study drug, the 
AE should be reported nevertheless.  For each AE, the relationship or association 
(causality) of the AE to study drug will be assessed by the investigator and characterized 
as not related, unlikely related, possibly related, or related as follows: 
• Not related:  If there is a confirmed cause of the AE (other medical condition, other 
therapy) which does not involve the study drug  
• Unlikely related:  If the temporal association between the AE and the study drug is 
such that the AE is not likely to be related to the study drug 

Protocol: TRx-237-020 
TauRx Therapeutics Ltd 
24 March 2016 
EUDRACT # 2014-002013-37 
Protocol Version 3.0 / 24 March 2016 
CONFIDENTIAL  
 
 
Page 38 of 80 
• Possibly related:  If the AE shows a reasonable temporal association to study drug 
administration but could be due to the subject’s clinical state or other therapies 
administered 
• Related:  If the AE shows a reasonable temporal association to study drug 
administration and cannot be explained by the known characteristics of the subject’s 
clinical state 
7.1.3 
Adverse Events of Special Interest 
The following adverse events are of special interest because additional steps are to be 
taken by the investigator to assess and manage them.  The medical monitor shall be 
informed (either directly by the laboratory or the site, depending on the nature of the 
event).  AESIs include: 
• Signs or symptoms consistent with hemolytic anemia (see Section 7.1.3.1)   
• A case clinically judged to possibly represent serotonin syndrome (see Section 7.1.3.2) 
See Section 6.2.3 for additional details regarding dose interruption, reduction, or 
discontinuation in response to these AESIs. 
Each AESI should be recorded as for any other adverse event. 
7.1.3.1 
Hemolytic Anemia 
The subject should be evaluated at each visit for possible clinical symptoms associated 
with hemolytic anemia, in conjunction with review of hematology results.  Should 
hemolytic anemia be suspected, follow-up testing should be performed as described in 
Section 7.3.2.  The medical monitor should be contacted to discuss whether or not 
resumption of dosing is indicated or for any other questions.  
The signs and symptoms of anemia include: 
• 
Cyanosis, headache, anxiety, exercise intolerance, fatigue, confusion, dizziness, 
tachypnea, palpitation, dysrhythmia, seizures, and coma  
Signs of possible hemolytic anemia include: 
• 
Decrease by 20% from Baseline in RBC count and/or hemoglobin 
• 
Abnormal RBCs in peripheral blood smear 
• 
Elevation of reticulocyte count to above laboratory normal range 
• 
Increase in LDH or indirect bilirubin, or low haptoglobin 
7.1.3.2 
Serotonin Syndrome (Toxicity) 
Subjects are to be monitored for signs and symptoms indicative of potential serotonin 
toxicity, especially when initiating LMTM in this study or any medication with 
serotonergic potential.  At each post-Baseline visit, subjects are to be evaluated by a 
medically qualified person by targeted physical and neurological examination and 
measurement of temperature, respiratory rate, blood pressure, and pulse.  Results of the 
MMSE should also be taken into consideration.  The evaluation should focus on detecting 

Protocol: TRx-237-020 
TauRx Therapeutics Ltd 
24 March 2016 
EUDRACT # 2014-002013-37 
Protocol Version 3.0 / 24 March 2016 
CONFIDENTIAL  
 
 
Page 39 of 80 
signs and symptoms of serotonin syndrome (or serotonin toxicity) that include mental 
changes (confusion, hyperactivity, memory problems not attributed to underlying 
condition), muscle twitching, excessive sweating, shivering or shaking, diarrhea, trouble 
with coordination, and/or fever.  A further guide is provided below. 
Table 7-1  Overview of Monitoring and Management of Serotonin Syndrome (Toxicity) 
Signs and Symptoms of 
Serotonin Toxicity 
Monitoring at Each Clinic Visit 
Action 
Any one of the following: 
Autonomic findings (temperature 
≥38 ºC, diaphoresis, shivering, 
tachypnea/dyspnea, diarrhea, 
hypertension or hypotension)  
Neuromuscular changes (tremor; 
hyperreflexia; spontaneous, 
inducible, or ocular clonus; 
muscle rigidity1; hypertonia; 
dizziness; incoordination; or 
mydriasis) 
Other central nervous system 
changes (agitation/akathisia, 
elevated mood, insomnia) 
Oral (sublingual) temperature2 
Discontinue 
study drug 
Appropriate 
medical 
management to 
be undertaken 
Report to 
Medical Monitor 
as AESI  
 
Seated blood pressure and pulse 
Targeted PE and neurological examination, 
focused on the following: 
deep-tendon reflexes, clonus, and muscle 
rigidity; size and reactivity of pupils; dryness of 
oral mucosa; intensity of bowel sounds; skin 
color; and presence or absence of diaphoresis 
MMSE (Baseline3, Weeks 26, 52, at the 4-week 
follow-up visit, and as needed to respond to 
changes) 
1 Muscle rigidity can overwhelm other neuromuscular findings and mask the diagnosis  
2 Oral (sublingual) temperature measurements are preferable; aural temperature is an acceptable alternative (use of 
alternate measurement is to be noted in the eCRF) 
3 MMSE to be rated at Baseline if not available from within the prior 42 days in the previous study of participation 
 
Should serotonin syndrome (toxicity) be suspected clinically, “serotonin toxicity” should 
be recorded as the adverse event rather than the individual signs or symptoms.  These 
should be indicated by answering “yes” or “no” to each of the signs and/or symptoms 
indicated on the form provided in the eCRF.  These signs and symptoms, based on 
physical and neurological examination, include the following:   abnormal conscious level 
(delirium), agitation or akathisia, elevated mood, insomnia, myoclonus, tremor, 
mydriasis, nystagmus, clonus, hyperreflexia, hypertonia (rigidity), dizziness, 
incoordination, shivering, diaphoresis (sweating), diarrhea, pyrexia (fever), tachycardia, 
tachypnea or dyspnea, hypertension or hypotension.  An “other” field should also be 
included in the eCRF to indicate any additional findings. 
7.1.4 
Serious Adverse Events 
An SAE is defined as any event that: 
• Results in death (including suicide) 
• Is life-threatening 
• Results in inpatient hospitalization or prolongation of existing inpatient 
hospitalization  

Protocol: TRx-237-020 
TauRx Therapeutics Ltd 
24 March 2016 
EUDRACT # 2014-002013-37 
Protocol Version 3.0 / 24 March 2016 
CONFIDENTIAL  
 
 
Page 40 of 80 
o Planned admissions for respite care are not to be considered an SAE (the 
medical monitor should be contacted for confirmation regarding whether or 
not an admission for respite care should be considered planned or unplanned).  
Unplanned admissions for respite care will constitute an SAE unless it is as a 
result of caregiver needs that are independent of the subject's condition.   
o An admission or prolongation of existing hospitalization because the subject 
does not want to be discharged, or because the caregiver is unable or 
unwilling to care for the subject, is not to be considered an SAE. 
o Admissions to a hospital that were planned or anticipated before the start of 
the study for an unrelated pre-existing medical condition are not to be 
considered an SAE.  
• Results in persistent or significant disability or incapacity 
• Is a congenital anomaly or birth defect  
• Other medically significant events that require immediate medical or surgical 
intervention.   
Medical and scientific judgment should be exercised in deciding whether an event is 
serious and whether expedited reporting is appropriate in other situations, such as 
important medical events that may not be immediately life-threatening or result in death 
or hospitalization but may jeopardize the subject or may require intervention to prevent 
one of the outcomes listed in the definitions above. 
All SAEs must be reported on the eCRF.  An assessment should be made by the 
investigator of whether the event is study-drug related, i.e., is ‘causally’ related to the 
study drug.   
7.1.5 
Pregnancy 
Pregnancy is to be considered an immediately reportable event.  This includes pregnancy 
of a female subject or a female sexual partner of a male subject.  
Subjects who become pregnant during the clinical study should discontinue study drug 
immediately and contact the investigator. 
Subjects should be instructed to notify the investigator of a pregnancy either during the 
treatment period of the study or within 3 months after the last dose of study drug.  
Whenever possible, a pregnancy should be followed to term, any premature terminations 
reported, and the status of the mother and child should be reported to the Sponsor after 
delivery. 
Although the pregnancy is not considered to be an AE or SAE, any pregnancy 
complications should be recorded as AEs or SAEs (if applicable).  Any pregnancy should 
be followed through delivery for the observation of any SAE.  Therefore, regardless of 
whether or not a pregnancy is actually considered an SAE, a pregnancy form should be 
completed for all pregnancies.   
Pregnancies should initially be reported in the Pregnancy Notification Form, Part I and 
sent by e-mail to the following address: 

Protocol: TRx-237-020 
TauRx Therapeutics Ltd 
24 March 2016 
EUDRACT # 2014-002013-37 
Protocol Version 3.0 / 24 March 2016 
CONFIDENTIAL  
 
 
Page 41 of 80 
drugsafety@wwctrials.com.    
When the outcome of the pregnancy is known, site personnel will complete the 
Pregnancy Notification Form, Part II and e-mail it to the following address: 
drugsafety@wwctrials.com.   
All data related to pregnancy, pregnancy outcome, and SAE associated with pregnancy 
will be recorded in a safety database maintained by personnel responsible for 
pharmacovigilance at Worldwide Clinical Trials. 
7.1.6 
Reporting Requirements and Timeframes 
The requirements for reporting SAEs and pregnancies are described below.  A Safety 
Management Plan will be implemented to further describe and document the process for 
safety reporting. 
7.1.6.1 
Investigator Reporting of SAEs and Pregnancy to 
Sponsor  
If any of the adverse events are SAEs as defined by this protocol (see Section 7.1.4) or a 
pregnancy (see Section 7.1.5), special procedures will be followed.  All such events will 
be reported to the Sponsor designee, Worldwide Clinical Trials, immediately (and not 
exceeding 24 hours following knowledge of the event) and followed by follow-up reports 
as soon as possible, whether or not the events are deemed study drug-related.  
Serious Adverse Events must be reported by entering the SAE information in the 
AE/SAE section of the Electronic Data Capture (EDC) system.  The information 
provided in the EDC system should be as complete as possible, but must contain the 
following minimum fields: 
• Subject number 
• Brief description of the SAE (diagnosis or signs/symptoms) 
• Serious criteria 
• Causality assessment 
• Assessment of the intensity of the event 
WCT Drug Safety will receive notification of the initial SAE via an e-mail alert 
generated from the EDC system.  In the event of any temporary disruption of the EDC 
system, an alternative SAE reporting mechanism will be available to site personnel; in 
this instance, a paper SAE Report Form will be available.  Site personnel will complete 
the paper SAE report form, scan and e-mail it within 24 hours to the following address:  
drugsafety@wwctrials.com   
Site personnel must complete the AE/SAE section with the SAE information as soon as 
the EDC system becomes available.  Serious adverse events that are ongoing should be 
followed until resolved or stabilized to a level acceptable to the investigator. 
The investigator is obliged to provide additional information as requested by the medical 
monitor.  In general, this will include a description of the event in sufficient detail to 

Protocol: TRx-237-020 
TauRx Therapeutics Ltd 
24 March 2016 
EUDRACT # 2014-002013-37 
Protocol Version 3.0 / 24 March 2016 
CONFIDENTIAL  
 
 
Page 42 of 80 
allow for a complete medical assessment of the case and independent determination of 
possible causality.  In the case of a subject death, a summary of available autopsy 
findings, if performed, must be submitted as soon as possible to the contract research 
organization.  However, any supporting information provided should not reveal a 
subject’s identity beyond the agreed study identifier.  The investigator should ensure that 
information reported is accurate and consistent.  
Information not available at the time of the initial report (e.g., an end date for the AE, 
laboratory values received after the report, or hospital discharge summary) must be 
documented on a follow-up form.  All follow-up information must be reported in the 
same timelines as initial information. 
Any SAEs considered related to the study drug and discovered by the investigator at any 
interval after the study must also be reported to the Sponsor within 24 hours following 
knowledge of the event. 
7.1.6.2 
Sponsor Reporting of SUSARs to Regulatory 
Authorities 
Suspected, unexpected serious adverse reactions (SUSARs) are adverse events that are 
believed to be related to an investigational medicinal product and are both unexpected 
(i.e., the nature or severity is not expected from the information provided in the 
Investigator's Brochure) and serious.  As stated in the EU ‘CT-3’ Communication from 
the Commission (2011/C 172/01) and the US Code of Federal Regulations (21 CFR 
312.32), for there to be a reasonable possibility of a causal relationship between the event 
and study drug there must be facts (evidence) or arguments to suggest a causal 
relationship.  Final assessment of expectedness for purposes of regulatory reporting is the 
responsibility of the Sponsor. 
It is the responsibility of the Sponsor to determine whether a reported SAE fits the 
classification of a SUSAR and to notify the investigator of the decision as soon as 
possible.  Requirements for SUSAR reporting are described below.  All SUSAR 
reporting will adhere to European Directives 2001/20/EC, 21 CFR 312.32 of the U.S.  
Code of Federal Regulations, Health Canada Food and Drug Regulation C.05.014, and 
other regions as applicable. 
7.1.6.2.1 Unblinding Treatment Allocation 
As this is an open-label study, treatment allocation in this study is by default unblinded 
for all SUSAR reporting to the pertinent regulatory authorities.  The onset of a possible 
SUSAR relative to the prior treatment history is an important aspect of the assessments.  
Therefore, should treatment assignment in the previous double-blind study of 
participation (i.e., Studies TRx-237-005, TRx-237-007, TRx-237-008, and TRx-237-015) 
not yet be unblinded, the treatment assignment for a given subject will be made available 
for assessment of the SUSAR and will be included in the reporting of the event to a 
regulatory authority (as of implementation of Amendment 3.0). 
When an event may be a SUSAR, the blind should be broken only for that specific 
subject.  The blind should be maintained for individuals responsible for the ongoing 
conduct of the study (e.g., management, monitors and investigators) and those 

Protocol: TRx-237-020 
TauRx Therapeutics Ltd 
24 March 2016 
EUDRACT # 2014-002013-37 
Protocol Version 3.0 / 24 March 2016 
CONFIDENTIAL  
 
 
Page 43 of 80 
responsible for data analysis and interpretation of results at the conclusion of the study 
(e.g., biometrics personnel).  
Unblinded information should only be accessible to those who need to be involved in the 
safety reporting to pertinent regulatory authorities, independent ethics 
committees/independent review boards (IECs/IRBs) and DSMBs, or individuals 
performing ongoing safety evaluations during the study. 
7.1.6.2.2 Fatal or Life-threatening SUSARs 
It is the responsibility of the Sponsor to report fatal or life-threatening SUSARs to the 
pertinent regulatory authorities as soon as possible, but no later than 7 calendar days (or 
earlier if locally mandated).  These will be reported to the DSMB in parallel. 
7.1.6.2.3 Other SUSARs 
It is the responsibility of the Sponsor to report other SUSARs to the pertinent regulatory 
authorities as soon as possible, but no later than 15 calendar days (or earlier if locally 
mandated).  These will be reported to the DSMB in parallel. 
7.1.6.3 
Reporting to IECs/IRBs 
The IEC/IRB will be notified of any SUSARs according to local regulations and within 
the designated timeframe. 
The investigator (or prospectively agreed to designee) is required to notify the IEC/IRB 
of any fatal SUSAR as soon as possible but no later than 7 calendar days after he/she first 
became aware of the reaction (or earlier if locally mandated). 
The investigator (or prospectively agreed to designee) is required to notify the IEC/IRB 
of any other SUSAR as soon as possible but no later than 15 calendar days after he/she 
first became aware of the reaction (or earlier if locally mandated). 
7.2 
Urgent Safety Measures 
The Sponsor and investigator may take appropriate urgent safety measures in order to 
protect the subjects of the clinical study against any immediate hazard to their health or 
safety. 
The Sponsor and the Medical Monitor or designated deputy will be notified of any urgent 
safety measures taken by the investigator or qualified designee and advised of their 
responsibility to notify the licensing authority.  The investigator or qualified designee 
will notify the IEC/IRB. 
If these measures are taken, the Sponsor or investigator shall immediately give written 
notice to the pertinent regulatory authorities consistent with the regional/national 
requirements and IEC/IRB of the measures taken and the circumstances giving rise to 
those measures.  In any event, the written notice shall be no later than 7 days from the 
date the measures are taken. 

Protocol: TRx-237-020 
TauRx Therapeutics Ltd 
24 March 2016 
EUDRACT # 2014-002013-37 
Protocol Version 3.0 / 24 March 2016 
CONFIDENTIAL  
 
 
Page 44 of 80 
7.3 
Clinical Laboratory Tests 
Scheduled blood samples for hematology and chemistry panels will be obtained at each 
visit during the study, including Baseline (if not available within the prior 42 days), after 
2 weeks, and approximately every 13 weeks (relative to Baseline) thereafter (or upon 
early termination).  Laboratory testing will be repeated at the 4-week post-treatment 
follow-up visit if applicable.   
A trained and authorized person will collect blood samples from the subject by 
venipuncture from a suitable vein.  
Kits with supplies for the collection of blood samples will be provided to each study site 
before the study initiation visit.  The kits will be labeled to identify the clinical study, and 
will include specimen labels, pre-printed laboratory requisition forms, all supplies needed 
for specimen collection and shipping, instructions for collection and preparation of 
specimens, and pre-printed forms to expedite shipment.   
A protocol-specific laboratory manual will be provided to each study site.  The laboratory 
manual will include contact details, lists of the contents of collection kits, shipment 
schedule of collection kits, and detailed guidelines and recommendations for completing 
laboratory requisition and for specimen collection, preparation, storage, and 
transportation. 
A central laboratory will process all scheduled laboratory blood samples unless otherwise 
noted.  Data will be transferred electronically for inclusion in the database.  Investigators 
are to enter the results of any testing performed at local laboratories (and the 
corresponding normal ranges) into the eCRF.   
7.3.1 
Serum Chemistry 
The blood volume for each chemistry panel will be approximately 3.5 mL.  Blood 
samples collected for serum chemistry panels are to be destroyed approximately 1 week 
after testing has been completed.  The chemistry panel will include the following 
analytes: 
 
Sodium 
Gamma-glutamyl transpeptidase (GGT) 
Potassium 
Alanine transaminase (ALT) 
Calcium 
Aspartate transaminase (AST) 
Albumin 
Glucose (random, not fasted) 
Total protein 
Creatinine2 
Urea nitrogen, urea1 
Phosphorus 
Total and direct (conjugated) bilirubin (indirect 
bilirubin calculated as the difference) 
Uric acid 
Alkaline phosphatase 
Chloride 
Lactate dehydrogenase (LDH) 
Creatine kinase (CK) 
1 The analytical method measures urea in serum. In the Covance CLS database, the test is named either 
Urea Nitrogen or Urea, depending on whether the results are expressed in conventional or SI units, 
respectively. Urea Nitrogen is reported in mg/dL while Urea is reported in mmol/L per SI unit convention. 
2 Creatinine clearance is to be estimated by the central laboratory using the Cockcroft-Gault equation. 

Protocol: TRx-237-020 
TauRx Therapeutics Ltd 
24 March 2016 
EUDRACT # 2014-002013-37 
Protocol Version 3.0 / 24 March 2016 
CONFIDENTIAL  
 
 
Page 45 of 80 
 
7.3.2 
Hematology 
The blood volume for each hematology panel will be approximately 2.0 mL.  Blood 
samples collected for hematology panels are to be destroyed approximately 3 days after 
testing has been completed.  The hematology panel will include the following analytes: 
 
Hematocrit 
White blood cells (WBC) 
Hemoglobin 
and absolute and percent differential 
Mean corpuscular hemoglobin (MCH) 
(neutrophils, lymphocytes, monocytes, 
eosinophils, basophils); any abnormal cells 
Mean corpuscular hemoglobin concentration (MCHC)  will be noted 
Red blood cells (RBC) and any immature forms 
Platelet count 
RBC morphology 
Reticulocyte count and percent 
Mean cell volume (MCV) 
 
 
 
 
If the investigator is concerned on the basis of significant hematological abnormalities 
that Heinz bodies may be present, a blood sample may be sent to the local laboratory for 
assessment and screening of Heinz bodies.  The percent of erythrocytes with Heinz 
bodies should be reported based on a suitably prepared slide; blood samples should be as 
fresh as possible at the time of slide preparation.  If Heinz bodies are present, study 
medication must be stopped (see Section 6.2.3.1) and another blood sample should be 
obtained within 1 week.  Hematological indices should continue to be monitored until 
this resolves.   
7.3.3 
Other Laboratory Tests  
A serum pregnancy test for qualitative testing for the beta subunit of human chorionic 
gonadotropin (β-hCG) will be obtained for all women of childbearing potential at 
Baseline (if the Baseline visit does not coincide with the final double-blind study visit) 
and each subsequent study visit (or upon early termination).  In the event of a borderline 
result, testing will be repeated and if the result is still borderline, quantitative testing for 
β-hCG will be performed. 
7.3.4 
Review of Laboratory Results 
Laboratory results from each study visit will be assessed in a timely manner.  The 
investigator or an authorized physician sub-investigator must interpret the laboratory 
findings and confirm their review.  
The clinical significance of all laboratory values which are outside the laboratory normal 
reference range should be noted and commented upon by the investigator.   
Abnormal values which are considered by the investigator to be clinically significant, 
taking the age of the subject into account, should be documented as an AE, unless 

Protocol: TRx-237-020 
TauRx Therapeutics Ltd 
24 March 2016 
EUDRACT # 2014-002013-37 
Protocol Version 3.0 / 24 March 2016 
CONFIDENTIAL  
 
 
Page 46 of 80 
accounted for by a pre-existing medical condition detailed in the subject’s medical 
history.  The diagnosis associated with a clinically significant laboratory abnormality 
generally should be recorded as the underlying abnormality or diagnosis (e.g., renal 
insufficiency) if there is sufficient overall information to permit a diagnosis to be made 
by the investigator.  Otherwise, the observed deviation in the laboratory result should be 
recorded (e.g., elevated creatinine). 
The investigator must review and assess laboratory results for clinically significant 
abnormalities.  If any of these suggest hemolytic anemia, treatment interruption should be 
considered (see Section 6.2.3.1).   
Additional tests and other evaluations required to establish the significance or etiology of 
an abnormal result or to monitor the course of an AE may be obtained from the central 
laboratory.  If a local laboratory needs to be used in some circumstances, the data and 
corresponding normal ranges will be recorded in the eCRF, entered directly from a 
laboratory slip.  When clinically indicated, the medical monitor should be informed in 
such circumstances.  In particular, if a clinically significant abnormal result is observed 
that is not resolved by the following visit, repeated tests should be performed until 
resolution of the abnormality. 
7.4 
Vital Sign Measurements 
In the clinic, measurements of the vital signs described below will be made by a trained 
and authorized person.  These will be made at Baseline (if not available from within the 
prior 42 days) and every subsequent visit thereafter (or upon early termination), including 
the 4-week post-treatment follow-up visit if applicable. 
7.4.1 
Blood Pressure and Pulse 
Blood pressure and pulse should be measured with the subject in a seated position for at 
least 5 minutes.  A manual or automated sphygmomanometer will be used to measure 
systolic and diastolic blood pressure, with results recorded in mmHg.  Pulse rate will be 
measured in the radial artery for 60 seconds and will be recorded as beats/minute.  If 
possible, blood pressure and pulse rate preferably should be measured in the same arm at 
each visit. 
7.4.2 
Temperature and Respiratory Rate  
Temperature and respiratory rate will be measured for evaluation in the assessment for 
signs and symptoms indicative of potential serotonin toxicity.  Oral (sublingual) 
temperature measurements are preferable; aural temperature is an acceptable alternative 
(this alternate means of measuring temperature is to be recorded in the eCRF). 
7.4.3 
Weight 
Body weight will be recorded at Baseline (if not available from within the prior 42 days) 
and every subsequent visit thereafter (or upon early termination), including the 4-week 
post-treatment follow-up visit if applicable.  Weight will be measured while the subject is 
clothed with shoes off and recorded in kilograms (kg). 

Protocol: TRx-237-020 
TauRx Therapeutics Ltd 
24 March 2016 
EUDRACT # 2014-002013-37 
Protocol Version 3.0 / 24 March 2016 
CONFIDENTIAL  
 
 
Page 47 of 80 
7.5 
Electrocardiography 
A 12-lead ECG of at least 10 seconds in duration will be obtained in triplicate (taken 
within a period of 5 minutes) at Baseline (if not available from within the prior 42 days) 
and approximately every 6 months thereafter (or upon early termination), including the 
4-week post-treatment follow-up visit if applicable.  Recordings will be evaluated by a 
centralized ECG reading facility.  Interval data (including QT and corrected QT 
intervals), ventricular rate, and overall interpretation are to be reported for every ECG.  
The interval data and ventricular rate are to be noted in the eCRF as averages of the three 
readings (with the exception of values that are not evaluable and reported as zero, in 
which case the average will exclude this zero value and note in the eCRF the average of 
values > 0). 
A local cardiology consult should be sought if the investigator deems it necessary.  For 
evaluation of subjects with left bundle branch block, a cardiology consult is strongly 
recommended.  
7.6 
Physical and Neurological Examinations  
Targeted examinations (as described below) are to be performed at Baseline (if not 
available from within the prior 42 days) and every subsequent visit thereafter (or upon 
early termination), including the 4-week post-treatment follow-up visit if applicable.  In 
the event of an abnormality, subjects should continue to be followed until resolution or 
stabilization. 
The targeted examinations are to be focused on, but not limited to, evaluating subjects for 
potential serotonin toxicity (see Section 7.1.3.2 for guidance on assessment) and also as 
clinically indicated (e.g., targeted to any changes in medical history, in the event of an 
AE that requires such follow up, or any reported change in the subject's physical 
condition).  At a minimum (in addition to assessments for serotonin toxicity), they are to 
include evaluation of deep tendon reflexes, clonus, and muscle rigidity; size and 
reactivity of pupils; dryness of oral mucosa; intensity of bowel sounds; skin color; and 
presence or absence of diaphoresis.  
Additional targeted examinations may be performed as clinically indicated (e.g., in the 
event of an AE that requires such follow up or any reported change in the subject’s 
physical condition).   
Findings will be documented in the subject's medical record and in the eCRF. 
 
8 
OTHER ASSESSMENTS 
8.1 
Mini-Mental State Examination (MMSE) 
The MMSE (Folstein et al., 1975) was originally developed to differentiate between 
psychiatric patients with functional and organic conditions, to quantify the level of 
cognitive impairment, and to monitor changes over time.  The MMSE subsequently has 
become a widely used and extensively validated cognitive test demonstrating satisfactory 
reliability, validity, and change sensitivity under a wide variety of conditions (Tombaugh 
and McIntyre, 1992). 

Protocol: TRx-237-020 
TauRx Therapeutics Ltd 
24 March 2016 
EUDRACT # 2014-002013-37 
Protocol Version 3.0 / 24 March 2016 
CONFIDENTIAL  
 
 
Page 48 of 80 
Over a 12-month period, Alzheimer’s disease patients might typically show a decline in 
MMSE score of 2-4 points (Schneider, 2001).  
The utility of the MMSE as a means of assessing treatment response in Alzheimer’s 
disease has been questioned (Bowie et al., 1999), but its status as a clinical outcome 
measure has been supported by the UK National Institute for Clinical Excellence 
guidance (NICE, 2001).  Furthermore, the MMSE has demonstrated an ability to detect 
change in clinical studies with AChEIs (Birks and Harvey, 2004).  
In an epidemiological study (Mukaetova-Ladinska et al., 2000), pre-mortem MMSE 
scores have been correlated with post-mortem Braak stage (based on the spread of tau 
pathology through the brain).  MMSE is also sensitive to decline in bvFTD (Knopman et 
al., 2008). 
The MMSE will be performed at Baseline (if not available from within the prior 42 days) 
and approximately every 6 months thereafter (or upon early termination) and at the 
4-week follow-up visit (if applicable) by raters deemed appropriate and delegated by the 
principal investigator.  For each individual subject, the MMSE questionnaire to be 
utilized in this study will be the same version utilized for the subject in the respective 
originating double-blind study (to maintain longitudinal consistency per subject).  The 
MMSE scores will be used to inform the evaluation for possible serotonin toxicity (to be 
included in the targeted physical and neurological examinations).   
8.2 
Resource Utilization in Dementia Questionnaire (RUD Lite) 
The RUD was developed as a comprehensive instrument to measure resource use by 
patients in a clinical trial setting, which in a further step can be calculated into costs 
(Wimo et al., 1998; Wimo et al., 2003; Jonsson, 2007).  The RUD Lite is a shorter 
version of the RUD (Wimo and Winblad, 2003).  The RUD and RUD Lite assess both 
formal and informal resource use, making it possible to calculate costs from a societal 
perspective.  The RUD is administered as an interview with the caregiver.  The validity 
and reliability of the RUD instrument has been investigated both in residential care and 
community care settings by comparing responses to the RUD questions with actual 
observations of care-giving time (Jonsson, 2007; Wimo and Nordberg, 2007). 
The following dimensions are captured on the subjects’ part:  accommodation/long term 
care, respite care, hospital care, social service, and home nursing care.  In addition, the 
following aspects are covered from the caregiver perspective:  caregiving time for the 
subject and work status. 
The RUD Lite will be performed at Baseline (if not available from within the prior 
42 days) and approximately every 6 months thereafter (or upon early termination).   
8.3 
EuroQol – 5 Dimension – 5 Level Instrument (EQ-5D-5L) 
The EQ-5D-5L is a standardized instrument developed by the EuroQol Group to describe 
and value health-related quality of life.  It has been utilized in a global Phase 3 study in 
patients with AD (using the EQ-5D Proxy version completed by caregivers)6.  The 
                                                 
6 https://clinicaltrials.gov/ct2/show/NCT00762411 

Protocol: TRx-237-020 
TauRx Therapeutics Ltd 
24 March 2016 
EUDRACT # 2014-002013-37 
Protocol Version 3.0 / 24 March 2016 
CONFIDENTIAL  
 
 
Page 49 of 80 
instrument comprises the following five dimensions:  mobility, self-care, usual activities, 
pain/discomfort and anxiety/depression.  Each dimension is rated by the subject and 
caregiver on a 5-point scale as having “no problems” (a score of “1”), “slight problems” 
(a score of “2”), “moderate problems” (a score of “3”), “severe problems” (a score of 
“4”), and “extreme problems” (a score of “5”) based on descriptive examples; the scores 
are not intended to be summed.  Present overall state of health is also to be rated on a 
vertical visual analogue scale (approximately 20 cm in length) from 0 to 100 (the higher 
the number the better the quality of life).  
The EQ-5D-5L will be performed at Baseline and approximately every 6 months 
thereafter (or upon early termination).  There will be two applications of the self-reported 
EQ-5D-5L at each visit:  one version will be completed by the subject and a second copy 
of this version will be completed by the caregiver.   
For application to the subject, the rater should explain to the subject what is required and 
how to complete the scale.  If the rater deems that the subject can then complete without 
further assistance, the subject should then proceed to complete the scale without further 
assistance from the rater.  If a subject cannot complete the scale, the rater will be 
permitted to read the questions and options for response and report the subject’s 
responses.  There should be no assistance from the caregiver.  
For application to the caregiver on behalf of the subject, the rater should guide the 
caregiver in completing the scale as though the caregiver is responding for the subject, 
giving what the caregiver believes to be an accurate response to each question.  If the 
caregiver cannot complete the scale, the rater will be permitted to read the questions and 
options for response and report the caregiver’s responses. 
It is important to ensure that the subject and caregiver each complete the EQ-5D-5L 
independently (although the subject and caregiver may each be assisted by a rater), with 
the assessments not influenced by knowledge of the other’s responses.  If independence 
cannot be assured, the order of administration of the EQ-5D-5L is subject first, followed 
by the caregiver. 
 
9 
STATISTICAL PLAN   
A statistical analysis plan (SAP) will be written and finalized prior to database lock.  A 
detailed description of the planned statistical analyses will be provided in the SAP; 
changes from analyses described in this protocol will be documented in the final study 
report.  The database will be locked after review of data is complete, all queries are 
resolved, and all decisions made about the inclusion or exclusion of any spurious data 
and the handling of unused or missing data.   
For purposes of safety reporting and regulatory submissions, one or more interim reports 
may be prepared prior to study termination. 

Protocol: TRx-237-020 
TauRx Therapeutics Ltd 
24 March 2016 
EUDRACT # 2014-002013-37 
Protocol Version 3.0 / 24 March 2016 
CONFIDENTIAL  
 
 
Page 50 of 80 
9.1 
Efficacy Endpoints  
Not applicable to this open-label extension study.   
9.2 
Sample Size Calculations 
Not applicable to this open-label extension study. 
9.3 
Statistical Analysis  
9.3.1 
Analysis Populations 
The Safety Population will include all subjects who take at least one dose of study drug.  
Subjects dispensed study medication who subsequently are lost to follow up without any 
contact are not included in the Safety Population but will be included in the study 
disposition tabulation and listings.  With the exception of study disposition, all tables and 
listings will be generated on the basis of the Safety Population. 
9.3.2 
General Considerations 
Results will be summarized descriptively; no inferential statistics are planned.  
Tabulations will be on the basis of all subjects pooled and also with subjects categorized 
separately by diagnosis and also by study of original participation.  Data from the prior 
study will be mapped into the open-label database. 
For purposes of calculations of change from baseline, Baseline (Visit 1) for the open-
label study will be used.  Depending on the parameter, the data may have been acquired 
during the double-blind study of prior participation.   
For purposes of data tabulations, target visit windows will be assigned in the SAP. 
Listings of by-subject data will be organized by subject number. 
9.3.3 
Health Economic Analysis 
A summary of the planned analyses is provided below; a detailed description of the 
planned analyses, as well as intended sensitivity analyses, will be provided in the SAP. 
In order to investigate the pharmacoeconomic impact of LMTM, two approaches will be 
used: 
• a cost consequence analysis (CCA), and 
• a cost utility analysis (CUA). 
With a cost consequence analysis, a broad set of relevant outcomes (here the primary and 
secondary outcomes) can be tabulated and discussed in relation to costs (Mauskopf et al., 
1998).  Costs and outcomes are presented separately. 
In the cost utility analysis, the incremental cost effectiveness ratio (ICER) is analyzed.  
As an outcome, the gained quality adjusted life years (QALY) derived from the EQ5D 
instrument will be used. 
Both pharmacoeconomic approaches mentioned above include a risk of getting non-
significant effects regarding costs, as clinical trials evaluating efficacy are typically 

Protocol: TRx-237-020 
TauRx Therapeutics Ltd 
24 March 2016 
EUDRACT # 2014-002013-37 
Protocol Version 3.0 / 24 March 2016 
CONFIDENTIAL  
 
 
Page 51 of 80 
underpowered with respect to pharmacoeconomic results and long-term effects cannot be 
assessed due to time constraints in the clinical trials.  Therefore, a modeling approach 
will complement the analysis. 
9.3.3.1 
Resource Use 
The Resource Utilization in Dementia instrument (RUD) is a comprehensive and 
validated instrument collecting data on resource use in trials, with the aim to calculate 
costs from a societal viewpoint.  The RUD Lite questionnaire, a short version of RUD 
mainly discarding the resource use by the caregivers, is employed in this study.  All 
subjects for whom RUD Lite data was collected for at least one time point will be 
included in the summaries. 
Together with costs of institutional care, the value of informal care is the heaviest cost 
driver in dementia care.  Three components of caregiver time will be included in the 
analysis: 
• time spent on toilet visits, eating, dressing, grooming, walking and bathing; 
• time spent on shopping, food preparation, housekeeping, laundry, transportation, 
taking medication and managing financial matters; and 
• time spent on supervising the subject. 
Each component of caregiver time will be calculated as the hours of care on a typical day 
multiplied by days spent on providing these services.  The caregiver time will be 
summarized for each treatment group by visit and with AChEI and/or memantine status 
at randomization, severity, and geographic region. 
Caregiver work status, whether the subject was admitted to a hospital, whether the 
subject received services in a hospital emergency room, whether the subject visited any 
health care professional, and whether the subject received any nursing services will be 
summarized likewise.  
Caregiver relationship with subject and the subject’s living accommodations will be 
summarized descriptively. 
9.3.3.2 
Unit Costs 
Costs will be calculated as the multiplication of the amount of units of resource use and 
the unit cost for this particular resource.  Unit costs for each unit will be collected for 
each country (if unit cost data are not available for each trial country, then unit cost data 
for the dominant country only will be used).  An average wage will be used as a proxy for 
the opportunity cost of informal care.  Caregiver time for retired carers will be given a 
value of 35% of caregivers of working age (Johannesson et al., 1991). 

Protocol: TRx-237-020 
TauRx Therapeutics Ltd 
24 March 2016 
EUDRACT # 2014-002013-37 
Protocol Version 3.0 / 24 March 2016 
CONFIDENTIAL  
 
 
Page 52 of 80 
9.3.3.3 
 Statistical Analysis  
In order to statistically support the descriptive analysis, regression models will be 
employed.  Generalized linear models assuming gamma distributed dependent variables 
will be used accounting for the skewness of resource use and cost data.  Bootstrapping 
methods will complement the analysis by providing estimates for the confidence intervals 
(Ramsey et al., 2005) in the univariate analyses. 
If there is a substantial amount of missing data on resource use (> 20%), multiple 
imputation approaches will be tested. 
9.3.3.4 
Economic Modelling 
As the long term cost-effectiveness of LMTM beyond the trial periods is of great interest, 
economic evaluations based on various modeling techniques will be used.  These models 
most often have a CUA design in which the relation between costs and outcomes is 
expressed as the ICER.  The QALY concept is the most frequently used outcome. 
External data for disease progression and mortality as well as data on resource use and 
costs beyond the trial period are used as inputs.  From the trial, data on efficacy are used 
as an empirical core for the model.  Within trial data on resource use and costs as well as 
the EQ5D data calibrates the external sources in the model.  Often-used modeling 
techniques such as Markov models (Sonnenberg and Leventhal in Wimo et al., 1998) and 
Discrete Event Simulations (DES) (Guo et al., 2014) will be tested. 
9.4 
Baseline Characteristics and Concomitant Medications 
Tabular summaries of demographics and baseline characteristics will be prepared based 
on data collected at the Baseline visit for the original study of participation and at 
baseline for the open-label extension study.  Tabular summaries of concomitant 
medication use (ongoing at start of study and newly initiated) will be restricted to the 
open-label extension study.  All data, including study eligibility, will be listed. 
Concomitant medications and recently used medications (anti-dementia and psychiatric 
drugs used within the prior 3 months) will be coded using the most current version of the 
World Health Organization (WHO) drug dictionary.  Tabulations will be prepared of all 
drugs used concomitantly (relative to the first dose of study drug in the open-label 
extension study) based on WHO Anatomical Therapeutic Classification (ATC) level 1 
term, ATC level 3 term, and Preferred Term (generic name) with frequency and 
percentage of subjects using each concomitant medication.  Concomitant medications are 
to be listed with these elements as well as the verbatim drug name. 
9.5 
Study Drug Exposure 
Total duration of exposure and mean daily dose per subject over the treatment period in 
the open-label study will be summarized descriptively.  The proportion of subjects with 
dose interruptions and/or dose reductions will be summarized descriptively.   
9.6 
Safety Analysis 
The analysis of safety will include summaries of AEs, laboratory tests, vital signs, ECGs, 
and physical and neurological examinations (including serotonin toxicity assessments).  

Protocol: TRx-237-020 
TauRx Therapeutics Ltd 
24 March 2016 
EUDRACT # 2014-002013-37 
Protocol Version 3.0 / 24 March 2016 
CONFIDENTIAL  
 
 
Page 53 of 80 
9.6.1 
Adverse Events 
Adverse events will be coded to System Organ Class and preferred term using the 
Medical Dictionary for Regulatory Activities (MedDRA) version adopted at the start of 
the double-blind study in which the subject previously participated (Version 15.0 or 
later).   
Adverse events will be regarded as treatment-emergent (TEAE) if they start on or after 
the first dose of study drug administration in the open-label study or if they were present 
prior to the first date of study drug administration and increased in severity or 
relationship to study drug while on study treatment.  Those that resolved prior to the first 
dose or were ongoing at the same intensity and relationship will be regarded as pre-
treatment AEs and not summarized.   
Tabular summaries are described below, with the number and percentage of subjects 
reporting each type of event presented.  If a subject reports the same preferred term more 
than once, it is counted only once within that category.  Further, for a given tabulation, 
the preferred term will only be counted once in its worst severity, greatest relationship to 
treatment, and worst action taken. 
Pre-study AEs, those present at the time of the first dose of study drug administration, 
will be presented separately. 
An overall summary table of TEAEs will be produced showing the number and percent 
of subjects with the following: TEAE, severe intensity TEAE, TEAE related to study 
drug, AESIs, serious TEAE, TEAE with outcome of death, and TEAE leading to 
interruption, dose reduction, or discontinuation from the study.  In addition, the summary 
table will include the number of TEAEs, severe TEAEs, TEAEs related to study drug, 
and serious TEAEs.  
Separate summaries of incidences (number and percentage of subjects) of all individual 
TEAEs and the subsets of drug-related TEAEs, TEAEs that are severe in intensity, 
serious TEAEs, and TEAEs leading to change in dose will be provided.   
The subset of TEAEs that have an onset more than 7 days after the last dose of study drug 
will be considered post-treatment.  An overall summary table of the number and percent 
of subjects with post-treatment AEs will be prepared. 
All AEs will be presented in a data listing.  In addition, listings also will be provided for 
SAEs, AEs leading to death, AEs leading to discontinuation of study drug, AEs leading 
to dose reduction and/or interruption, and any other AEs that are of special interest (to be 
defined prior to database lock). 
9.6.2 
Laboratory Tests 
Descriptive statistics will be based on central laboratory results as described below.  
Laboratory results that are obtained from laboratories other than the central laboratory 
will not be included in tabular summaries.  They will, however, be listed separately.  
Normal ranges will be provided by the central laboratory and each local laboratory used 
for testing parameters other than Heinz bodies. 

Protocol: TRx-237-020 
TauRx Therapeutics Ltd 
24 March 2016 
EUDRACT # 2014-002013-37 
Protocol Version 3.0 / 24 March 2016 
CONFIDENTIAL  
 
 
Page 54 of 80 
Categorical laboratory parameters will be summarized for each target visit using counts 
and percent of subjects in each result category.  Continuous laboratory parameters will be 
summarized for each target visit using descriptive statistics for both the original values 
and the change from Baseline.  For each analyte, Baseline values will be restricted to 
those subjects in the Safety Population for whom there is at least one post-Baseline value. 
Selected parameters for which normal ranges differ may additionally be summarized by 
gender, age, and country (or region).  
Box and whisker plots will be presented for selected parameters including hemoglobin, 
reticulocytes, neutrophils, and liver function tests. 
Shift tables will be provided cross tabulating the number of subjects who are low, normal, 
or high at Baseline (with respect to the normal range) against results at each target week. 
Potentially clinically significant ranges will be defined in the SAP for selected 
parameters, and the number and percent of subjects meeting these criteria summarized.  
Tabular summaries will be based on those subjects who meet criteria at Baseline and 
those in whom the values represent a treatment-emergent worsening. 
Listings of laboratory parameters will be presented.  Listings will flag results above and 
below the normal range as well as those that meet criteria for being potentially clinically 
significant (whether or not a treatment-emergent worsening).  Separate listings for each 
hematology and chemistry parameter will show results that meet criteria for being 
potentially clinically significant.  In addition, for subjects who have one or more result 
that meets criteria, all laboratory results will be displayed. 
9.6.3 
Vital Signs and Weight 
Blood pressure, pulse, temperature, respiratory rate, and weight will be summarized for 
each target visit using descriptive statistics for both the original values and the change 
from Baseline.   
Potentially clinically significant vital sign changes will be defined, and the number and 
percent of subjects meeting these criteria will be summarized. 
Listings of vital sign measurements will be presented.  Listings will flag results that meet 
criteria as being potentially clinically significant.  Separate listings for each vital sign 
parameter will show results that meet criteria for being potentially clinically significant.  
In addition, for subjects who have one or more result that meets criteria, all 
corresponding vital sign results will be displayed. 
9.6.4 
Electrocardiogram 
ECG results will be provided by the central ECG reader.  Tabular summaries and 
analyses are to be based on the central ECG data.  Machine-read ECG results and 
interpretations are to be recorded in the eCRF and included in a separate listing; this also 
applies to any subsequent local interpretations if used to make dosing or patient 
management decisions.  
ECG interval data will be summarized based on the average of the triplicate measures.    
All other study visit ECG data (interpretations or means of triplicate measurements if 

Protocol: TRx-237-020 
TauRx Therapeutics Ltd 
24 March 2016 
EUDRACT # 2014-002013-37 
Protocol Version 3.0 / 24 March 2016 
CONFIDENTIAL  
 
 
Page 55 of 80 
performed for clinical reasons) will be summarized separately.  ECG interval and 
ventricular rate data will be summarized using descriptive statistics for both the original 
values and the change from Baseline.  Windows for each target visit will be used 
(additional details provided in the SAP).   Parameters to be analyzed include heart rate 
(HR) and PR, QRS, QT, and corrected QT (using Fridericia’s and Bazett’s corrections), 
and RR intervals.  Counts and percent of subjects in each result category will be 
tabulated.  Overall interpretations of abnormality(ies) will also be tabulated, with subjects 
categorized by whether or not they have treatment-emergent abnormalities. 
Subjects are also to be categorized and enumerated on the basis of QTc interval and 
change from Baseline as follows: 
• QTcB/F outliers (in categories of > 450 to ≤ 480, > 480 to ≤ 500, > 500 msec) 
• Change in QTcB/F outliers (in categories of > 30 to ≤ 60, > 60 to < 90, ≥ 90 
msec) 
All HR, interval data, and interpretations will be listed.  Any new finding after Baseline 
will be categorized into diagnostic groups: rhythm, conduction, hypertrophy, arrhythmia, 
ischemia, infarction, other.   
9.6.5 
Physical and Neurological Examinations and 
Serotonin Syndrome (Toxicity) 
Physical and neurological examination results obtained at Baseline (Visit 1) will be 
summarized by body system.  Evaluation at subsequent visits will be summarized in a 
treatment-emergent fashion.  Summaries will present the number and percentage of 
subjects with normal and abnormal observations by body system/parameter evaluated.  
By-subject listings will detail the abnormality(ies).  Ratings for signs and symptoms of 
serotonin syndrome (toxicity) will also be summarized.  For each target visit, the number 
of subjects for whom “yes” is answered for any of the signs and/or symptoms will be 
tabulated.  A by-subject listing of results will also be prepared. 
9.6.6 
Health Economics and Quality of Life Measure 
The individual items and overall scores for the RUD-Lite and EQ-5D-5L will be 
summarized descriptively by visit.  Results will be listed by subject.  A summary of the 
planned analyses is provided in Section 9.3.3; a detailed description of the planned 
analyses, as well as intended sensitivity analyses, will be provided in the SAP. 
 
10 
REGULATORY  
Investigators and all other parties involved in the conduct of the study are responsible for 
ensuring that the study is conducted at their sites in accordance with the approved 
protocol, the principles of the most current applicable version of the Declaration of 
Helsinki (in the European Union, the study shall be conducted in accordance with the 
1996 version as per Directive 2005/28/EC), the International Conference on 
Harmonisation (ICH) Guidelines for Good Clinical Practice (GCP) (CPMP/ICH/135/95, 
July 1996), and with applicable country and local regulatory requirements and laws. 

Protocol: TRx-237-020 
TauRx Therapeutics Ltd 
24 March 2016 
EUDRACT # 2014-002013-37 
Protocol Version 3.0 / 24 March 2016 
CONFIDENTIAL  
 
 
Page 56 of 80 
The Sponsor will be responsible for ensuring that the relevant approval is obtained from 
the local regulatory authority prior to the start of the study.  The relevant documents will 
be provided to the investigator.  The Sponsor or designee will forward any protocol 
amendments to the regulatory authority and will ensure that SAEs are reported, and 
progress reports and details of any serious protocol violations are provided as required.  
The regulatory authority will be informed should the study be terminated early. 
 
11 
APPROVAL OF THE PROTOCOL AND AMENDMENTS 
Following authorization by the Sponsor, the final protocol and all related documents 
(e.g., information sheets and ICFs) will be submitted to the IEC/IRB. 
The Sponsor will be responsible for ensuring that regulatory and IEC/IRB approvals are 
obtained prior to the start of the study.  The relevant documents will be provided to the 
investigator.  
Neither the investigator nor the Sponsor will modify this protocol.  If modification is 
necessary, either party must first obtain the concurrence of the other.  The party initiating 
a modification will confirm it in writing, and the investigator will be responsible for 
informing the IEC/IRB.  In case of a substantial amendment, prior approval of the 
IEC/IRB is required. 
The Sponsor or designee is responsible for submission of a protocol amendment to the 
regulatory authority.  In the event of a substantial amendment, prior approval is required. 
 
12 
SERIOUS BREACHES  
The investigator and all other parties involved in the conduct of this study will comply 
with the protocol and ICH GCP.  All deviations will be reported to the study monitor. 
It is the responsibility of the Sponsor to notify the licensing authority of any serious 
breach which is likely to affect, to a significant degree, the safety or mental integrity of 
the subjects of the study or the scientific value of the study. 
All serious breaches will be notified to the pertinent regulatory authorities according to 
the relevant national regulatory requirement.  The reporting will be via the Sponsor in 
accordance with the Sponsor Standard Operating Procedures. 
 
13 
INFORMED CONSENT 
It is the responsibility of the investigator or a medically trained, medically qualified sub-
investigator to obtain informed consent from each subject participating in this study, or 
his/her representative who is permitted to provide consent in accordance with local 
legislation.  Where required by local law, the person who informs the subject must be a 
physician.  
Subjects and/or their legal representative(s) must give written (signed and personally 
dated) informed consent prior to study entry and before any study specific procedures are 
undertaken; in Germany (as per §40, section 1 of the German Drug Law [AMG]) and in 

Protocol: TRx-237-020 
TauRx Therapeutics Ltd 
24 March 2016 
EUDRACT # 2014-002013-37 
Protocol Version 3.0 / 24 March 2016 
CONFIDENTIAL  
 
 
Page 57 of 80 
the Netherlands, the subject must be able to provide his or her own written informed 
consent.  The identified caregiver(s) for each subject also must provide written consent to 
his/her own participation as outlined below.  Where there is a change of caregiver, the 
new caregiver must provide written informed consent. 
Potential subjects will be assessed for whether they have capacity to understand the ICF 
and give consent.  
Where possible, fully informed consent will be obtained from the subject.  However, 
subjects entering this study may lack the necessary mental capacity to give fully informed 
consent.  If the potential subject is unable to comprehend the ICF, then one or more 
legally acceptable representatives will be required to sign the ICF as required by national 
law.  In this situation, and provided that it is permitted by local legislation, the subject’s 
agreement to participate in the study will still be obtained to his/her best level of 
understanding and recruitment will not proceed if the subject refuses or shows significant 
distress. 
Informed consent can be obtained only after the aims, methods, anticipated benefits, and 
known potential hazards of the study have been explained to and discussed with the 
potential subject and caregiver by the investigator.  A subject information sheet, 
providing a written summary of all relevant information, will be given to the potential 
subject and caregiver prior to written informed consent being obtained.  The caregiver 
will also be given an information sheet.  The information sheet will make clear that 
access to the subject’s medical records will be required.  It is the responsibility of the 
investigator to ensure that the potential subject and/or caregiver are aware of this.  The 
investigator will explain to the potential subject and caregiver that they are at liberty to 
refuse to take part in the study or, should they decide to participate, they may withdraw 
from the study at any time.  Such a decision should not, in any way, impinge on the 
future management of the subject.  The potential subject and caregiver will be allowed as 
much time as they need to decide whether or not to participate in the study and will be 
provided with a contact point where further information about the study may be obtained. 
The study is multinational and includes sites in the European Union and the United States 
of America, two geographic regions that maintain descriptions of clinical studies on the 
internet.  As required by the U.S.  Food and Drug Administration, the ICF must contain 
the following text:  “A description of this clinical trial will be available on 
http://www.ClinicalTrials.gov, as required by U.S. Law.  This Web site will not include 
information that can identify you.  At most, the Web site will include a summary of the 
results.  You can search this Web site at any time.” Consistent with European Union law, 
the ICF also indicates that information will be on https://www.clinicaltrialsregister.eu.  
Information regarding other national registries will also be included in the ICF, where 
applicable. 
For subjects transferring to a geographically close investigational site, informed consent 
should be accompanied by a signed Authorization for Transfer of Subject Medical 
Records prior to transferring a subject’s medical data to the new site. 
Continued participation will be re-evaluated approximately every 12 months on the basis 
of safety, tolerability, and continued benefit as judged by the investigator.  Subjects 
deemed eligible for continued treatment (and/or their caregivers) must provide informed 

Protocol: TRx-237-020 
TauRx Therapeutics Ltd 
24 March 2016 
EUDRACT # 2014-002013-37 
Protocol Version 3.0 / 24 March 2016 
CONFIDENTIAL  
 
 
Page 58 of 80 
consent for re-enrollment.  The same 13-week and 26-week schedules of assessments (as 
described in Section 4.4) will be maintained for continued treatment beyond the first 
12 months (including re-consent at Visit 6).  Subjects for whom consent is not provided 
consistent with national requirements and IRB/EC approval will be discontinued. 
 
14 
INVESTIGATOR RESPONSIBILITIES  
The primary responsibility of all investigators participating in the study is for the well-
being and interests of their subjects, including subjects enrolled in this study.  The 
investigator has overall responsibility for the conduct of the trial at his/her study site and 
may delegate specific duties to appropriately trained members of his/her research team or 
to other hospital staff, e.g., the pharmacy.  Any delegation must be clearly documented in 
a study site specific delegation list.  
The investigator is responsible for the following: 
• Performing the study in accordance with ICH GCP  
• Ensuring that adequate time and appropriate resources are available to perform 
the study as described in this protocol 
• Ensuring that all persons assisting with the trial are adequately qualified, trained, 
and informed about the protocol, trial-related duties, and functions 
• Maintaining a list of sub-investigators and other appropriately qualified persons to 
whom duties have been delegated 
• Signing an Investigator Agreement to confirm acceptance and willingness to 
comply with the study protocol 
• Maintaining adequate control of study drug and appropriate records of drug 
disposition 
• Maintaining adequate records of each subject's participation 
Where local laws require it, national regulatory requirements with regard to the inclusion 
of subjects who are unable to consent will be followed by the investigators.  In particular, 
in Germany, the risk threshold and degree of burden/distress will be monitored constantly 
by the investigators in accordance with §41, section 3 of the German Drug Law (AMG).  
The Sponsor and the appointed DSMB will constantly evaluate the risk threshold of this 
particular study by assessing the safety profile according to Sections 4.8 and 7, as well as 
assessing the safety profile of other ongoing studies with the same active moiety.  Any 
changes in the risk profile during the course of the study will be communicated to the 
investigators.  In addition, the investigators will review adverse events at each visit in 
accordance with the schedule of assessments (see Table 4-1), and have the right to reduce 
the dose, interrupt or discontinue study drug for safety reasons as described in 
Sections 5.3 and 6.2.2.  
The burden/distress associated with participation in this study is addressed in the patient 
information leaflet.  During the study, the investigators should obtain information from 
the subjects in order to adequately monitor the degree of burden/distress.  Subjects are 

Protocol: TRx-237-020 
TauRx Therapeutics Ltd 
24 March 2016 
EUDRACT # 2014-002013-37 
Protocol Version 3.0 / 24 March 2016 
CONFIDENTIAL  
 
 
Page 59 of 80 
advised that they have the right to discontinue study drug and withdraw from the study at 
any time for any reason and should inform the investigators accordingly in order to assist 
the investigators with monitoring activities. 
 
15 
CONFIDENTIALITY AND DATA PROTECTION   
All study-related documentation is confidential, whether obtained by the investigator or 
provided by the Sponsor or their representative. 
The investigator must ensure the anonymity of subjects in the trial is maintained on 
eCRFs, samples, specimens, and other documents leaving the study site and submitted to 
the Sponsor or its designees.  Subjects must NOT be identified by name, but by an 
identification code (usually trial number).  For all subjects (including subjects who were 
screened but not enrolled), the investigator must keep a separate log of subject codes, 
names, and addresses.   
To conform to the requirements of EU Directive 95/46/EC, subjects will be explicitly 
asked to consent to transmission of their data outside the European Economic Area.  In 
the United States, data will be protected consistent with the Health Insurance Portability 
Accountabilty Act (HIPAA). 
Confidentiality of the records identifying the subject will be maintained.  Representatives 
of the Sponsor such as monitor(s) or auditor(s), IRB/IEC, and pertinent regulatory 
authorities will be permitted direct access to these records and other source 
data/documents as appropriate. 
Details of access to the subjects’ data will be fully described within the subject 
information sheet.  The consequence of the subject's withdrawal of consent with regards 
to the use of data will also be described. 
 
16 
QUALITY ASSURANCE AND CLINICAL MONITORING   
Standard operating procedures (SOPs) will be adhered to for all activities relevant to the 
quality of the study, including protocol compliance, data collection, quality control, and 
data analyses and reporting.  
All aspects of the study will be subject to a Quality Assurance (QA) audit plan.  QA 
audits will be conducted on critical phases during the clinical and reporting phases of the 
study.  These audits will be carried out by quality assurance personnel, independent of the 
staff involved in the study, according to relevant SOPs.   
Clinical monitoring will be performed by trained clinical research personnel.  Detailed 
expected on-site and remote monitoring activity will be described in a clinical monitoring 
plan, which will be modified on an ongoing basis to ensure subject safety and data 
integrity.   
The investigator (or his/her designated deputy) agrees to cooperate with the monitor and 
other clinical research personnel to ensure that any problems detected in the course of 
these monitoring visits are quickly resolved. 
Audits of study sites and/or trial processes may be carried out at any stage. 

Protocol: TRx-237-020 
TauRx Therapeutics Ltd 
24 March 2016 
EUDRACT # 2014-002013-37 
Protocol Version 3.0 / 24 March 2016 
CONFIDENTIAL  
 
 
Page 60 of 80 
 
17 
DOCUMENTATION 
The protocol, its amendments, and any other required documents must be submitted for 
appropriate regulatory review and approval. 
The investigator at each study site must generate and maintain adequate records (medical 
records, source documents, and eCRFs) to enable the conduct of this study to be fully 
documented.  
Initially, data will be collected on source documents which will then be transcribed to the 
eCRF.  The eCRF may serve as the primary collection medium for any data (to be agreed 
with the investigator and documented in the Source Data Verification Agreement).  Each 
enrolled subject must have an eCRF completed and this must be reviewed and approved 
by the investigator.   
The documents specified by ICH GCP (e.g., copies of protocols, CRF pages, original 
copies of test results, reports, drug dispensing logs, correspondence, records of informed 
consent, and other documents pertaining to the conduct of the study) must be kept on file 
by the investigator for a minimum of 15 years or for the period of time specified by local 
law for the preservation of hospital patient documents, whichever is the longest.  No 
study documents should be destroyed without prior written agreement between the 
Sponsor and the investigator.  Should the site wish to assign the study records to another 
party, or move them to another location, the Sponsor must be informed.  
A record must be kept of all subjects consenting for the study and subsequently excluded.  
The reason for non-participation in the study should be recorded. 
Documents that must be provided before or at site initiation include (but are not limited 
to) the following:   
• Protocol and amendments (if applicable) signed and dated by applicable Sponsor 
representatives, as well as by the investigator 
• Regulatory approval (or in absence of document, evidence that study may 
proceed) 
• Signed and dated IEC approval 
• Approved subject information sheet, ICF, and advertisement for recruitment (if 
any) 
• eCRFs 
• Confidentiality agreement(s) 
• Financial disclosure 
• Study drug/shipping records 
• Authorized signature log/delegation list 
• Signed Form FDA 1572 

Protocol: TRx-237-020 
TauRx Therapeutics Ltd 
24 March 2016 
EUDRACT # 2014-002013-37 
Protocol Version 3.0 / 24 March 2016 
CONFIDENTIAL  
 
 
Page 61 of 80 
• Signed curricula vitae (CV) for personnel who have signed the authorized 
delegation log (including principal investigator, all sub-investigators, and 
designated assistants) 
• Investigator Brochure with signed and dated Investigator Brochure receipt 
• Signed and dated clinical trial agreement 
• Research and development (or institution) approval, if applicable  
• Signed and dated indemnity/insurance statement (if applicable) 
• Laboratory reference ranges and accreditation for all applicable laboratories 
(central and local, as applicable) 
• Pharmacy agreement (if any) 
• Instructions for handling investigational product 
• Sample label 
• SAE forms 
 
18 
PUBLICATION 
Since this is a multiple site study, the community of investigators and delegated 
individual investigators shall not publish any partial results before the end of the study or 
before the analysis and publication of the results of the entire study. 
The investigator and/or institution shall have the right to publish, display, or otherwise 
communicate orally, in writing, or electronically (hereafter a “publication”) the results of 
their work conducted under this protocol after 12 months from NDA or equivalent filing, 
or earlier only with explicit consent of the Sponsor in advance and in writing.  
Sites and/or investigators must provide the Sponsor with the opportunity to review the 
contents of any proposed abstract or publication concerning the work, including any 
results of the study, in advance of publication, and agree to delay the publication if, in the 
Sponsor’s reasonable view, the publication may prejudice the Sponsor’s intellectual 
property.  The Sponsor will make every reasonable effort to consider and release each 
proposed abstract or publication within 60 days of submission.  The investigator and/or 
site will include where possible comments made by the Sponsor.  Authorship will be 
determined by mutual agreement.  Access to data will be in accordance with authorship. 
 
19 
INDEMNITY, INSURANCE AND COMPENSATION 
A clinical trials insurance and product liability insurance policy will be in place to cover 
the conduct of this study. 
 

Protocol: TRx-237-020 
TauRx Therapeutics Ltd 
24 March 2016 
EUDRACT # 2014-002013-37 
Protocol Version 3.0 / 24 March 2016 
CONFIDENTIAL  
 
 
Page 62 of 80 
20 
ADMINISTRATIVE AND FINANCIAL AGREEMENT 
Agreed costs for each participating study site will be met by the Sponsor.  For each study 
site, an agreement will be prepared and signed off by the relevant authority on behalf of 
the institution (e.g., National Health Service Trust, University) and by the Sponsor or its 
designee before the initiation of the trial.  Each investigator and sub-investigator must 
also sign a Form FDA 3455 or its equivalent to disclose any financial arrangements or 
interests. 
 
21 
STUDY ADMINISTRATION 
This trial will be conducted in compliance with ICH GCP and other applicable regulatory 
requirements.  
Contract Research Organizations and/or independent contract personnel will be 
contracted to manage and monitor the trial, to provide services for data management and 
statistical analysis, to provide regulatory advice and services, to handle the reporting of 
Serious Adverse Events, to provide services for laboratory analysis, to package and 
distribute the clinical trial supplies, and to provide quality assurance support and services.  
Calibration certification for the following equipment used to generate study data will be 
confirmed:  pharmacy temperature loggers and ECG machines.   
 

Protocol: TRx-237-020 
TauRx Therapeutics Ltd 
24 March 2016 
EUDRACT # 2014-002013-37 
Protocol Version 3.0 / 24 March 2016 
CONFIDENTIAL  
 
 
Page 63 of 80 
22 
REFERENCES 
 
Bierer LM, Hof PR, Purohit DP, et al. Neocortical neurofibrillary tangles correlate with 
dementia severity in Alzheimer's disease. Arch Neurol 1995; 52(1):81-8. 
Birks JS, Harvey R. Donepezil for dementia due to Alzheimer’s disease (Cochrane 
Review). In: The Cochrane Library, Issue 3, 2004. Oxford: Update Software, Ltd. 
Bowie P, Branton T, Holmes J. Should the Mini Mental State Examination be used to 
monitor dementia treatments? Lancet 1999; 354(9189):1527-8. 
Doody RS, Thomas RG, Farlow M, et al. Phase 3 trials of solanezumab for mild-to-
moderate Alzheimer's disease. N Engl J Med 2014; 370(4):311-21.  
Folstein MF, Folstein SE, McHugh PR. “Mini-mental State”: A practical method for 
grading the cognitive state of subjects for the clinician. J Psychiatr Res. 1975; 1:189-198. 
Guo S, Getsios D, Revankar N et al. Evaluating disease-modifying agents: a simulation 
framework for Alzheimer's disease. Pharmacoeconomics 2014; 32(11):1129-39. 
Hodges JR, Davies RR, Xuereb JH, et al. Clinicopathological correlates in 
frontotemporal dementia. Ann Neurol 2004;56(3):399-406. 
Johannesson M, Borqquist L, Jönsson B et al. The costs of treating hypertension--an 
analysis of different cut-off points. Health Policy 1991; 18(2):141-50. 
Jonsson L. Assessing health economic outcome in Alzheimer’s disease clinical trials. J 
Nutr Health Aging 2007; 11(4):353-5. 
Knopman DS, Kramer JH, Boeve BF, et al. Development of methodology for conducting 
clinical trials in frontotemporal lobar degeneration. Brain 2008; 131(pt 11):2957-2968. 
Mauskopf JA, Paul JE, Grant DM et al. The role of cost-consequence analysis in 
healthcare decision-making. Pharmacoeconomics 1998; 13(3): 277-88. 
Mukaetova-Ladinska EB, Garcia-Siera F, Hurt J, et al. Staging of cytoskeletal and 
β-amyloid changes in human isocortex reveals biphasic synaptic protein response during 
progression of Alzheimer's disease. Am J Pathol 2000; 157(2):623-36. 
National Institute for Clinical Excellence (NICE) Technology Appraisal Guidance No 19. 
Guidance for the use of donepezil, rivastigmine and galantamine for the treatment of 
Alzheimer’s disease, 2001. London: NICE. 
Rademakers R, Cruts M, van Broeckhoven C. The role of tau (MAPT) in frontotemporal 
dementia and related tauopathies. Hum Mut 2004; 24(4): 277-295. 
Ramsey S, Willke R, Briggs A et al. Good research practices for cost-effectiveness 
analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report. Value Health 
2005; 8(5):521-33. 
Rascovsky K, Hodges JR, Kipps CM, et al. Diagnostic criteria for the behavioral variant 
of frontotemporal dementia (bvFTD): current limitations and future directions. Alzheimer 
Dis Assoc Disord 2007; 21(4):S14–18. 

Protocol: TRx-237-020 
TauRx Therapeutics Ltd 
24 March 2016 
EUDRACT # 2014-002013-37 
Protocol Version 3.0 / 24 March 2016 
CONFIDENTIAL  
 
 
Page 64 of 80 
Salloway S, Sperling R, Fox NC, et al. Two phase 3 trials of bapineuzumab in mild-to-
moderate Alzheimer's disease. N Engl J Med 2014; 370(4): 322-33. 
Schneider LS. Assessing outcomes in Alzheimer disease. Alzheimer Dis Assoc Disord 
2001; 15(suppl 1):s8-s18. 
Shi J, Shaw CL, Du Plessis D, et al. Histopathological changes underlying 
frontotemporal lobar degeneration with clinicopathological correlation. Acta Neuropathol 
2005; 110(5): 501-512. 
Sonnenberg FA, Leventhal EA. Modeling disease progression with Markov models.  
In Wimo A et al. Health economics of dementia. Wiley 1998:171-96. 
Tombaugh TN, McIntyre NJ.  The Mini-Mental State Examination: A comprehensive 
review. J Am Geriatr Soc 1992; 40(9):922-935. 
Wimo A, Winblad B. Resource utilisation in dementia: RUD Lite. Brain Aging. 2003; 
3:48-59. 
Wimo A, Winblad B, Stöffler A, et al. Resource utilisation and cost analysis of 
memantine in patients with moderate to severe Alzheimer's disease. Pharmacoeconomics 
2003; 21(5):327-40. 
Wimo A, Wetterholm AL, Mastey V, et al. Evaluation of the resource utilization and 
caregiver time in Antidementia drug trials - a quantitative battery. In: The Health 
Economics of dementia. Eds. Wimo A, et al. 1998. London: John Wiley & Sons. 465-99. 
Wimo A, Nordberg G. Validity and reliability of assessments of time. Comparisons of 
direct observations and estimates of time by the use of the resource utilization in 
dementia (RUD)-instrument. Arch Gerontol Geriatr 2007; 44:71-81. 
Wischik CM, Lai RYK, Harrington CR. Modelling prion-like processing of tau protein in 
Alzheimer’s disease for pharmaceutical development. In: Brain Microtubule Associated 
Proteins: Modifications in Disease. Eds. Avila J, Brandt R, Kosik KS 1997. Amsterdam: 
Harwood Academic Publishers, 185-240. 
 
 

Protocol: TRx-237-020 
TauRx Therapeutics Ltd 
24 March 2016 
EUDRACT # 2014-002013-37 
Protocol Version 3.0 / 24 March 2016 
CONFIDENTIAL  
 
 
Page 65 of 80 
23 
APPENDICES 
 

Protocol: TRx-237-020 
TauRx Therapeutics Ltd 
24 March 2016 
EUDRACT # 2014-002013-37 
Protocol Version 3.0 / 24 March 2016 
CONFIDENTIAL  
 
 
Page 66 of 80 
23.1 
Appendix A: Assessments by Visit 
Before participation in this extension study may begin, the subject and caregiver will 
each be provided with an information sheet and both will be given as much time as 
needed to decide whether or not to participate in this study.  Subjects and caregivers must 
re-consent to continue participation annually (approximately Weeks 52, 104, etc.). 
Baseline Visit (Visit 1, Day 1) 
For potential subjects, the safety and efficacy assessments completed at the final  
designated visit of the prior TauRx study in which they were enrolled will serve as 
Baseline assessments for this extension study (unless otherwise noted).  If the final visit 
occurred more than 42 days prior, assessments are to be repeated as specified below.   
Subjects may continue participation at the same site at which they participated in the 
originating double-blind study or transfer to a geographically close investigational site 
(that also participated in the same study).  Eligibility for continued open-label treatment 
is to be determined by the original investigator and, if applicable, a referral to a new site 
made.  The new investigator will have access to the subject’s prior study eCRFs and is to 
confirm eligibility.  Baseline assessments may be repeated (also within 42 days) as 
determined by the new investigator for subjects transferring to a new site.    
Screening / Baseline Assessments  
The following assessments will be obtained, performed or measured at Baseline to 
confirm eligibility for enrollment prior to dosing or, in the case of the EQ-5D-5L, to 
provide a Baseline assessment (as this scale is not used in the prior double-blind studies):  
• Written Informed Consent for participation in the study from the subject (or 
legally acceptable representative) and from the identified caregiver(s) (before any 
study related procedures may be performed)  
• Inclusion and exclusion criteria review (to confirm eligibility) 
• EQ-5D-5L (applied to the subject and to the caregiver on behalf of the subject) 
In addition to the assessments listed above, the following assessments are to be 
performed if Baseline (Visit 1) does not coincide with the final designated visit in the 
prior double-blind study (Visit 11 in TRx-237-005, Visit 9 or Visit 10 in TRx-237-007, 
Visit 7 in TRx-237-008, or Visit 10 in TRx-237-015): 
• Adverse events review (after signing of the Informed Consent) 
• Medical history  
• Prior and concomitant medication review  
o Details of current and recent medication (since last study visit), including dose 
changes 
• Blood sample for serum pregnancy test in women of childbearing potential only 

Protocol: TRx-237-020 
TauRx Therapeutics Ltd 
24 March 2016 
EUDRACT # 2014-002013-37 
Protocol Version 3.0 / 24 March 2016 
CONFIDENTIAL  
 
 
Page 67 of 80 
In addition to the assessments listed above, the following assessments are to be 
performed if Baseline (Visit 1) is not within 42 days of the final designated visit in the 
prior double-blind study (Visit 11 in TRx-237-005, Visit 9 or Visit 10 in TRx-237-007, 
Visit 7 in TRx-237-008, or Visit 10 in TRx-237-015): 
• Blood pressure and pulse measured with subject in a seated position for at least 
5 minutes 
• Respiratory rate and preferably oral (sublingual) temperature; aural temperature is 
an acceptable, but less preferable, alternative 
• Body weight 
• Blood samples for the following Baseline tests: 
o 
Chemistry panel  
o 
Hematology panel 
• 12-lead ECG measurements performed in triplicate (three ECG tracings within an 
approximate 5-minute interval) 
• Physical and neurological examination (includes an assessment for signs and 
symptoms of serotonin toxicity) 
• MMSE  
• RUD-Lite 
The subject and caregiver will be provided with information about how to correctly take 
study drug.  Study drug will be dispensed to the subject and/or the subject’s caregiver.  
Enough study drug will be dispensed to last for approximately 13 weeks (Visit 3).  
 
Visit 2 (Week 2 ± 3 Days)  
The following assessments will be performed: 
• Blood pressure and pulse measured with subject in a seated position for at least  
5 minutes  
• Respiratory rate and preferably oral (sublingual) temperature; aural temperature is 
an acceptable, but less preferable, alternative  
• Concomitant medication recording/review 
• Adverse events review 
• Blood samples for the following tests: 
o 
Chemistry panel  
o 
Hematology panel 
o 
Serum pregnancy test for women of childbearing potential only  
• Body weight  

Protocol: TRx-237-020 
TauRx Therapeutics Ltd 
24 March 2016 
EUDRACT # 2014-002013-37 
Protocol Version 3.0 / 24 March 2016 
CONFIDENTIAL  
 
 
Page 68 of 80 
• Physical and neurological examination (includes an assessment for signs and 
symptoms of serotonin toxicity) 
The subject and caregiver will be questioned to assess compliance with prescribed dose 
of study drug (no tablet count will be undertaken). 
 
Telephone Contact (Week 6 ± 14 Days) 
After the Week 2 visit (Visit 2), a telephone contact will occur with the subject’s 
caregiver at Week 6 (± 14 days). 
 
Visit 3 (Week 13 ± 14 Days)  
Subjects are to bring all remaining study drug to the clinic to assess compliance (to be 
assessed by counting returned tablets as well as by questioning the subject and caregiver).   
The following assessments will be performed: 
• Blood pressure and pulse measured with subject in a seated position for at least  
5 minutes  
• Respiratory rate and preferably oral (sublingual) temperature; aural temperature is 
an acceptable, but less preferable, alternative  
• Concomitant medication recording/review 
• Adverse events review 
• Blood samples for the following tests: 
o 
Chemistry panel  
o 
Hematology panel 
o 
Serum pregnancy test for women of childbearing potential only  
• Body weight  
• Physical and neurological examination (includes an assessment for signs and 
symptoms of serotonin toxicity) 
Study drug will be dispensed to the subject and/or the subject’s caregiver.  Enough study 
drug will be dispensed to last until the Week 26 visit (Visit 4).  
 
Visit 4 (Week 26 ± 14 Days)  
Subjects are to bring all remaining study drug to the clinic to assess compliance (to be 
assessed by counting returned tablets as well as by questioning the subject and caregiver).  
The following assessments will be performed:  
• Blood pressure and pulse measured with subject in a seated position for at least 
5 minutes  

Protocol: TRx-237-020 
TauRx Therapeutics Ltd 
24 March 2016 
EUDRACT # 2014-002013-37 
Protocol Version 3.0 / 24 March 2016 
CONFIDENTIAL  
 
 
Page 69 of 80 
• Respiratory rate and preferably oral (sublingual) temperature; aural temperature is 
an acceptable, but less preferable, alternative  
• Concomitant medication recording/review 
• Adverse events review 
• Blood samples for the following tests: 
o 
Chemistry panel  
o 
Hematology panel  
o 
Serum pregnancy test for women of childbearing potential only 
• Body weight  
• 12-lead ECG measurements performed in triplicate (three ECG tracings within an 
approximate 5-minute interval) 
• Physical and neurological examination (includes an assessment for signs and 
symptoms of serotonin toxicity) 
• MMSE  
• RUD-Lite 
• EQ-5D-5L (applied to the subject and to the caregiver on behalf of the subject) 
Study drug will be dispensed to the subject and/or the subject’s caregiver.  Enough study 
drug will be dispensed to last until the Week 39 visit (Visit 5). 
 
Visit 5 (Week 39 ± 14 Days) 
Subjects are to bring all remaining study drug to the clinic to assess compliance (to be 
assessed by counting returned tablets as well as by questioning the subject and caregiver).  
The following assessments will be performed:  
• Blood pressure and pulse measured with subject in a seated position for at least 
5 minutes  
• Respiratory rate and preferably oral (sublingual) temperature; aural temperature is 
an acceptable, but less preferable, alternative  
• Concomitant medication recording/review 
• Adverse events review 
• Blood samples for the following tests: 
o 
Chemistry panel  
o 
Hematology panel 
o 
Serum pregnancy test for women of childbearing potential only  
• Body weight  

Protocol: TRx-237-020 
TauRx Therapeutics Ltd 
24 March 2016 
EUDRACT # 2014-002013-37 
Protocol Version 3.0 / 24 March 2016 
CONFIDENTIAL  
 
 
Page 70 of 80 
• Physical and neurological examination (includes an assessment for signs and 
symptoms of serotonin toxicity) 
Study drug will be dispensed to the subject and/or the subject’s caregiver.  Enough study 
drug will be dispensed to last until the Week 52 visit (Visit 6). 
 
Visit 6 (Week 52 ± 14 Days) 
Subjects are to bring all remaining study drug to the clinic to assess compliance (to be 
assessed by counting returned tablets as well as by questioning the subject and caregiver).  
The following assessments will be performed:  
• Blood pressure and pulse measured with subject in a seated position for at least  
5 minutes 
• Respiratory rate and preferably oral (sublingual) temperature; aural temperature is 
an acceptable, but less preferable, alternative  
• Concomitant medication recording/review 
• Adverse events review 
• Blood samples for the following tests: 
o 
Chemistry panel  
o 
Hematology panel  
o 
Serum pregnancy test for women of childbearing potential only 
• Body weight  
• 12-lead ECG measurements performed in triplicate (three ECG tracings within an 
approximate 5-minute interval) 
• Physical and neurological examination (includes an assessment for signs and 
symptoms of serotonin toxicity) 
• MMSE 
• RUD-Lite 
• EQ-5D-5L (applied to the subject and to the caregiver on behalf of the subject) 
 
Subjects who complete treatment through the Week 52 on-treatment visit (Visit 6) will be 
offered an opportunity to continue in the open-label study, provided the investigator 
judges that the potential benefit of continued treatment outweighs the potential risk.  
Consent forms will have been given to both the subject and his/her caregiver prior to this 
visit.  Those subjects who wish to continue in the subsequent extension phase (and/or 
their caregivers) will be consented at Visit 6 before further supplies of study drug are 
dispensed.   

Protocol: TRx-237-020 
TauRx Therapeutics Ltd 
24 March 2016 
EUDRACT # 2014-002013-37 
Protocol Version 3.0 / 24 March 2016 
CONFIDENTIAL  
 
 
Page 71 of 80 
 
Early Termination Visit (± 14 Days of Last Dose of Study Drug) 
Subjects are to bring all remaining study drug to the clinic to assess compliance (to be 
assessed by counting returned tablets as well as by questioning the subject and caregiver).  
The following assessments will be performed:  
• Blood pressure and pulse measured with subject in a seated position for at least  
5 minutes 
• Respiratory rate and preferably oral (sublingual) temperature; aural temperature is 
an acceptable, but less preferable, alternative  
• Concomitant medication recording/review 
• Adverse events review 
• Blood samples for the following tests: 
o 
Chemistry panel  
o 
Hematology panel  
o 
Serum pregnancy test for women of childbearing potential only 
• Body weight  
• 12-lead ECG measurements performed in triplicate (three ECG tracings within an 
approximate 5-minute interval) 
• Physical and neurological examination (includes an assessment for signs and 
symptoms of serotonin toxicity) 
• MMSE  
• RUD-Lite 
• EQ-5D-5L (applied to the subject and to the caregiver on behalf of the subject) 
 
Subjects who do not wish to continue with open-label treatment will cease taking study 
drug after the Week 52 or early termination visit.  They will be seen for a post-treatment 
follow-up visit 4 weeks (± 14 days) after the last dose of study drug (Visit 7); otherwise, 
the post-treatment follow-up visit will not be required for subjects who elect to continue 
as they will transition directly into the additional extension phase.   
 
Unscheduled Visit 
Subjects are to bring all remaining study drug to the clinic to assess compliance (to be 
assessed by counting returned tablets as well as by questioning the subject and caregiver). 
The following assessments will be performed as appropriate in response to safety 
concerns: 
• Blood pressure and pulse measured with subject in a seated position for at least 
5 minutes 

Protocol: TRx-237-020 
TauRx Therapeutics Ltd 
24 March 2016 
EUDRACT # 2014-002013-37 
Protocol Version 3.0 / 24 March 2016 
CONFIDENTIAL  
 
 
Page 72 of 80 
• Respiratory rate and preferably oral (sublingual) temperature; aural temperature is 
an acceptable, but less preferable, alternative 
• Body weight 
• Blood samples for the following tests: 
o Chemistry panel  
o Hematology panel 
• 12-lead ECG measurements performed in triplicate (three ECG tracings within an 
approximate 5-minute interval) 
• Physical and neurological examination (includes an assessment for signs and 
symptoms of serotonin toxicity) 
• Recording of adverse events 
• Concomitant medication recording/review  
• Any additional assessments (such as pulse co-oximetry) required to monitor a 
treatment-emergent AE to resolution or stabilization 
The subject is to be scheduled to return to the clinic for the next scheduled visit or 
additional unscheduled visits as appropriate.   
 
Post-Treatment Follow-up Visit (If Applicable) – Visit 7 (Week 56 ± 14 Days) 
A follow-up visit will be performed approximately 28 (± 14) days after the last dose of 
study drug for those subjects who do not wish to continue with open-label treatment.   
The following assessments will be performed: 
• Blood pressure and pulse measured with subject in a seated position for at least 
5 minutes 
• Respiratory rate and preferably oral (sublingual) temperature; aural temperature is 
an acceptable, but less preferable, alternative 
• Concomitant medication recording/review 
• Adverse events review 
• Blood samples for the following tests: 
o 
Chemistry panel  
o 
Hematology panel 
o 
Serum pregnancy test for women of childbearing potential only 
• Body weight  
• 12-lead ECG measurements performed in triplicate (three ECG tracings within an 
approximate 5-minute interval) 
• Physical and neurological examination (includes an assessment for signs and 
symptoms of serotonin toxicity) 
• MMSE 

Protocol: TRx-237-020 
TauRx Therapeutics Ltd 
24 March 2016 
EUDRACT # 2014-002013-37 
Protocol Version 3.0 / 24 March 2016 
CONFIDENTIAL  
 
 
Page 73 of 80 
23.2 
Appendix B: Summary of Changes to the Protocol 
23.2.1 
Protocol Version 1.1 
The final protocol for Study TRx-237-020 (Version 1.0 dated 25 April 2014) has been 
revised (Version 1.1 dated 11 June 2014) to include the EudraCT number issued for this 
study (2014-002013-37), identify the responsible personnel for medical monitoring and 
pharmacovigilance, modify the format for study identification numbers to be assigned to 
subjects, and modify the administrative and financial agreement.  The revisions and 
affected sections are summarized in the table below. 
Additional revisions are editorial and intended to correct typographical errors. 
 
Summary of Changes 
Affected Sections in Revised Protocol (Version 1.1) 
The EudraCT number (2014-002013-37) is now 
specified in the protocol. 
Not applicable (only affects page headers) 
The responsible personnel for medical 
monitoring and pharmacovigilance are now 
identified. 
Section 1.2 Responsible Personnel 
The format for study identification numbers to 
be assigned to subjects has been modified; 
subjects will now be assigned a unique study 
identification number with the first three digits 
reflecting this open-label extension study (020). 
Section 4.5 Assignment of Treatment 
There will be no reimbursement of subjects’ 
travel and accommodation costs.  
Section 20 Administrative and Financial Agreement 
 
 

Protocol: TRx-237-020 
TauRx Therapeutics Ltd 
24 March 2016 
EUDRACT # 2014-002013-37 
Protocol Version 3.0 / 24 March 2016 
CONFIDENTIAL  
 
 
Page 74 of 80 
23.2.2 
Protocol Version 2.0 
The final protocol for Study TRx-237-020 (Version 1.1 dated 11 June 2014) has been 
revised (Version 2.0 dated 2 June 2015) to include modifications and/or clarifications to 
administrative and background information, exclusion and discontinuation/withdrawal 
criteria for subjects in Germany, study drug administration and storage conditions, study 
assessments and procedures, and regulatory requirements as summarized in the table 
below.   
Additional revisions are included which are editorial and/or intended to add minor 
clarification. 
 
Summary of Changes 
Affected Sections in Revised Protocol 
(Version 2.0) 
Administrative and Background Information 
The registered address (in Singapore) for the Sponsor has 
changed and has been updated accordingly. 
Title Page 
The Sponsor’s Global Project Lead and contact for 
Pharmacovigilance have changed for this study and have been 
updated accordingly. 
Section 1.2 Responsible Personnel 
Updates have been incorporated to include more current data 
available from the ongoing double-blind studies in support of 
the rationale for safety assessments performed in this open-label 
extension study, as well as for consistency with the current 
Investigator’s Brochure. 
Section 2 Background 
The approximate number of participating clinical study sites has 
been updated to 170 sites (previously 200-250 sites). 
Synopsis 
Section 4.2 Population 
Exclusion and Discontinuation / Withdrawal Criteria 
Clarification has been added to indicate that subjects who 
participated in Study TRx-237-015 and did not consent to 
extended treatment for up to 15 months as per Protocol v3.0 
(extended from 12 months as per the original study protocol) 
may be enrolled into this extension study following completion 
of the 12-month double-blind treatment period and 4-week post-
treatment follow-up visit for TRx-237-015. 
Synopsis 
Section 4.2 Population 
Section 5.1 Inclusion Criteria 
In response to requests received from the EC of the State of 
Berlin for this study, exclusion criteria have been added to 
specify that in Germany, subjects meeting the following criteria 
are to be excluded:  subjects who reside in a continuous care or 
assisted living facility if mandated by an order issued by either 
the judicial or the administrative authorities, and subjects whose 
willingness to participate in the clinical trial may be unduly 
influenced by the expectation (regardless of whether justified) of 
benefits associated with participation, or of a retaliatory 
response from family, caregivers, or treating personnel in case 
of refusal to participate. 
Synopsis 
Section 5.2 Exclusion Criteria 
In response to requests received from the EC of the State of 
Berlin for this study, the discontinuation / withdrawal criteria 
have been modified to more clearly specify medically 
measureable criteria, and lack of efficacy has been expanded to 
include worsening of cognitive capacity; in Germany, this 
includes loss of the ability to give consent if the legal 
representative or caregiver is not available or does not agree to 
continued participation. 
Section 5.3 Discontinuation/Withdrawal 

Protocol: TRx-237-020 
TauRx Therapeutics Ltd 
24 March 2016 
EUDRACT # 2014-002013-37 
Protocol Version 3.0 / 24 March 2016 
CONFIDENTIAL  
 
 
Page 75 of 80 
Summary of Changes 
Affected Sections in Revised Protocol 
(Version 2.0) 
Study Drug Administration and Storage Conditions 
The protocol has been modified to indicate that in those 
countries where limited by a CA or EC, the maximum allowable 
dose is 200 mg/day (rather than 300 mg/day). 
Synopsis 
Section 2 Background 
Section 3 Objectives 
Section 4.1 General Description 
Section 4.6 Study Treatment 
Section 6.2.2 Flexible Dosing 
The protocol now indicates that interruption(s) of dosing for up 
to 30 days on a given occasion may be allowed at any time 
(rather than restricting this to Visit 2) if the investigator 
determines this is indicated. Subjects should now be withdrawn 
from treatment if there is a need for a single interruption of 
dosing longer than 30 days (the protocol previously allowed two 
30-day dose interruptions), only for safety reasons.  
Synopsis 
Section 2 Background 
Section 4.1 General Description 
Section 4.6 Study Treatment 
Section 6.2.2 Flexible Dosing 
Dose escalation is to be allowed at the drug dispensing visit 
(Visit 3) rather than at the first post-baseline visit (Visit 2), or at 
any subsequent dispensing visit as determined by the 
investigator during the treatment period. The dose can be 
decreased at any time at or after Visit 2. 
Synopsis 
Section 4.1 General Description 
Section 4.6 Study Treatment 
Section 6.2.2. Flexible Dosing 
As the bvFTD subjects from Study TRx-237-007 are not 
required to return for a 4-week post-treatment visit prior to 
entering this open-label extension study, these subjects may 
choose to enroll in this extension study at Visit 9 (i.e., on the 
same day that they receive the last dose of study drug) in Study 
TRx-237-007. Guidance has been added to clarify appropriate 
study drug dosing for bvFTD subjects entering this extension 
study. 
Section 4.1 General Description 
Section 6.2.1 Initial Dose 
Additional details have been added regarding the study drug 
packaging. The appropriate study drug storage temperature 
condition (not more than 30°C) is now specified. Guidance has 
been added to indicate that study drug should remain in the 
package as dispensed until it is ingested by the subject, and 
should not be placed in an alternate pill box including 
commonly-used weekly pill organizers. 
Section 6.3 Packaging, Labeling, and Storage 
Study Assessments and Procedures 
Additional guidance is provided for investigators’ assessment of 
the acceptable risk/benefit balance and evaluation of continued 
benefit from study participation in any given subject. Guidance 
has also been added for confirming eligibility and appropriate 
assessment of AD subjects transferring to a geographically close 
investigational site (that also participated in the same originating 
double-blind study). Baseline assessments may be repeated (also 
within 42 days) as determined by the new investigator for AD 
subjects transferring to a new site. 
Synopsis 
Section 2 Background 
Section 4.1 General Description 
Section 4.2 Population 
Section 4.4 Schedule of Assessments 
Section 23.1 Appendix A: Assessments by Visit 
Corrections have been incorporated to indicate that the EQ-5D-
5L will be performed at Baseline (as this assessment will not be 
evaluated in the previous double-blind study of participation). 
Synopsis 
Section 4.4 Schedule of Assessments 
Section 23.1 Appendix A: Assessments by Visit 
The procedure for administering the EQ-5D-5L has been 
modified. There will be two applications of the EQ-5D-5L at 
each visit:  one version will be completed by the subject and a 
second copy of this version will be completed by the caregiver. 
Guidance has been added to clarify appropriate application of 
the scale to the subject and caregiver. 
Synopsis 
Section 4.4 Schedule of Assessments 
Section 8.2 EQ-5D-5L 
Section 23.1 Appendix A: Assessments by Visit 
Corrections have been incorporated to clarify that at Visit 2, 
compliance with study drug will be assessed by questioning the 
Section 4.4 Schedule of Assessments 
Section 6.4 Dispensing 

Protocol: TRx-237-020 
TauRx Therapeutics Ltd 
24 March 2016 
EUDRACT # 2014-002013-37 
Protocol Version 3.0 / 24 March 2016 
CONFIDENTIAL  
 
 
Page 76 of 80 
Summary of Changes 
Affected Sections in Revised Protocol 
(Version 2.0) 
subject and caregiver. At each study visit thereafter during the 
treatment period, compliance will also be assessed by counting 
returned tablets (in addition to questioning the subject and 
caregiver). 
Section 6.5 Compliance 
Section 23.1 Appendix A: Assessments by Visit 
Corrections have been incorporated to indicate that serum 
pregnancy testing should be performed (in women of 
childbearing potential) if Visit 1 does not coincide with the final 
designated visit of the previous double-blind study of 
participation.  
Section 4.4 Schedule of Assessments 
Section 7.3.3 Other Laboratory Tests 
Section 23.1 Appendix A: Assessments by Visit 
It is further clarified that the same schedule of assessments will 
be followed in subjects who enter subsequent 12-month 
extension phases (including re-consent and study drug 
dispensing at Visit 6), with no requirement for the Week 2 visit 
or Week 6 telephone contact in any subsequent year of 
participation. 
Section 4.4 Schedule of Assessments 
Section 13 Informed Consent 
Guidance regarding contraceptive measures now also indicates 
that women of childbearing potential should be encouraged to 
return to the clinic in the event of a delayed menstrual period to 
rule out possible pregnancy. 
Section 4.7.7 Contraceptive Measures 
Aural temperature measurement is now specified as an 
acceptable (but less preferable) alternative to oral (sublingual) 
temperature (to be measured in response to concerns about 
serotonin toxicity); this alternate means of measuring 
temperature is to be recorded in the eCRF. 
Section 6.2.3.2 Serotonin Syndrome 
Section 7.4.2 Temperature (Optional) 
Section 9.6.3 Vital signs and Weight 
Section 23.1 Appendix A: Assessments by Visit 
The discussion of AE recording has been modified to specify 
that when describing an AE in terms of a diagnosis, events and 
signs/symptoms leading up to a diagnosis should be retained. 
Section 7.1 Adverse Events 
For the reporting of SUSARs, a determination will now be made 
(on a case-by-case basis) regarding whether unblinding prior 
treatment is required for any unexpected events. 
Section 7.1.5.2 Sponsor Reporting of SUSARs to 
Regulatory Authorities 
The description of the RUD Lite scale has been corrected, as 
work status for the subject is not captured in the RUD Lite. 
Section 8.1 Resource Utilization in Dementia 
Questionnaire (RUD Lite) 
For AD subjects transferring to a geographically close 
investigational site, informed consent should be accompanied by 
a signed Authorization for Transfer of Subject Medical Records 
prior to transferring a subject’s medical data to the new site. 
Section 13 Informed Consent 
Statistical Analyses 
Clarification has been added to indicate that subjects dispensed 
study medication who subsequently are lost to follow up without 
any contact are not included in the Safety Population, but will be 
included in the study disposition tabulation and listings.  With 
the exception of study disposition, all tables and listings will be 
generated on the basis of the Safety Population. 
Synopsis 
Section 9.3.1 Analysis Populations 
A summary of the planned statistical analyses has been added 
for health economics and quality of life measures; a detailed 
description of the planned analyses, as well as intended 
sensitivity analyses, will be provided in the SAP. 
Synopsis 
Section 9.3.3 Health Economic Analysis (and all 
subsections) 
Section 22 References 
Regulatory 
The protocol now specifies that in the European Union, this 
study shall be conducted in accordance with the 1996 version of 
the Declaration of Helsinki as per Directive 2005/28/EC. 
Section 10 Regulatory 

Protocol: TRx-237-020 
TauRx Therapeutics Ltd 
24 March 2016 
EUDRACT # 2014-002013-37 
Protocol Version 3.0 / 24 March 2016 
CONFIDENTIAL  
 
 
Page 77 of 80 
23.2.3 
Protocol Version 2.1 
The final protocol for Study TRx-237-020 (Version 2.0 dated 2 June 2015) has been 
revised (Version 2.1 dated 22 June 2015) to no longer specify that a subject’s inability to 
self-complete the EQ-5D-5L scale must be for reasons associated with his or her disease 
in order for it to be acceptable to allow rater assistance, as summarized in the table below. 
 
Summary of Changes 
Affected Sections in Revised Protocol (Version 2.1) 
The protocol no longer specifies that a rater is only 
permitted to assist a subject with completing the 
EQ-5D-5L scale if the subject cannot complete the 
scale for reasons associated with his or her disease, 
as there may be other acceptable reasons to allow 
assistance from the rater on a case-by-case basis.  
Section 8.2 EQ-5D-5L 

Protocol: TRx-237-020 
TauRx Therapeutics Ltd 
24 March 2016 
EUDRACT # 2014-002013-37 
Protocol Version 3.0 / 24 March 2016 
CONFIDENTIAL  
 
 
Page 78 of 80 
23.2.4 
Protocol Version 3.0 
The final protocol for Study TRx-237-020 (Version 2.1 dated 22 June 2015) has been 
revised (Version 3.0 dated 24 March 2016) to include modifications to administrative and 
background information, inclusion criteria, study assessments and statistical analyses for 
safety evaluations, and other procedures.  The revisions and affected sections are 
summarized in the table below. 
Additional revisions are included which are editorial or intended to add clarification. 
 
Summary of Changes 
Affected Sections in Revised Protocol (Version 3.0) 
Administrative / Background 
The Sponsor’s Global Project Lead and Head of 
Safety and Medical Monitoring have changed for this 
study and have been updated accordingly.  
Responsible personnel for ECG assessments have 
also been added. 
Section 1.2 Responsible Personnel 
The background discussion of clinical data has been 
updated to reflect the most current Investigator’s 
Brochure and Development Safety Update Report for 
LMTM. 
Section 2 Background 
Inclusion Criteria 
It is now specified that in the Netherlands, subjects 
must be able to provide their own written informed 
consent to participate in this study; continuation of 
treatment is not permitted if the subject is unable to 
give consent. 
Synopsis 
Section 5.1 Inclusion Criterion No. 3 
Section 5.3 Discontinuation/Withdrawal 
Section 13 Informed Consent 
Safety Assessments / Procedures 
A 12-lead ECG (in triplicate) will now be obtained in 
all subjects at Baseline (if not available from within 
the prior 42 days) and approximately every 6 months 
thereafter (or upon early termination) and at the 
4-week follow-up visit if applicable (previously, ECG 
testing was only to performed as needed in response 
to an AE or changes in the subject’s physical 
condition or medical history). Guidance for the 
management of abnormalities has been added 
accordingly. 
Synopsis 
Abbreviations 
Section 1.2 Responsible Personnel 
Section 2 Background 
Section 4.1 General Description 
Section 4.4 Schedule of Assessments 
Section 5.3 Discontinuation/Withdrawal 
Section 6.2.3.3 Other Safety Reasons Requiring Dose 
Adjustment 
Section 7 Assessment of Safety 
Section 7.5 Electrocardiography 
Section 9.6 Safety Analysis 
Section 9.6.4 Electrocardiogram (Section added) 
Section 13 Informed Consent 
Section 21 Study Administration 
Section 23.1 Appendix A: Assessments by Visit 
Targeted physical and neurological examinations will 
now be performed in all subjects at Baseline (if not 
available from within the prior 42 days) and 
approximately every 6 months thereafter (or upon 
early termination) and at the 4-week follow-up visit if 
applicable (previously, these examinations were only 
to performed as needed in response to an AE or 
changes in the subject’s physical condition or medical 
history).  
 
Synopsis 
Section 2 Background 
Section 4.1 General Description 
Section 4.4 Schedule of Assessments 
Section 4.7.2 Drugs with Serotonergic Potential 
Section 6.2.3.2 Serotonin Syndrome 
Section 7 Assessment of Safety 
Section 7.1.3.2 Serotonin Syndrome (Toxicity) 
Section 7.4.2 Temperature and Respiratory Rate 
Section 7.6 Physical and Neurological Examinations 

Protocol: TRx-237-020 
TauRx Therapeutics Ltd 
24 March 2016 
EUDRACT # 2014-002013-37 
Protocol Version 3.0 / 24 March 2016 
CONFIDENTIAL 
Page 79 of 80
Summary of Changes 
Affected Sections in Revised Protocol (Version 3.0) 
As part of these targeted examinations, subjects will 
also be assessed for signs and symptoms indicative of 
potential serotonin toxicity (and temperature and 
respiratory rate will be measured for evaluation in 
this assessment); guidance on assessment and 
recording adverse events is provided in 
Section 7.1.3.2.  
Section 9.6 Safety Analysis 
Section 9.6.3 Vital Signs and Weight 
Section 9.6.5 Physical and Neurological Examinations 
and Serotonin Syndrome (Toxicity) 
Section 13 Informed Consent 
Section 23.1 Appendix A: Assessments by Visit 
The AESIs in this study are signs and symptoms 
consistent with hemolytic anemia and serotonin 
syndrome (toxicity).  Potential interruption or 
discontinuation of study drug in response to these 
events is discussed in Section 6.2.3; guidance on 
monitoring subjects is now provided in Section 7.1.3. 
Section 4.7.2 Drugs with Serotonergic Potential 
Section 5.3 Discontinuation/Withdrawal 
Section 6.2.3 Dose Adjustment for Selected Adverse 
Events / Test Abnormalities (and all subsections) 
Section 7.1.3 Adverse Events of Special Interest (and all 
subsections) 
Adverse events of suicidal ideation and serotonin 
toxicity are no longer specified as required to be 
reported as SAEs per the study protocol; the reporting 
of these events will be left to the discretion of the 
investigator. 
Section 7.1.4 Serious Adverse Events 
For SUSAR reporting in this study, should treatment 
assignment in the previous double-blind study of 
participation not yet be unblinded, the treatment 
assignment for a given subject will be made available 
for assessment of the SUSAR and will be included in 
the reporting of the event to a regulatory authority (as 
the onset of a possible SUSAR relative to the prior 
treatment history is an important aspect of the 
assessments); guidance for SUSAR reporting and 
unblinding treatment allocation has been revised 
accordingly. 
Section 7.1.6.2 Sponsor Reporting of SUSARs to 
Regulatory Authorities  
Section 7.1.6.2.1 Unblinding Treatment Allocation 
(Section added)  
Clarification has been added regarding serum 
chemistry panel analytes (urea nitrogen, urea) and the 
reporting of results in the Covance CLS database. 
Section 7.3.1 Serum Chemistry 
Clarification has been added regarding the inclusion 
of subjects and selected parameters in the statistical 
analyses of adverse events and laboratory tests. For 
the analysis of adverse events, the summarization of 
certain TEAEs, subgroup analyses, and interactions 
between MT and selected concomitant medications 
have been removed as these analyses will be done for 
the Integrated Summary of Safety (which takes into 
consideration the totality of a subject’s exposure). 
Section 9.6.1 Adverse Events 
Section 9.6.2 Laboratory Tests 
Other Assessments / Procedures 
The MMSE will now be performed at Baseline (if not 
available from within the prior 42 days) and 
approximately every 6 months thereafter (or upon 
early termination) and at the 4-week follow-up visit if 
applicable.  The MMSE scores will be used to inform 
the evaluation for possible serotonin toxicity (to be 
included in the targeted physical and neurological 
examinations). 
Synopsis 
Abbreviations 
Section 4.1 General Description 
Section 4.4 Schedule of Assessments 
Section 7.1.3.2 Serotonin Syndrome (Toxicity) 
Section 8.1 Mini-Mental State Examination (MMSE) 
Section 22 References 
Section 23.1 Appendix A: Assessments by Visit 

Protocol: TRx-237-020 
TauRx Therapeutics Ltd 
24 March 2016 
EUDRACT # 2014-002013-37 
Protocol Version 3.0 / 24 March 2016 
CONFIDENTIAL  
 
 
Page 80 of 80 
Summary of Changes 
Affected Sections in Revised Protocol (Version 3.0) 
Clarification has been added to indicate that if a 
subject discontinues prematurely, an early 
termination visit should be conducted at which time 
all assessments identified for the final on-treatment 
visit (e.g., Visit 6) should be performed.  For all 
subjects who cease to take LMTM, a post-treatment 
follow-up visit 4 weeks after the last dose of study 
drug is to be scheduled, regardless of the reason for 
discontinuation.  
Synopsis  
Section 4.1 General Description 
Section 4.4 Schedule of Assessments 
Section 5.3 Discontinuation/Withdrawal 
Section 23.1 Appendix A: Assessments by Visit 
The protocol now also permits bvFTD subjects to 
transfer to a geographically close investigational site 
that also participated in the same study (this is no 
longer restricted to AD subjects). 
Synopsis 
Section 4.1 General Description 
Section 4.4 Schedule of Assessments 
Section 13 Informed Consent 
Section 23.1 Appendix A: Assessments by Visit 
Regarding the potential for LMTM to cause staining 
of underclothes and other fabrics, the protocol now 
also indicates that the possibility of such staining 
should be clearly discussed with subjects and their 
caregivers. 
Section 6.1.1 Active Ingredient 
Subject compliance with prescribed dose of study 
drug will be assessed by questioning the subject and 
caregiver at the Week 2 visit (Visit 2); clarification 
has been added to indicate that compliance data 
(including dates of any dose deviations and/or 
interruptions, and any other pertinent information) 
will also be recorded for information obtained at 
Visit 2 in the source documentation and on the 
appropriate field of the eCRF based on the 
investigator determination. 
Section 6.5 Compliance